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Autoantibodies and antigens
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Heterogeneity and multifactoriality complicate diagnostics and our
understanding of pathogenesis of rheumatoid arthritis (RA). The only
accepted serologic parameter (rheumatoid factor [RF]) is not disease
specific, nor are any of several novel RA autoantibodies. We aimed at
identifying profiles instead of individual autoreactivities allowing for
unambiguous prediction of RA.
Selected RA autoantigens were tested by ELISA (RF and anti-cyclic
citrullinated peptide [anti-CCP]) or Western blot (heavy-chain-binding
protein [BiP], heterogeneous ribonucleoprotein particle A2 [RA33/
hnRNP A2], calpastatin and calreticulin). Antibody reactivities were
assayed from serum samples of 149 RA patients and 132 patients
with other rheumatic diseases and from synovial fluids (SF) (58 RA,
65 non-RA).
No single autoreactivity was sufficient for unambiguous prediction of
RA. Frequencies of multiparameter profiles consisting of 3, 4, 5 and 6
autoreactivites were determined. Fifteen six-parameter serum profiles
were exclusively expressed in RA patients, representing a cumulative
sensitivity of 59%. Twelve SF profiles were exclusively expressed in
64% of RA patients. The self-learning classification algorithm
CLASSIF1 was capable of accurately predicting RA when these profiles
were present. Data profile analysis of RF/CCP/BiP/calpastatin/calretic-
ulin/RA33 provided specific discrimination of 64% of RA. Most impor-
tantly, RA specific profiles were observed in 64% of patients with early
disease (<12 months).
For the first time, the accurate prediction of the class RA has been
achieved by the use of multiparametric autoreactivity profiles. Because
of early expression in disease, these profiles make it possible to start a
disease-modifying therapy long before irreversible bone and joint
destruction may develop. Additional RA-specific profiles are required to
cover the entire group of RA patients.
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Antifilaggrin antibodies comprise a heterogeneous population of anti-
bodies directed to citrullinated proteins.
Recent studies have shown that their production is highly specific for
rheumatoid arthritis (RA) and the initial antigenic trigger for these
autoantibodies can be localised to the inflammed synovial tissue.
The aim of our study was to compare the reactivity and specificity of anti-
bodies in sera and synovial fluids towards citrullinated epitopes. Peptide
sequence corresponding to human profilaggrin (amino acid residues
306–324) and sequences with citrulline substitution at different posi-
tions were synthetised by mutipin peptide synthesis on solid supports.
Shortened versions of the peptide were also produced by removal of
amino acid residues from its N and C terminals. Completely citrullinated
variant of the 14-mer peptide was also prepared. Peptide with no cit-
rulline replacement was used as a control antigen. We found significant
differences in the sensitivity for RA of 19 individual peptides tested (from
5% to 68%), reflecting previous results that the surrounding amino acids
play an important role in creation of an autoantigenic epitope. Further, we
tested the reactivities of paired serum and synovial fluids and found very
similar peptide recognition patterns in serum and synovial IgG from the
same individuals. Studies on larger number of samples are in progress to
evaluate the results statistically that may support further evidence of the
synovial origin of antifilaggrin autoantibodies. 
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A number of rheumatoid arthritis (RA) sera contain antibodies specific
for peptides in which arginine is substituted by the deiminated form cit-
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rulline (AKA). These antibodies are a marker of RA, as they are absent
in other disorders. The enzyme responsible for the generation of cit-
rulline residues, peptidylarginine deiminase (PAD), has different iso-
forms, with a specific tissue distribution. PAD V, expressed in
monocytes, might be responsible for the deimination of arginine
residues of synovial proteins and thus be involved in the generation of
epitopes for RA-specific antibodies. The ECRAF genome scan showed
suggestive linkage evidence at PAD V locus on chromosome 1
(P<0.005). We decided to analyze PAD V as a candidate gene for RA,
studying a cohort of 100 RA patients (tested for AKA) and their unaf-
fected parents. Investigation (by single-strand conformation polymor-
phism [SSCP] analysis and sequencing) of the 16 exons, 5′ and 3′
regions of the PAD V gene provided polymorphisms in the 5′, exons
3, 4, and 7 and 3′ regions. Analysis used the transmission disequilib-
rium test and the haplotype relative risk for alleles and haplotypes with
Analyze and Genhunter2 programs.
We found an association between RA and one PAD V haplotype (38%
in RA versus 17% in controls) (P<0.007). The association was also
observed in the AKA+ RA subgroup (41%) (P<0.03).
In conclusion, the PAD V gene may be considered one of the genetic
factors that confer susceptibility to RA. Studies are in progress to
clarify the relationship between the PAD V  haplotypes, the enzyme
activity and the production of anticitrulline antibodies.
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Background: Antifilaggrin autoantibodies, previously known as ‘antik-
eratin’ antibodies or antiperinuclear factor, are serum IgG that consti-
tute the most specific diagnostic markers of rheumatoid arthritis (RA).
We showed that they specifically recognise deiminated forms of the
α and β chains of fibrin in the rheumatoid synovium. Subsequently, we
developed a new ELISA for these autoantibodies, using in vitro deimi-
nated human fibrinogen as immunosorbent (AhFibA-ELISA). We evalu-
ated its diagnostic performance in a cohort of 617 patients with
well-characterised rheumatic diseases, including 181 patients with
established RA: at a diagnostic specificity of 98.5%, the ELISA pre-
sents a diagnostic sensitivity of 76%. It is to date the most efficient test
for the diagnosis of RA.
Objective: On the basis of this test, we undertook to determine the
subclass distribution of AhFibA.
Methods: From the AhFibA-ELISA, four ELISAs using monoclonal anti-
bodies to each IgG subclass (IgG1, IgG2, IgG3 and IgG4) were devel-
oped. The ELISAs were adjusted to allow the respective proportions of
each AhFibA subclass to be determined in each serum sample tested.
141 RA patients positive for AhFibA were analysed.
Results: For each IgG subclass, the titres (optical density [OD] values)
in the whole population of patients were found to be significantly corre-
lated with those obtained with the AhFibA-ELISA. IgG1 AhFibA
reached the highest OD values (range 0.137–3.028, median: 1.125),
followed by IgG4 AhFibA (range 0–2.846, median 0.043), IgG3
AhFibA (range 0–1.448, median 0.034) and lastly IgG2 AhFibA (range
0–0.695, median 0.040). The predominance of IgG1 AhFibA was also
observed at the individual level since, among the 141 AhFibA-positive
sera, all but one contained at least 40% of IgG1 AhFibA. In 39.7% of
the sera, one or several other subclasses accounted for more than
10% of total AhFibA. IgG4 AhFibA was the most frequently associated
subclass, 25% of the sera containing more than 10% of these antibod-
ies. Only 10.7 and 7.9% of the sera contained more than 10% of IgG2
and IgG3 AhFibA, respectively.
Conclusion:  These results confirm and extend those previously
obtained by indirect immunofluorescence for ‘antikeratin’ antibodies.
The predominance of IgG1 AhFibA, and their frequent association with
IgG4 AhFibA, raises the question of the Th1/Th2 balance in RA. More-
over, the predominance of IgG1 AhFibA is compatible with effector
mechanisms involving complement activation and/or the engagement
of Fc gamma receptors.
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Background: Antifilaggrin autoantibodies (AFAs) are highly specific for
rheumatoid arthritis and are probably involved in its pathophysiology.
We showed that they are synthesised in the rheumatoid synovial mem-
brane and that their target antigens in the tissue correspond to variants
of the α and β chains of fibrin. The variants are generated by deimina-
tion, i.e. transformation of their arginine into citrulline residues. Deimina-
tion, mediated by a peptidylarginine deiminase (PAD) activity,
generates the epitopes recognised by AFA/antifibrin autoantibodies.
Four PAD isoforms (or types), have been identified and cloned in
humans and rodents (mouse and rat). Expression of one or several of
these isoforms has been reported in numerous tissues, but their targets
are still poorly known.
Objective: Since fibrin deimination occurs in the rheumatoid synovial
tissue, we undertook to identify which PAD types are expressed in the
tissue.
Methods: By immunising rabbits with peptides situated in the most vari-
able regions of the otherwise highly conserved PAD type sequences
(three synthetic peptides per PAD), we produced antisera specific for
each of the four PAD isoforms. The antisera were affinity-purified on the
corresponding peptides. Each set of anti-peptide antibodies was con-
firmed to be specific for one isoform by immunoblotting on recombinant
or purified PADs. Additional antisera or purified antibodies to whole
human PADs II, III and V were used to confirm the results obtained with
the anti-peptide antibodies.
The synovial tissue from seven patients with rheumatoid arthritis was
analysed. In all the tissues, the presence of deiminated proteins and
particularly of deiminated fibrin was demonstrated by immunoblotting
and/or immunohistology. Then low-salt extracts of the tissues were
analysed by immunoblotting with all the immunological tools to PADs.
Results: Expression of PAD type V was clearly detected in all seven
patients. Expression of PAD type II was observed in six patients. No reac-
tivities were observed with antibodies specific for PAD types I and III.
Conclusion: Of the four PAD isoforms, only the types II and V are sig-
nificantly expressed in the synovial tissue of patients with rheumatoid
arthritis. Their respective roles in deimination of fibrin in the tissue
remain to be determined.
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To ascertain the heterogeneity of anti-prothrombin antibodies (aPT), we
compared three in-house aPT ELISAs: A) medium binding plates, phos-
phatidylserine, prothrombin, Tris-buffered saline, calcium; B) high
binding plates, prothrombin, Tris-buffered saline; and C) high binding
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plates, prothrombin, PBS. One serum, exhibiting high positive aPT in all
three ELISAs, was selected as the calibrator. Sera from 47 patients
(41 with SLE, 4 with pAPS, 2 with arterial thromboses) were tested for
IgG and IgM aPT.
The results showed six different patterns: 1) similar results were
obtained with A, B and C (similar analytical sensitivity); 2) similar results
were obtained with A and B while C showed lower analitycal sensitivity;
3) B and C seemed analytically less sensitive than A; 4) A and B were
analytically less sensitive than C; 5) A showed very low analytical sensi-
tivity; 6) A and C showed lower analytical sensitivity than B.
The analysis of all the presented patterns showed noncomparable
results of the three ELISAs. In our experiments, prothrombin was rec-
ognized by relevant antibodies when the protein was bound to phos-
phatidylserine-coated microtiter plates using calcium ions or when it
was bound to high binding plates with or without calcium ions. Never-
theless, detected aPT values were not of the same fine specificity. Dif-
ferent binding conditions for prothrombin exposed different epitopes,
resulting in the detection of various subgroups of aPT.
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Background:  Antibodies against β2-glycoprotein I (anti-β2GPI) are
believed to be of low affinity and thus unable to bind to the free antigen
in a solution.
Objective: The aim of our study was to determine the affinity of IgG
anti-β2GPI, isolated by affinity chromatography.
Methods: A β2GPI affinity column was prepared by CNBr-activated
agarose without spacer arms and human purified unnicked β2GPI. The
IgG fraction from the protein G column was applied to the column and
bound antibodies were eluted with various solutions: A) 0.1M glycine /
0.5M NaCl / 0.1% Tween 20pH2.5; B) 0.1M glycine / 4M NaCl /
0.1% Tween 20pH2.5; C) 0.1M sodium borate pH10 and D) 25%
ethylene glycol. Eluted fractions containing anti-β2GPI antibodies were
neutralised and analysed by ELISA using various binding buffers. The
level of anti-β2GPI antibodies in each sample was derived from the
standard curve according to the defined dilutions of monoclonal anti-
bodies (AUG are arbitrary units of IgG monoclonals).
Results: Increased concentrations of sodium ions in the binding solu-
tion from 0.15, 0.25, 0.50, 1.11, 2.07 and 4.0MNaCl did not com-
pletely prevent the binding between isolated antibodies and β2-GPI
(79.8, 65.3, 36.1, 19.9, 12.0 and 8.1AUG, respectively).
Conclusion: In contrast to the common opinion that all anti-β2GPI
autoantibodies are of low affinity, we clearly showed that at least one
subset among them was of high affinity.
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Background: AntiRo are found in 5–15% of RA. Significant associa-
tions were reported with sicca, vasculitis, hypergammaglobulins, ANA,
high-titer RF, toxicity to D-penicillamine and gold salts treatment. Aim of
the study: to evaluate clinical features, radiologic progression and
response to disease-modifying antirheumatic drugs (DMARDs) in
antiRo-RA patients.
Patients and methods: We studied 210 patients with RA: antiRo
were determined by CIE, with human spleen extract, and by ELISA with
recombinant Ro proteins (Pharmacia). Cutoff values for ELISA were
determined testing 177 sera from routine.
Results: AntiRo were detected in 27 patients (F:M 12.5:1). Two groups
(antiRo+ and antiRo–) did not show any difference with regard to disease
duration, arthritis onset and articular erosions. AntiRo were associated
with xerophthalmia (P<0.0000001), xerostomia (P=0.0012), oral ulcers
(P=0.0067), scleritis (P=0.0067) and amyloidosis (P=0.042).
Rheumatoid factor, antiperinuclear factor and anticitrulline were recorded
in 70% in both groups; hypergammaglobulinemia, ANA, anti-dsDNA and
AMA were frequently detected in antiRo+ patients. Patients were given a
mean of 3.93 DMARDs, with no statistical difference between antiRo+
and antiRo–: hydroxychloroquine, methotrexate and gold salts are the
most frequently used. Patients who were antiRo– were more frequently
treated with hydroxychloroquine and infliximab, while D-penicillamine was
used more frequently in those who were antiRo+. DMARD toxicity was
detected in 9.3% of antiRo+, with no statistically significant difference
between the two groups.
Conclusion: AntiRo, found in 12.8% of patients with RA, is associated
with extra-articular features and with an autoantibody profile unusual for
RA. No difference with respect to DMARD toxicity was found in anti-
Ro+ patients.
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Background: Systemic lupus erythematosus (SLE) is an autoimmune
rheumatic disease characterised by the production of autoantibodies.
The most common serious feature of SLE is renal involvement. An
association with anti-RNP antibodies remains controversial.
Aim: To identify associations of autoantibodies and renal symptoms in
a consecutive cohort of SLE patients.
Methods: Sera and clinical data from 235 consecutive SLE patients,
fulfilling the ACR criteria for SLE, were collected in four centres. The
presence of renal disease was defined as the presence of cellular
casts in the urine, proteinuria (>0.5g/day), or glomerulonephritis during
the course of the disease. Autoantibody profiles were determined by
the INNO-LIATM ANA Update (a line immunoassay with recombinant
and/or native antigens, including SmB, SmD, RNP-70, RNP-A, RNP-C,
Ro52, Ro60, SSB, and ribosomal P) and anti-dsDNA antibodies by
indirect immunofluorescence on Crithidia luciliae. Odds ratios (ORs)
and their 95% confidence intervals (CI) were computed to determine
the associations between antibodies and renal symptoms. No correc-
tion was made for multiple testing.
Results: The presence of anti-RNP-A and anti-RNP-C appeared to be
protective against renal involvement (OR=0.445, CI=0.210–0.942
and OR=0.484, CI=0.243–0.964, respectively). Concerning the indi-
vidual symptoms, anti-RNP-C was associated with a lower occurrence
of proteinuria (OR=0.470, CI=0.236–0.938), cellular casts
(OR=0.324, CI=0.150–0.696) and glomerulonephritis (OR=0.460,
CI=0.226–0.934), whereas anti-RNP-A was only significantly associ-
ated with a lower occurrence of cellular casts (OR=0.303,
CI=0.129–0.716). In contrast, antibodies to dsDNA were associated
with a higher risk for cellular casts (OR=2.014, CI=1.057–3.839).
We found no associations between renal symptoms and other specific
antinuclear reactivities. More specifically, for anti-RNP-70 a trend was
only detected for the association with the presence of cellular casts
(OR=0.411, CI=0.153–1.106).
Conclusion: Anti-RNP-A and anti-RNP-C antibodies appear to be
associated with a lower risk for renal disease.
Available online http://arthritis-research.com/supplements/5/S1S4
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Sjögren’s syndrome (SS) is characterized by exocrine gland destruc-
tion associated with lymphocytic infiltrations and chronic autoimmune
antigen-driven responses against the intracellular Ro/SSA and La/SSB
ribonucleoproteins. Epithelial cells, which are the main targets of
autoimmune responses, appear to have a central role in the pathogene-
sis of SS. In recent years we have presented evidence indicating that
salivary gland epithelial cells (SGECs) of SS patients are inherently
capable of functioning as antigen-presenting cells. Recently, a novel,
cell-free mechanism of antigen presentation has been identified. This
mechanism involves exosomes, which are small (30–200nm) mem-
brane vesicles of endosomal origin secreted by a variety of cell types,
such as reticulocytes, B lymphocytes and dendritic cells. In the present
study we investigated the capacity of cultured SGEC lines established
from SS patients and disease controls to release exosomal vesicles
that contain intracellular ribonucleoproteins. Membrane vesicles were
isolated by differential centrifugation from SGEC culture supernatants
and their nature was confirmed by electron microscopy. Cultured
SGECs from patients and controls secreted significant amounts of exo-
somal vesicles, in a manner largely indistinguishable from other exosome-
secreting cells. Exosome release was not associated with apoptosis or
other cellular destruction processes. SGEC-derived exosomes were
found by Western blot analysis to contain Ro/SSA, La/SSB, and Sm
ribonucleoproteins. Our results indicate that SGECs are capable of
secreting exosomes. This mechanism may represent a pathway through
which intracellular epithelial antigens are exported and subsequently pre-
sented to the immune system. In this context, exosomes produced by
epithelial cells may have a role in the pathogenesis of SS.
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Objective: Clinical data from patients who were positive for anticardi-
olipin antibodies (ACAs), tested on a routine basis in an autoimmune
laboratory, were obtained by questionnaires from the referring physi-
cians. One hundred and sixty-two individuals had experienced a recent
(within <6 months) thromboembolic event. All sera were tested for IgG
and IgM antibodies against cardiolipin, β2-glycoprotein 1 (β2-glp 1),
and the complex of phosphatidylserine/prothrombin (PPC) by in-house
ELISA methods.
Results: Among the 162 ACA-positive patients, 31 (19%) were also
positive for antibodies against PPC. In the group with ACA only, 73%
of the patients had no pre-existing rheumatic condition, compared with
32% in the PPC group (P=0.00002). Thirty-two percent in the PPC
group had SLE, vs 12% in the ACA group (P=0.016). The fractions of
patients with deep venous thrombosis (DVT), pulmonary embolism
(PE), or myocardial infarction (MI) were equal, whereas cerebrovascular
incidents (CVI) were more frequent among ACA patients; 51% vs 26%
(P=0.02). Antibodies against β2-glp 1 were also more frequent in the
PPC group 61% vs 30% (P=0.002).
Conclusion: Antibodies against both ACA and PPC seem to define a
subset of patients with autoimmune thrombophilia. More patients with
PPC antibodies had SLE and also tested positive for antibodies
against β2-glp 1. The distribution of thrombotic manifestations differed
between the two populations in that CVI was more frequent in the
ACA-only group, whereas the fractions with DVT, PE, and MI were
equal.
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Objective:  To correlate the distribution and levels of anticardiolipin
(ACA) and anti-β2-glycoprotein 1 (a-β2-glp 1) antibodies of IgG and
IgM isotypes to the clinical spectrum of recent (within <6 months)
thromboembolic events.
Method: During one year, all sera positive for IgG or IgM ACA submit-
ted on a routine basis from hospitals or primary-care physicians from all
parts of Denmark were recorded. Information about thromboembolic
events and any underlying rheumatic disease was obtained by ques-
tionnaires from the referring physicians. Sera were analysed for
IgG/IgM ACA and a-β2-glp 1 antibodies by in-house ELISA assays, and
the results were expressed in arbitrary units.
Results: One hundred and sixty-two patients fulfilled criteria for recent
thromboembolic disease. Cerebrovascular infarction (CVI) was present
in 82 patients, deep venous thrombosis (DVT) in 34, pulmonary
embolism (PE) in 14, myocardial infarction (MI) in 4, and other throm-
boses in 28 patients. Isolated IgG ACA was found in 31 of 48 patients
with DVT+PE (65%), but in only 21 of 82 patients with CVI (26%)
(P=0.00002). In contrast, isolated IgM ACA was found in 9 (19%) of
patients with DVT+PE, but in 46 (56%) CVI patients (P=0.00007).
IgG a-β2-glp 1 antibodies were found in 13 (16%) CVI patients and
23 (48%) DVT+PE patients (P=0.0002).
Conclusion: IgG and IgM ACA isotypes seem to define different clini-
cal subsets of patients with recent thromboembolic events, with IgG
ACA being most prevalent in the group having DVT+PE whereas IgM
ACA is found primarily among CVI patients. There was a linear correla-
tion between levels of IgG a-β2-glp 1 antibodies and IgG ACA.
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Objective: We have previously shown that inflammatory cytokines are
up-regulated in chondrocytes of osteoarthritis (OA) patients. However,
the inflammatory responses associated with OA are still ill defined. To
investigate in more detail the involvement of the immune system in the
pathogenesis of OA, we here analyzed patients for the presence of
autoantibodies.
Methods: Both sera and synovial fluids obtained from 85 OA patients
at the time of joint replacement were tested for autoreactivity. Autoanti-
bodies reacting against synovial membranes were detected performing
immunofluorescence on cryosections. Autoantibodies recognizing
lysate components of various cell lines (B-cell, T-cell, monocyte, fibrob-
last and chondrosarcoma) were shown by the use of Western blot
analyses. In preparation for the identification of the respective autoanti-
gens, we started to immunoprecipitate the proteins of interest.
Results: Sera from the OA patients reacted strongly with cells in the
synovial membranes whereas sera obtained from healthy donors did
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not (Fig.1). Furthermore, about 50% of the OA sera and none of the
control or RA sera reacted very strongly against lysate components of
the different cell lines tested. The corresponding synovial fluids reacted
against the same lysate components, but the signals obtained were of
reduced intensity.
Conclusion: Our results demonstrate the presence of autoantibodies
in sera and synovial fluid in about half the OA patients. The specificities
of these autoantibodies are not restricted to the joints, as reactivity was
detected towards any cell line tested. Hoping to design new diagnostic
tools and to shed light on the role of autoantibodies in the development
and progression of OA, we are in the process of identifying the corre-
sponding autoantigens.
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The antiphospholipid syndrome (APS) is characterized by the presence
of pathogenic autoantibodies against β2-glycoprotein I (β2GPI). The
factors causing production of anti-β2GPI remain unidentified, but an
association with infectious agents has been reported. We recently identi-
fied a hexapeptide (TLRVYK) that is recognized specifically by a patho-
genic anti-β2GPI monoclonal antibody. In the present study we evaluated
the APS-related pathogenic potential of microbial pathogens, which
share structural homology with the this hexapeptide. Mice were immu-
nized with a panel of TLRVYK-related microbial particles and were
studied for the development of mouse anti-β2GPI autoantibodies. Mouse
IgG specific to the TLRVYK peptide were affinity purified from the immu-
nized mice and passively infused i.v. into naive mice at day 0 of preg-
nancy. APS parameters were evaluated in the infused mice on day 15 of
pregnancy. Following immunization, high titers of anti-peptide, anti-β2GPI
antibodies were observed in mice immunized with Haemophilus influen-
zae, Neisseria gonorrhoeae or tetanus toxoid. Naive mice infused with
the affinity-purified anti-peptide antibodies had a significant thrombocy-
topenia, prolonged aPTT and elevated percentage of fetal loss, similar to
the findings in a control group of mice immunized with a pathogenic anti-
β2GPI monoclonal antibody. Our study establishes a mechanism of mol-
ecular mimicry in experimental APS, demonstrating that bacteria
homologous with β2GPI structure are able to induce the generation of
pathogenic anti-β2GPI antibodies along with APS manifestations.
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Using various FcγR-deficient mice, we have obtained suggestive evi-
dence that FcγRI on macrophages is responsible for severe cartilage
destruction during arthritis mediated by immune complexes (ICs) and
Th1 cells. In contrast, in arthritis mediated solely by ICs, FcγRIII seems
more important. This suggests that T-cell-mediated FcγRI up-regulation
promotes pronounced cartilage destruction. A likely Th1-cell-derived
cytokine mediating FcγRI expression is interferon-γ (IFN-γ).
In the present study we investigated whether IFN-γ is able to up-regulate
cartilage destruction during experimental immune complex-mediated arthri-
tis (ICA) and, if so, whether this mechanism is indeed regulated by FcγRI.
IFN-γ was locally overexpressed in the murine knee joint prior to ICA
induction by the use of adenoviral vectors. This had no significant effect
on joint inflammation as studied by histology. However, irreversible carti-
lage destruction as studied by the degree of chondrocyte death was
markedly enhanced. IFN-γ overexpression resulted in a fivefold increase
in chondrocyte death, in comparison with the control group, which had
received a control adenoviral vector expressing GFP (AdGFP).
To study whether this effect of IFN-γ was related to the presence of
ICs, IFN-γ was also overexpressed in a naive joint and during zymosan-
induced arthritis, which is an IC-independent arthritis model. No severe
cartilage destruction was found, implying a crucial role for ICs and their
receptors (FcγRs) in the IFN-γ effect.
When IFN-γ was overexpressed in murine knee joints, FcγRI mRNA
expression was up-regulated in synovial cells. To prove that the aggra-
vation of chondrocyte death by IFN-γ is indeed FcγRI-mediated, ICA
was raised in FcγRI–/–. IFN-γ overexpression did not result in significant
elevation of joint inflammation either in FcγRI–/– or their wild-type con-
trols. Interestingly, although IFN-γ was overexpressed, chondrocyte
death remained absent in FcγRI–/–, whereas in wild-type controls chon-
drocyte death was highly increased after IFN-γ overexpression.
These results indicate that IFN-γ can aggravate cartilage destruction in
an IC-dependent fashion, mediated by FcγRI.
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The diagnostic significance of autoantibodies in
patients with very early rheumatoid arthritis
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In the past few years, several novel autoantibodies (autoAbs) have
been described in patients with rheumatoid arthritis (RA), including an
autoAb to citrullinated antigens (anti-CCP) and anti-RA33 autoAb. It
was our aim to assess the value of these two autoAbs in relation to
rheumatoid factor (RF) in discriminating RA from non-RA in a cohort of
patients with very early arthritis.
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Figure 1
Immunofluorescence reveals the presence of autoantibodies in OA
sera. Cryosections of synovial membranes were incubated with
control (A) or OA (B) sera. The binding of autoantibodies was detected
via FITC-labeled anti human IgG antibodies (green). Fibroblasts were
stained with the specific antibody (5B5) and developed via SA-
rhodamine (red). Nuclei are counterstained using DAPI (blue). 
The full colour version of this figure can be viewed online at
http://arthritis-research.com/supplements/5/S1/13S6
Ninety-four patients with arthritis of less than 3 months’ duration were
included in this prospective study. Follow-up was for at least 1 year.
Sixty-one patients had a final diagnosis of RA and 33 had other arthri-
tides. Among the RA patients, RF was present in 34 (56%), anti-CCP
in 18 (30%), and anti-RA33 in 15 (25%) at their first visit. Among
the 33 non-RA patients, 6 were RF-positive, 3 had anti-RA33, and
1 had anti-CCP. Thus, anti-CCP was very specific for RA with a posi-
tive predictive value (PPV) of 95%, while RF and anti-RA33 were
somewhat less specific, with PPVs of 85% and 83%, respectively.
However, the co-occurrence of anti-RA33 and RF was observed exclu-
sively in RA patients and thus had a PPV of 100% in this relatively
small cohort of patients. In conclusion, these data suggest that the
determination of autoantibodies such as anti-CCP and anti-A2/RA33 in
addition to RF may be quite helpful in the early diagnosis of RA.
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Peptidylarginine deiminases (PADs; EC 3.5.3.15) are a family of
calcium-dependent enzymes that convert peptidylarginine into peptidyl-
citrulline. The recent finding that patients with rheumatoid arthritis (RA)
produce autoantibodies against citrulline-containing epitopes greatly
increased the interest in the PAD enzymes and their activities. It is not
yet known whether there is a causative relationship between the gener-
ation of antibodies targeting citrullinated epitopes and the development
of the disease. Characterisation of the structure and function of PADs
may help to understand the production process of citrullinated antigens
and possibly also the aetiology of RA.
Several assays are known to monitor PAD activity in biological
samples. However, these assays either have a low sensitivity or are
laborious. Here, we describe the development of a simple, rapid
method for the simultaneous analysis of many PAD-containing samples.
This new method is based on the binding of an antibody specifically
recognising a citrulline-containing epitope in a defined peptide. We
show that this method is very sensitive and can be applied to monitor
PAD activity in many types of biological samples, such as bacterial
lysates, mammalian cell extracts and tissue extracts.
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Background and objectives: Autoantibodies to deiminated proteins
are known to be the most specific serological marker for the diagnosis
of rheumatoid arthritis (RA). We recently showed that deiminated fibrin
is the major target of this family of autoantibodies in rheumatoid syn-
ovial tissue. We subsequently developed, and validated on a large
series of patients with established rheumatic diseases, an ELISA for
the detection of circulating autoantibodies to deiminated human fibrino-
gen (AhFibA). The test was shown to be the most efficient (specific
and sensitive) serological criterion for the diagnosis of RA.
Methods: We collected 352 sera from patients with arthritides of
recent onset (disease duration <1 year). The diagnosis was estab-
lished after at least 2 years’ follow-up. The patients were then classified
into two groups, 175 with RA and 177 with non-RA inflammatory
rheumatic diseases. The previously developed ELISA, using in vitro
deiminated human fibrinogen as immunosorbent, was used for detec-
tion and titration of AhFibA. Antibodies to cyclic citrullinated peptide
(CCP) were sought in accordance with the manufacturer’s procedure
(Immunoscan RA, Euro-diagnostica). Rheumatoid factor (RF) was
titrated by nephelometry (RF-reagent for Image, Beckman Coulter).
Results: The diagnostic sensitivity of AhFibA was found to be signifi-
cantly higher than those of CCP (P<0.05) and RF (P<0.001)
(Table 1). The positive predictive values (PPV) of the three tests were
all found to be very high and were not significantly different. The nega-
tive predictive values (NPV) were too low to be diagnostically useful.
Among the AhFibA-positive RA sera 83% were RF-positive, while
among the AhFibA-negative, only 13% were RF-positive.
Table 1
Diagnostic indices computed at thresholds allowing 0.985 specificity to
be reached
Antibodies to Se PPV
AhFibA 0.646 0.974
CCP 0.543 0.969
RF 0.274 0.941
PPV, positive predictive value.
Conclusion: Unlike the case with RF, autoantibodies to deiminated
proteins are confirmed to be of diagnostic value in early arthritides. The
detection of these autoantibodies by ELISA using their synovial target
(deiminated fibrin) appears the most efficient method for the diagnosis
of early RA.
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Background: We have implicated the human chaperone protein BiP in
the pathogenesis of rheumatoid arthritis (RA). Increased immunoglobu-
lin binding of RA sera to BiP is seen on Western blot analysis.
Methods:  We now describe an ELISA developed to enable rapid
screening of sera for antibody reactivity to BiP.
Results: Specificity of the assay has been shown by free ligand com-
petition and extensive correlations with other immunological parame-
ters. We show no correlation between anti-BiP and rheumatoid factor
or with cyclic citrullinated peptide. We confirm the increased binding of
immunoglobulin to BiP in the sera of a group of patients with RA
(n=96) in comparison with controls (n=96). Our data show a speci-
ficity of 71% and a sensitivity of 73% for RA. Furthermore, these data
show that antibody will bind to a nonglycosylated form of BiP, since the
protein is produced in an Escherichia coli expression system.
Conclusion: We have developed a robust protocol for the detection of
antibodies to the human chaperone molecule BiP. Our data show an
elevated antibody response to BiP in RA patients and hence support a
role for this molecule in the disease.
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Antineutrophil cytoplasmic antibodies in synovial
fluid from patients with early rheumatoid arthritis
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Background: Antineutrophil cytoplasmic antibodies (ANCAs) occur in
vasculitides, including Wegener’s granulomatosis and Churg-Strauss
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syndrome. Their presence in sera of patients with some other
rheumatic diseases has been well documented. ANCAs have also
been detected in synovial fluid (SF) of patients with RA; however, their
presence and potential role in early stages of the disease is not known.
Objective: The aim of the study was to evaluate the prevalence and
specificity of ANCAs in SF in early RA.
Methods: SF samples were obtained from 114 patients with early RA.
Control SF were taken from 76 patients with knee osteoarthritis (OA).
ANCAs were detected by indirect immunofluorescence and by ELISA.
Proteinase 3, myeloperoxidase, elastase, lactoferrin and lysozyme, as
well as cathepsin G, were used as antigens in ELISA method. At the
same time antinuclear antibodies (ANAs) and rheumatoid factor (RA)
were detected in SF samples under study.
Results: ANCAs were found by indirect immunofluorescence in SF of
26/114 (22.8%) patients with early RA and 2/76 (2.6%) patients with
OA. A perinuclear pattern (p-ANCA) was detected in 22/26 cases
(84.6%), and atypical pattern (a-ANCA) in 4/26 (15.3%). In patients
with OA, p-ANCAs only were observed. We did not observe a cyto-
plasmic pattern (c-ANCA) in indirect immunofluorescence or in the
reactivity against proteinase 3 in ELISA. p-ANCAs yielded reactivity
against lactoferrin in SF from 15/26 (57%) and against myeloperoxi-
dase in 5/26 (19.2%) SF samples from RA patients. a-ANCAs indi-
cated reactivity against cathepsin G in 3/26 cases (11.5%) and
against lysozyme in 1/26 (3.8%). RF was present in 18/26 (69.2%)
and ANA in 14/114 (12.2%) SF samples from patients with RA.
Conclusion: ANCAs are present in SF of over 20% of patients with
early RA We think that these antibodies in SF could be one of the early
RA markers. Their role in this stage of synovitis should be clarified.
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levels in recently diagnosed RA patients
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Objective: Antibodies against both type II collagen and citrulline
residue containing peptides can be found in rheumatoid arthritis (RA)
patients. We have noted that serum levels of both anticollagen and
anticitrulline antibodies show significant decline after inclusion in an
early arthritis clinic (EAC) cohort, and wanted to compare their kinetic
patterns of disappearance.
Methods: Two hundred and fifty-five EAC patients and 80 RA patients
were followed for 1 and 5 years, respectively, from the time of initial
referral. Anticollagen and anticitrulline antibodies were determined with
ELISA at inclusion and after 3 months and 1, 2, 3 and 5 years.
Results: At the patients’ inclusion, anticollagen and anticitrulline anti-
bodies were found in 6.3% and 48.2%, respectively, of EAC patients
and in 11.5% and 61.0% of the patients with definite RA. Serum levels
of antibodies against type II collagen declined continously for the entire
study period in both groups, being significant already at 3 months after
inclusion. Serum levels of anticitrulline antibodies, on the other hand,
showed a biphasic pattern. A significant decline from inclusion (for EAC
patients at 1 year, and for RA patients at 3 months and at 1 and 2 years)
was followed by increased serum levels (significant for RA patients
between 2 and 5 years). No correlation was found between changes in
serum levels of anticollagen and anticitrulline antibodies at any time.
Conclusion: These findings suggest that different immunological
events predispose to immunity against collagen type II and against cit-
rulline-containing peptides in RA.
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The Ro60kD polypeptide is associated with both RNA and the Ro52kD
protein. The specific protein–RNA and protein–protein interactions are
thought to occur through the RNP and zinc-finger secondary structure
elements located on the 92–161 and 301–327 regions of Ro60kD
protein, respectively. The zinc finger domain of Ro60kD is a good can-
didate to hold a conformational epitope, because both the binding of
zinc and the redox conditions can induce specific conformational
changes. In this study, we investigated the presence of antibodies
against synthetic peptides corresponding to the zinc finger domain of
Ro60kD protein (Zif-1b), to a truncated form possessing zinc-binding
regions but lacking the intermediate loop (Zif-2b) and to the intermedi-
ate loop (310–319) of the zinc finger domain (Zif-3b). We found that
the peptide Zif-1b, corresponding to the native sequence (301–327
aa) of Ro60kD, is recognized by antibodies from the majority (83%) of
anti-Ro/La-positive patients with primary Sjögren’s syndrome (pSS), in
the absence of zinc ions. The same sera failed to react with Zif-1b in
the presence of Zn2+ (2.5%). Its truncated form (Zif-2b) did not react
against the same sera, while the peptide corresponding to loop
310–319 (Zif-3b) exhibited high reactivity (85%). The presence of zinc
ions was necessary for binding of Zif-1b to recombinant Ro52kD, indi-
cating that discrete conformational states of the Ro60kD zinc finger
domain are employed in interaction with Ro52kD protein and autoanti-
bodies. The two different states of the zinc finger domain of Ro60kD
may reflect the existence of the Ro60kD autoantigen in different redox
environments (e.g. in the interior of the cell and cell membrane), where
the Cys residues have different capacities to coordinate zinc ions.
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Introduction: In rheumatoid arthritis (RA), the synovial membranes
contain lymphocytic infiltrates sometimes resembling germinal centres.
The production of clonally related immunoglobulin (Ig) transcripts, the
presence of plasma cells within RA synovial tissue, somatic mutations
and isotype switching in RF-specific synovial B lymphocytes have been
observed. In addition, the expression of recombination-activating
genes 1 and 2 (Rag1 and 2) has been detected in RA synovial B cells.
Objective:  Analysis of the presence of plasma cells, mutational fre-
quencies of their Ig heavy-chain transcripts, the signs of isotype switch-
ing and expression of Rag1 and 2 genes in inflamed RA synovial tissue.
Methods: Synovial tissue sections were labeled with anti-CD19, anti-
CD138 and anti-CD38 antibodies and visualized using the alkaline
phosphatase technique. Individual CD19+ CD38+ plasma cells were
isolated from digested synovium of two caucasian RA patients using
single-cell deposition. The cDNA from each single B cell was gener-
ated, and nested polymerase chain reaction specific for VH genes and
Rag1 and Rag2 genes was performed. After sequencing, the VBASE
database was used to assign VH, DH and JH gene segments and
somatic mutations.
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Results: Three different subsets of CD19+ CD38+ plasma cells were
detected. The first subset represents cells expressing only IgM tran-
scripts (IgM+, 13.5%), the second expressed only IgG transcripts
(IgG+, 48.7%) and the third produced both IgM and IgG mRNAs (IgM+
IgG+, 37.8%). All of these detected IgVH mRNAs contained mutated
sequences, indicating their memory cell origin. However, the differ-
ences of mutational frequencies between these subsets were statisti-
cally significant (IgM+ plasma cells 3.8%, IgG+ plasma cells 11.2% and
IgM+ IgG+ cells 6.3%). Interestingly, either Rag1 or Rag2 mRNA was
observed in 83.3% of all analyzed CD19+CD38+ plasma cells, with
the highest frequency in the IgM+ IgG+ subset of plasma cells (71.4%).
Conclusion: The population of CD19+ CD38+ plasma cells differentially
expressing mutated IgVH mRNAs and reinducing Rag 1 and 2 genes
was observed in RA synovium. The IgM+ IgG+ cells might represent cells
switching from IgM to IgG isotype and IgG+ plasma cells might corre-
spond to post-switched cells producing high-affinity (auto)antibodies.
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peptide (CCP) to predict rheumatoid arthritis in
patients with early arthritis
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Objective: We previously studied the diagnostic value of biological tests in
RA and found that IgG-AKA, first generation of anti-CCP, IgM-RF by
ELISA, and the latex test is the best combination in diagnosing RA. The
goal of the present study was 1) to study the diagnostic value of the
second generation of anti-CCP and 2) to determine the diagnostic value of
second-generation anti-CCP used in combination in the same population.
Methods: A cohort of 270 patients with early arthritis underwent a stan-
dardized examination, laboratory tests and radiographs in 1995–1997.
The final diagnosis was evaluated by a panel of five rheumatologists
between June and December, 1999. The respective diagnostic values
of antiperinuclear factor, antikeratin antibody, and anti-CCP (commercial
kits: Eurodiagnostica first generation [EFG], Eurodiagnostica second
generation [ESG], and Axis-Shield [AS]) carried out on sera taken at the
patients’ first visit in discriminating between patients who did (98/270;
36%) and did not have RA at the last visit was evaluated using receiv-
ing-operator characteristic curves. To evaluate the combination of anti-
CCP with other laboratory tests in discriminating between patients with
and without RA, a multiple logistic regression with backward selection
using the likelihood ratio test was applied.
Results: 1) Anti-CCP, APF and IgG AKA were not perfectly correlated
with each other. For anti-CCP EFG (cutoff 53UI), ESG (cutoff
0.120OD), and AS (cutoff 0.320OD), sensitivity and specificity were
47%–93%, 57%–94% and 58%–94%, respectively. 2) By the use of
a multiple logistic regression, second generation anti-CCP, IgG-AKA,
the latex test and IgM-RF ELISA were selected.
Conclusion: ESG and AS are the best tests for predicting RA. Com-
bining one of these tests with IgG-AKA, IgM-RF, and the latex test
slightly increases the diagnostic value.
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The autoantigen hnRNP-A2 (RA33) is targeted by autoantibodies
(autoAbs) of patients with rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE) and mixed connective tissue disease (MCTD).
To define the humoral autoimmune response in more detail, a series of
overlapping peptides covering the N-terminal part hnRNP-A2 known
to harbour the major epitopes was studied by ELISA in sera from
patients with SLE (n=40), RA (n=50), MCTD (n=11) and other
rheumatic diseases (n=86) and from healthy subjects (n=29). Anti-
peptide reactivities were detected in 25% of SLE sera but only rarely
in patients with RA or MCTD. Since most of the SLE patients investi-
gated had inactive disease, we next studied sequential sera of 15 indi-
vidual patients. Of those, only three patients were completely negative
for hnRNP-A2 antibodies, while all the other patients showed at least
one positive reaction during the observation period. These were
directed to the full-length protein and/or to 4 of the 13 peptides used:
p35–55, p50–70, p90–116 and p155–175. Interestingly, autoreactiv-
ities to the first three peptides were significantly associated with each
other but not with reactivity to p155–175 or to the complete protein.
This cluster of reactivity was also not linked to any clinical marker of
disease. In contrast, p155–175 was strongly correlated with reactivity
to the complete protein (P<0.001) and both reactivities were associ-
ated with autoAb to dsDNA and correlated significantly with clinical
disease activity, skin involvement and proteinuria (P<0.01). Remark-
ably, immunohistochemical analysis revealed overexpression of
hnRNP-A2 in affected skin of SLE patients. These data, together with
previously published findings in murine SLE models, are suggestive of
an involvement of hnRNP-A2 autoimmunity in the pathogenesis of
SLE.
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For a long time, detailed mechanisms of immune-complex-mediated
vasculitis have been unknown. The advent of gene knockout technol-
ogy and the characterization of the various Fc and complement recep-
tors as well as cytokines now allows the various pathogenetic elements
in vasculitic inflammation to be distinguished.
Using various murine knockout models, in particular Fcγ-receptor-defi-
cient animals, mast-cell-defective animals, and complement-deficient
animals in recent years, we have shown that FcγRIII and C5a receptor
are critical for induction of immune-complex-mediated vasculitis. In
several studies, it became clear that mast cells have a critical role in the
initiation of the inflammatory process. On these mast cells, again the
FcγRIII is a critical activating receptor used by immune complexes.
When examining the effects of immune complexes in glomerular
mesangial cells and GBM nephritis, we showed that IgG immune com-
plexes had opposing regulatory effects on FcγRII and FcγRIII receptors
in glomerular mesangial cells. Whereas activation by TNF-α/IL-1β
induces substantial FcγRII expression, IFN-γ showed a complete down-
regulation of FcγRII. At the same time, IFN-γ induced the Fc receptor
γ-chain as well as the low-affinity IgG receptor FcγRIII. Triggering of
FcγRIII again induced chemoattractant protein 1, MCP-1, MCP-5 and
RANTES.
Examining the regulatory role in the cooperation of Fcγ receptors and
complement, we showed that C5a is critical in amplifying the inflam-
matory response to IgG. C5a is important on the one hand in down-
regulating FcγRII, and on the other hand in inducing the activating
FcγRIII.
Altogether, distinguishing the various components of vasculitis patho-
genesis allows for new strategies to intervene in this inflammatory
process.
Arthritis Research & Therapy    Vol 5 Suppl 1 Abstracts of the 23rd European Workshop for Rheumatology ResearchS9
27
Linear epitopes of two different autoantigens (La/SSB
and myelin basic protein) with a high degree of
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Backgkround: Sequences 147–154aa of La/SSB and 139–146aa of
human myelin basic protein (MBP) present 83% sequence similarity.
Objective: We investigated the immune response of both epitopes in
rabbits and in sera from patients with autoimmune diseases.
Methods: Peptides 147–154aa of La/SSB and 139–146aa of MBP
were used for immunizations of New Zealand White rabbits. Spreading
to the other epitopes of La/SSB (289–308aa, 349–364aa) as well as
the recombinant human MBP (hMBP) and La/SSB (recLa) was identi-
fied using ELISA assays. Sera from 49 patients with systemic lupus
erythematosus (SLE), 44 patients with Sjögren’s syndrome (pSS),
and 18 with rheumatoid arthritis (RA) with anti-Ro\La reactivity were
tested against the two peptides and the hMBP.
Results: Rabbits immunized with the La epitope developed early anti-
bodies against all three La/SSB peptides, hMBP, and recLa. In con-
trast, rabbits immunized with the MBP peptide developed a late
immune response to other La epitopes, hMBP, and recLa. Inhibition
experiments using the MBP peptide as inhibitor against the hMBP
showed that the 79% of reactivity was abolished, indicating that this
peptide is the major antibody target in MBP. Twenty percent of pSS,
27% of SLE, and none from RA patients reacted with the 147–154aa
La epitope; 28% of pSS, 22% of SLE, and 17% of RA sera reacted
with the MBP peptide. Finally, 17% of pSS, 37% of SLE, and 30% of
RA sera reacted with the hMBP.
Conclusion: La 147–154aa peptide when used for animal immuniza-
tions can induce immediate epitope spreading while the mimicking
epitope MBP 139–146aa induces a delayed response against the other
La epitopes. A significant proportion of human sera reacted with both
peptides and hMBP. Thus, despite the fact that these two peptides
present molecular similarity, they induce different immune responses.
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Background: Early intervention in rheumatoid arthritis (RA) reduces
long-term disability. However, early diagnosis of RA can be difficult, as
the disease may initially be indistinguishable from other forms of arthri-
tis. Recent studies indicate that autoantibodies can be detected years
before clinical symptoms develop. In a cohort with recent-onset arthri-
tis, we aimed to assess the value of autoantibodies in predicting the
development of RA in patients with undifferentiated arthritis (UA).
Methods: IgM rheumatoid factors (IgM-RF) and anti-cyclic citrullinated
peptide (CCP) antibody tests were performed at baseline in 936 con-
secutive, newly referred patients with recent-onset arthritis. Two weeks
after inclusion arthritis, patients who could not be properly classified
were categorized as UA. Patients with UA were followed for 3 years
and evaluated for progression to RA.
Results: At 2 weeks, 346 of 936 patients (37%) with recent-onset
arthritis were classified as having UA. After 3 years of follow-up, 127
UA patients (40%) had progressed to RA. However, RA had devel-
oped in 64 of 69 UA patients with a positive anti-CCP test, giving a
positive predictive value (PPV) of 93% and a negative predictive value
(NPV) of 74%. Progression to RA was observed in 51 of 68 UA
patients with IgM-RF antibodies at baseline (PPV 75%, NPV 70%).
Conclusion: Up to 3 years before a diagnosis of RA was made,
autoantibodies were detected in patients with UA. Detection of anti-
CCP antibodies had a high predictive value for the progression to RA.
Thus, screening for anti-CCP antibodies in UA allows physicians to
predict progression to RA.
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Autoantibodies to GPI are predominantly present in
extra-articular complications of human rheumatoid
arthritis
FA van Gaalen, REM Toes, HJ Ditzel, M Schaller, CL Verweij,
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Several years ago, Benoist et al. described in Cell a T-cell transgenic
mouse that spontaneously developed severe arthritis (KRN model).
Subsequent reports demonstrated that in this model, disease is caused
by antibodies against glucose-6-phosphate isomerase (GPI).
A link between this mouse model and human disease was made when
Schaller et al. reported that antibodies against GPI are present in 64%
of human rheumatoid arthritis (RA) (Nat Immunol 2001). However, this
finding remains controversial, since several other groups could not
reproduce these results. Given these apparently conflicting findings,
we hypothesized that GPI antibodies are present in a specific subset of
RA patients and set out to determine at what point autoantibodies to
GPI occur in RA. GPI antibodies were detected in only few sera of of
uncomplicated RA (2%)and healthy controls (3%). However, in RA
patients with disease manifestation outside their joints, GPI antibodies
were more common. 18% of RA patients with skin inflammation
(rheumatoid nodules) and 45% of RA patients with vascular inflamma-
tion had anti-GPI antibodies. Yet, in RA patients with arthritis compli-
cated by decreased numbers of circulating granulocytes (Felty’s
syndrome) 92% had GPI antibodies. But, since the GPI antigen was
not detected on RA granulocytes, we propose that GPI antibodies are
not likely to be directly involved in granulocyte destruction.
In summary, we conclude that anti-GPI antibodies that cause disease
in the KRN mouse model are common in human RA complicated by
inflammation outside the joint, demonstrating the relevance of the
mouse model to human disease.
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Citrullination of synovial proteins in murine models
of rheumatoid arthritis
E Vossenaar, S Nijenhuis, MM van Helsen, A van der Heijden,
WB van den Berg, WJ van Venrooij, L Joosten
Department of Biochemistry, University of Nijmegen, Nijmegen, The
Netherlands
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Antibodies directed to citrulline-containing proteins are highly specific
for rheumatoid arthritis (RA) and can be detected in up to 80% of RA
patients. Citrulline is an unnatural amino acid that can be incorporated
into proteins only by post-translational modification of arginine by pep-
tidylarginine deiminase (PAD) enzymes. We investigated the presence
of anticitrulline antibodies, PAD enzymes and citrullinated antigens in
an acute and a chronic destructive mouse model for arthritis: strepto-
coccal-cell-wall arthritis and collagen-induced arthritis. In both mouse
models, PAD2 mRNA is present in the synovium but not translated into
PAD2 protein. In contrast, PAD4 mRNA, although absent from healthy
synovia, is readily transcribed and translated by polymorphonuclear
neutrophils infiltrating the synovial tissue during inflammation. As a con-
sequence, several synovial proteins are subjected to citrullination. One
of these proteins was identified as fibrin, which has been reported to
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be citrullinated also in the synovia of RA patients. Although the genera-
tion of citrullinated antigens during synovial inflammation in the mice
was eminent, no anticitrullinated protein antibodies could be detected.
In conclusion, the citrullination of synovial antigens is an active process
during joint inflammation both in mouse and man, but the induction of
autoantibodies directed against these proteins is a more specific phe-
nomenon detectable only in RA patients.
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Fibrinogen-specific T cells in rheumatoid arthritis
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Rheumatoid arthritis (RA) is characterized by the occurence of autoreactive
antibodies and T cells. The family of antibodies directed to citrulline-contain-
ing antigens (anti-filaggrin, anti-CCP and anti-Sa) have the highest speci-
ficity (>98%) for RA. To investigate the presence of citrulline-specific
T cells in RA patients, we analyzed T-cell reactivity to unmodified and citrul-
linated filaggrin and fibrinogen in modified T-cell proliferation assays.
No T-cell responses were observed when either unmodified or citrulli-
nated filaggrin was used as the stimulating antigen in serum-free T-cell
proliferation assays. With unmodified fibrinogen, however, T-cell prolifer-
ation was observed in 8/15 (53%) of RA patients, while only 1/14
control patients (SLE, SSc, PsoA, Sjö) displayed clearly positive T-cell
proliferation. The difference was highly significant (P<0.0001). These
findings were even more pronounced when using citrullinated fibrinogen
as stimulating antigen: 10/15 (67%) RA patients were positive for T-cell
proliferation and again only 1/14 control patients was clearly positive
(P<0.0001). T-cell reactivity in RA patients was significantly (P<0.05)
higher against citrullinated as compared with unmodified fibrinogen.
We conclude that fibrinogen (citrullinated or not) can induce proliferation
of RA T cells, thereby further substantiating its pathogenic relevance.
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Elevated anti-serum amyloid P component (SAP)
antibodies in SLE patients
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Background: Serum amyloid P component (SAP) binds to DNA and
chromatin and plays a role in the clearance of apoptotic debris. One
postulated mechanism in the dysregulation of the immune system in
systemic lupus erythematosus (SLE) is the aberrant clearance of apop-
totic cells. We hypothesize that binding of SAP to anti-SAP antibody
may alter SAP function.
Objective: The aim of the study was to determine the presence of anti-
SAP antibodies in SLE patients and investigate the correlation with
clinical disease.
Methods: Samples from 481 subjects (357 SLE patients, 124 normal
controls) were screened for the presence of elevated anti-SAP anti-
body titers by the ELISA method (optical density 405nm above 3SD
were considered elevated). Clinical parameters and SLEDAI scores
were assessed from the review of files.
Results: Elevated anti-SAP antibody titers were detected in 47% of
SLE samples, versus 2% of the control group. In a representative
group (n=112), 62% of patients had elevated anti-SAP antibodies and
anti-dsDNA antibody titers. SLEDAI scores were assessed in 83
patients, of whom 54% had elevated anti-SAP antibody titers: 59%
had a SLEDAI score of at least 8, an indication of severe disease. The
distribution of 35 clinical manifestations in 34/135 patients with ele-
vated anti-SAP antibody titers did not reveal a specific pattern. Serial
sampling of two representative SLE patients revealed a decrease in
anti-SAP antibody titers after treatment with IVIg that correlated with a
decrease in anti-dsDNA antibody titers and with clinical improvement.
Conclusion: Elevated anti-SAP antibody titers were detected in SLE
patients and correlated with disease activity. In SLE patients, elevated
anti-SAP antibody titers may serve as an additional diagnostic and
prognostic marker.
Cytokines
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Clinical and immunological effects of anti-TNF
therapy in systemic lupus erythematosus (SLE)
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Background: Tumor necrosis factor (TNF) is increased in the sera of
patients with SLE and in lupus glomerulonephritis and is associated
with disease activity. We investigated clinical and immunological out-
comes in a pilot trial of TNF blockade in SLE.
Methods: Within an open safety study, SLE patients with nephritis or
arthritis receive the humanized chimeric anti-TNF antibody infliximab plus
azathioprine or methotrexate. Serum TNF (sTNF)was measured by
ELISA, the percentages of TNF-positive lymphocytes by fluorocytometry.
Results: In the first two lupus nephritis patients treated with infliximab,
proteinuria fell from 1.2 to 0.3g/24h and from 5.7 to 1.1g/24h,
respectively, within 3 months after the start of therapy; the (normal) cre-
atinine serum levels remained stable. Arthritis in a third SLE patient
remitted under therapy but relapsed 8 weeks after the last infusion.
Anti-dsDNA IgG antibodies increased transiently in all three patients at
around week 10 of therapy. An increase in anti-histone antibodies (as
well as anti-chromatin antibodies in two of the three patients) predated
the increase in anti-dsDNA, which was not associated with increased
disease activity. Interestingly, even the increase in anti-histone antibod-
ies was predated by an increase in sTNF (mean±SD of peak value
168±114pg/ml), while the percentage of lymphocytes carrying TNF
decreased at the same time.
Conclusion: Anti-TNF therapy improves SLE glomerulonephritis and
arthritis but leads to a transient increase in autoantibodies, which was
not associated with flares in our patients. The observation that anti-
dsDNA antibodies are predated by anti-histone antibodies and that this
increase follows the changes in TNF suggests that TNF-blocking
therapy is directly associated with an increase in anti-histone and a
subsequent transient increase in anti-dsDNA antibodies.
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Therapy with soluble TNF receptor (etanercept) induces
apoptosis in rheumatoid arthritis (RA) synovium
AI Catrina, C Trollmo, J Lampa, E af Klint, Y Hermansson,
L Klareskog, A-K Ulfgren
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Objectives: This study evaluates modulation of rheumatoid arthritis
(RA) synovial apoptosis by therapy with the soluble tumor necrosis
factor (TNF) alpha receptor (etanercept).
Methods: Apoptosis (TUNEL [transferase-mediated UTP end labeling]
combined with morphology), cell-surface markers (CD3, CD68,
CD163, Fas), FLIP and granzyme B were evaluated by immunohisto-
chemistry in synovial biopsies from 12 RA patients before and after
8 weeks of treatment with etanercept. Moreover, the in vitro effect of
etanercept on FLIP expression and on the death of mononuclear cells
(MNCs) derived from synovial fluid (SF) was determined in five RA
patients by flow cytometry.
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Results: Etanercept treatment increased synovial apoptosis and
decreased the number of CD68-positive and CD163-positive mono-
cyte/macrophages and FLIP expression (P<0.05). No significant
changes were observed for the expression of CD3, Fas and
granzyme B. In vitro, low concentrations of etanercept (1 and 10µg/ml)
increased cell death (P<0.05) in the SF CD14-positive monocyte/
macrophage population after 24 hours’ incubation, while higher con-
centrations (100µg/ml) had no effect. FLIP expression in this popula-
tion did not change after in vitro culture with either low or high doses.
The in vitro culture with etanercept did not induce any changes in FLIP
expression or apoptosis level in SF CD3-positive cells.
Conclusion: Therapy with etanercept at clinically relevant concentra-
tions increased RA synovial monocyte/macrophage apoptosis, sug-
gesting an alternate pathway to explain the decrease in synovial
cellularity observed after anti-TNF therapy.
35
The effect of methotrexate and mycophenolic acid on
monokine production in vitro
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Methotrexate (MTX) and mycophenolic acid (MPA) are used clinically
for their immunosuppressive properties. MTX is widely used for the
treatment of RA. MPA is used to prevent graft rejection and is now
experimentally used in SLE and RA. The precise mechanism of action
is still debated. Both drugs, though in different ways, inhibit the
de novo synthesis of DNA and RNA. We have analysed cytokine pro-
duction in short cell cultures in whole blood and isolated cells by
ELISA. We have shown before that both drugs inhibit the production of
several cytokines after T-cell stimulation, and we concluded that MTX
leads to irreversible elimination of activated T cells by apoptosis,
whereas MPA reversibly prevents activation of resting T cells.
We now show that when monocytes are stimulated by SAC or
lipopolysaccharide, both MTX and MPA decrease TNF-α, IL-6 and IL-8
production. However the inhibition is not as profound as after T-cell
stimulation. An exception is the effect on the production of the proin-
flammatory cytokine IL-1β. The production of IL-1β is not influenced by
MTX after SAC or LPS stimulation, whereas the production is increased
by MPA when cells are stimulated with LPS, but not with SAC. We have
investigated the cause for this increase. The expression of IL-1β mRNA
is not influenced by MPA. Immunoprecipitation and ELISA show that
MPA leads to a decrease in the intracellular pro- form of IL-1β. We con-
clude that MPA leads to enhanced cleavage of pro-IL-1β.
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Changes in rheumatoid factor reflect the inflammatory
response (CRP and ESR) to infliximab treatment
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Background: We showed previously that there is a reduction in both
rheumatoid factor (RF) Waaler Rose (WR) and RF latex fixation (LF)
titres after infliximab treatment, but that no differences are seen for anti-
cyclic citrullinated peptide antibodies.
Objectives: To analyze changes in C-reactive protein (CRP) and ery-
throcyte sedimentation rate (ESR) in relation to changes in RF.
Patients and methods: Sixty-two patients with refractory rheumatoid
artritis (RA) were treated with infliximab in an early-access program.
They received 3mg/kg infliximab IV at weeks 0, 2 and 6 and every
8 weeks thereafter in combination with methotrexate. Serum samples
were obtained at baseline and at week 30 and tested for RF WR, RF
LF, CRP and ESR. For statistical analysis, Mann–Whitney tests were
used. P-values ≤0.05 were considered significant.
Results: Patients with an increase in RF WR titre (n=9) were likely to
have an increase in CRP (median CRP increase of 0.59mg/dl) and
ESR (median ESR increase of 9mm/h), whereas patients with no
increase in RF WR titre (n=53) were more likely to have a decrease in
CRP (median CRP decrease of 0.89mg/dl) and ESR (median ESR
decrease of 5.5mm/h) during infliximab treatment. The changes in CRP
and ESR were significantly different when comparing patients with an
increase in RF WR titre and patients with no increase in RF WR titre
(P=0.046 for CRP and P=0.032 for ESR). When additionally also the
RF LF titre increased in the group of patients with an increase in RF
WR titre, all patients (n=3) had an increase in CRP (median CRP
increase of 2.3mg/dl) and ESR (median ESR increase of 16mm/h).
Conclusion: After infliximab treatment, RA patients with an increase in
RF WR titre are more likely to have increased inflammatory parameters,
in comparison with patients who had no increase in RF WR. Especially
when both RF titres increased, an increase of CRP and ESR was
present in all patients.
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Promoter polymorphisms in the IL-18 gene are
associated with rheumatoid arthritis in two
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JA Gracie1, N Koyama2, M Field1, F McGarry1, A Schobel2,
IB McInnes1, B Moller2
1Centre for Rheumatic Diseases, University of Glasgow, Glasgow, UK
2Rheumatology, University of Frankfurt, Frankfurt, Germany
Arthritis Res Ther 2003, 5 (suppl 1):37
Introduction: IL-18 in synovial tissues of patients with rheumatoid
arthritis (RA) promotes local inflammation via effects on innate and
adaptive immune responses. Promoter polymorphisms may modulate
IL-18 expression. Using two independent clinical cohorts, we deter-
mined the frequency of single nucleotide polymorphisms (SNPs) in the
IL-18 promoter for RA patients.
Methods: DNA was extracted from peripheral blood mononuclear cells
of 102 RA patients and 114 healthy donors in Frankfurt and from 153
RA patients and 187 healthy donors in Glasgow. In Frankfurt, DNA was
amplified by polymerase chain reaction (PCR) and the presence of
IL-18 SNP at positions -607 and -137 was determined by the restric-
tion fragment length technique. Independently, in Glasgow, allele-spe-
cific PCR was performed for the same SNP sites.
Results: Frankfurt cohort: The -607 C and -137 G alleles were signifi-
cantly more frequent in the RA population. Highly significant associa-
tions (P<0.001) for RA were found for the homozygous C genotype in
positions -607 and -137. Glasgow cohort: The -137 C allele was more
frequent in RA patients (P<0.01), but no effect was seen at position -
607. Moreover, the -137CC genotype was more frequent in RA
(P<0.01). However in contrast to the Frankfurt dataset, no effect was
seen at the -607 site.
Conclusion: SNPs at the -137 position in the IL-18 promoter appear to
contribute to the genetic background in RA pathogenesis. Importantly,
this has been independently identified in two clinical cohorts, by the
use of distinct methodologies, in Germany and the UK. IL-18 is a
promising therapeutic target and, as such, defining factors that modu-
late its regulation in rheumatoid tissues is important.
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Combination of the proinflammatory cytokines IL-1,
TNF-α α and IL-17 leads to enhanced expression and
additional recruitment of AP-1 family members, Egr-1
and NF-κ κB in osteoblast-like cells
C Granet, P Miossec
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Objectives: To determine the contribution of IL-1, TNF-α and IL-17 on
AP-1, NF-κB and Egr-1 activation in cytokine-induced bone destruction
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as in rheumatoid arthritis, we investigated the effect of these proinflam-
matory cytokines on transcription factor activation in osteoblasts.
Methods: Osteoblast-like ROS 17/2.8 cells were cultured with IL-1,
TNF-α and IL-17 alone and in combination. Effects of each cytokine
were explored by RT-PCR and immunocytochemistry.
Results: IL-1 and TNF-α induced most of these transcription factors
while IL-17 had a weak effect. IL-1 induced egr-1 and all AP-1 member
expression, except fosB and junD. TNF-α also induced AP-1 member
expression, with a longer expression for fra-1 and fra-2. These two
cytokines individually induced nuclear translocation at 30 min, except
for JunB. IL-17 enhanced fra-2 and egr-1 mRNA between T30-T120
with a peak at T90, while nuclear localisation was noticed at T30 for
Fra-1, JunD and NF-κB. More importantly, when these cytokines were
used at low concentrations with no effect when used alone, their com-
binations showed a synergistic effect on transcription and nuclear
translocation of AP-1 members, Egr-1 and NF-κB. Moreover, cytokine
combinations allowed an enhanced recruitment of factors not express
by cytokines used alone.
Conclusion: AP-1, Egr-1 and NF-κB pathways in osteoblast cells are
very sensitive to the combined effect of proinflammatory cytokines
through additive or synergistic mechanisms.
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synovial tissue of patients with rheumatoid arthritis,
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Background: Chemokine receptors and their ligands play a crucial role
in the recruitment of leukocyte subsets into inflamed tissue. Their exact
expression in synovial tissue (ST) of patients with various forms of
arthritis has yet to be determined.
Objective: The objective of this study was to determine the expression
of an extensive number of chemokines and their receptors in patients
with rheumatoid arthritis (RA) and other forms of arthritis.
Methods: Synovial biopsies were obtained with a Parker–Pearson
needle from patients with RA (n=23), osteoarthritis (OA) (n=16), and
reactive arthritis (ReA) (n=8). ST was studied in patients with both
early and late stages of disease. Sections were analyzed by immuno-
histochemistry using monoclonal antibodies against CD3 (T-cells),
CD68 (macrophages), CD13 (aminopeptidase N), CCR1, CCR2b,
CCR5, CXCR4, CCL2 (MCP-1), CCL8 (MCP-2), CCL7 (MCP-3),
CCL14 (hCC-1), CCL15 (hCC-2), CCL16 (hCC-4), and CCL5
(RANTES). Digital image analysis was used to quantify the staining and
for statistical analysis the Kruskal–Wallis H test and the Mann–Whitney
U test were used.
Results: All chemokines and chemokine receptors were detected in
inflamed synovium. There was abundant expression of especially
CD13, CCR1, CXCR4, CCR5, CCL7, and CCL8 in all forms of arthri-
tis. The ligands CCL7, CCL8, CCL14, CCL15, and CCL16, which
have not previously been described in ST, were all expressed in
inflamed ST. The expression of CCL5 (RA, 11182±2239 (mean inte-
grated optical density±SEM); OA, 8759±2930; ReA, 2081±1181;
P=0.010) and CCL15 (RA, 4993±1601 (mean integrated optical
density±SEM); OA, 1738±573; ReA, 1252±1919; P=0.043) was
significantly higher in rheumatoid ST compared with disease controls.
Conclusion: These results suggest a potentially important role for a
variety of chemokines and their receptors in the migration of inflamma-
tory cells towards the synovial compartment. Disruption of the
chemokine network might represent a novel therapeutic approach in
RA, but also in other arthritides.
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Background:  Chronic inflammatory conditions, such as rheumatoid
arthritis, are characterized by generalized loss of bone mass. Proinflam-
matory cytokines, such as TNF, are believed to play a central role in this
process by increasing bone resorption.
Objective:  We have investigated systemic bone changes in human
TNF-transgenic (hTNFtg) mice, which spontaneously develop severe
inflammatory arthritis.
Results: Osteodensitometry revealed a significant decrease of trabec-
ular bone mineral density (BMD) (–37%) in hTNFtg mice, and histomor-
phometry revealed a dramatic loss of bone volume (–85%) in
comparison with wild-type controls. Osteoclast-covered bone surface
and serum levels of deoxypyridinolin crosslinks were significantly ele-
vated, suggesting increased osteoclast-mediated bone resorption in
hTNFtg mice. Osteoprotegerin (OPG) completely blocked TNF-medi-
ated bone loss by increasing BMD (+89%) and bone volume (+647%).
Most strikingly, formation of primary spongiosa was dramatically
increased (+563%) in hTNFtg mice after OPG treatment. Osteoclast-
covered bone surface and serum levels of deoxypyridinolin crosslinks
were significantly decreased by OPG, suggesting effective blockade of
osteoclast-mediated bone resorption. OPG did not influence levels of
hTNF, TNF-receptor-1, IL-1β and IL-6. However, OPG decreased bone
formation parameters, which were elevated in hTNFtg mice. In contrast
to OPG, bisphosphonates and anti-TNF treatment did not affect gener-
alized bone loss in hTNFtg mice.
Conclusion: These data indicate that TNF-mediated generalized bone
loss is primarily dependent on RANKL/RANK signaling and can be
blocked by OPG. Thus, OPG may represent a potent tool to prevent
generalized loss of bone mass in chronic inflammatory disorders, espe-
cially rheumatoid arthritis.
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Influence of anti-TNF therapy on monocyte gene
expression in rheumatoid arthritis
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Background and objective: The joint in rheumatoid arthritis (RA) is
characterized by pannus formation and cartilage/bone destruction. In
RA, not only tissue macrophages but also blood monocytes (MO) are
known to be activated and spontaneously release inflammatory media-
tors. However, genes and functional pathways involved in RA mono-
cyte activation are recognized and characterized only in part.
Of all techniques for differential mRNA expression analysis, DNA arrays
raise most expectations and are applied for drug discovery and compound
testing in preclinical or clinical studies. This technique may also enable the
identification of genes and expression patterns associated with the type of
disease, stage of activation, disease progression and molecular therapeu-
tic mechanisms. For functional interpretation, the experimental concept is
important. Considering drawbacks and benefits, analysis of defined cell
populations is advantageous for functional interpretation.
Methods: Therefore, we analyzed the expression profile of untouched
negatively separated MO using the Affymetrix U133A/B array system.
MO were obtained from normal donors, patients with active RA before
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and after several months of anti-TNF antibody therapy. Bioinformatic
analysis of gene expression included background correction, normaliza-
tion, comparative statistics and cluster analysis.
Results: So far, six characteristic clusters have been obtained, includ-
ing genes relevant to RA and induced or decreased upon therapy. Fur-
thermore, RA regulated genes were identified, which returned to
‘normal’ upon anti-TNF treatment, indicating selective molecular effects
of the drug.
Conclusion: These promising results could open new avenues for the
identification of novel genes for a general definition of MO/macrophage
activation patterns and for pathways activated or blocked during differ-
ent stages of the disease or therapy-induced remission in RA.
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Endogenous IL-12p40 is crucial for antigen-induced
arthritis and is partly involved in chronic relapsing
streptococcal-cell-wall arthritis
M Jacobs, L Joosten, MMA Helsen, E Lubberts, WB van den
Berg
Rheumatology Research Laboratory, University Medical Center
Nijmegen, Nijmegen, The Netherlands
Arthritis Res Ther 2003, 5 (suppl 1):42
Background: Interleukin 12 (IL-12) is a proinflammatory cytokine with
important immunoregulatory activities and is critical in determining the
differentiation and generation of Th1 cells.
Objectives: For the present study, we investigated the role of endoge-
nous IL-12p40, component of both IL-12 and IL-23, in the pathogenesis
of antigen- and chronic relapsing streptococcal-cell-wall-(SCW-)
induced arthritis. To this end we used C57Bl6 (wild-type; WT) and
IL-12p40-deficient (IL-12 ko) mice. Chronic SCW was induced by intra-
articular (i.a.) injection of 25µg SCW fragments at days 0, 7, 14 and 21.
Joint swelling and histology were examined at day 28 after the first injec-
tion. Antigen-induced arthritis (AIA) was initiated by i.a. injection of
60µg mBSA in preimmunized mice. Joint swelling was measured at
days 3, 7 and 14, whereas histology was examined at days 7 and 14.
Results:  At day 28, joint swelling of the mainly macrophage-driven
chronic SCW arthritis was significantly reduced in IL-12p40 ko mice in
comparison with WT mice (P=0.0008). Although cell influx was
decreased (P=0.0194), no reduction in cartilage proteoglycan deple-
tion was found. In a predominantly T-cell-mediated process such as
AIA, joint swelling was significantly suppressed at days 3 and 7 in
IL-12p40 ko mice in comparison with WT (P=0.0021 and P=0.0260
respectively). Moreover, histopathology was drastically reduced in
IL-12p40 ko mice; the number of inflammatory cells was strongly sup-
pressed in IL-12p40 ko mice in comparison with WT animals (1.6±0.4
vs 0.2±0.2 and P<0.0001). In line with these findings matrix proteo-
glycan depletion was completely absent in IL-12p40 ko mice
(1.9±0.35 vs 0.05±0.11 and P<0.0001).
Conclusion: These results indicate that IL-12p40 plays a pivotal role in
antigen-induced arthritis and a minor role in chronic relapsing strepto-
coccal-cell-wall-induced arthritis.
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IL-18 directly promotes joint inflammation and
induces cartilage destruction through IL-1
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Background: Interleukin-18 is a member of the IL-1 family of proteins
that exerts proinflammatory effects and induces cartilage destruction
in vitro.
Objective: The goal of the present study was to investigate whether
IL-18 mediates joint destruction in vivo, directly or via induction of other
cytokines.
Results: To this end, we performed both in vitro and in vivo kinetic
studies. 35S-labeled explants of C57Bl/6 mice were cultured for 24 to
72 hours in either IGF-1, IGF-1/IL-18 or IGF-1/IL-1β in combination
with or without IL-1 receptor antagonist (IL-1Ra) or an ICE inhibitor.
Wild-type, TNFα-deficient and IL-1α,β-deficient mice were used for
in vivo IL-18 exposure studies. Mice were injected intra-articularly with
107pfu mIL-18 adenovirus at day 0, and histopathology was examined
at days 4, 7 and 14. In vitro IL-18 exposure for 24 or 48 hours did not
induce cartilage degradation, determined as release of prelabeled pro-
teoglycans. Cartilage degradation by IL-18 was only found after a
72-hour culture period. Blocking of IL-1 with IL-1Ra or ICE-inhibitor
resulted in almost complete protection against IL-18 mediated cartilage
degradation in vitro. Application of 107pfu AdmIL-18 resulted in pro-
longed elevated levels of IL-18, for up to 14 days. Histology at
days 4, 7, and 14 revealed that local overexpression of IL-18 resulted in
increasing joint inflammation and cartilage destruction in the wild-type
mice. Of high interest, IL-18 gene transfer in IL-1α,β–/– mice did not
show cartilage damage at the various time points, although joint inflam-
mation was similar to that in the wild-type animals. Overexpression of
IL-18 in TNFα-deficient mice showed that TNFα was partly involved in
IL-18-induced joint inflammation.
Conclusion: Here we showed that IL-18 induces joint inflammation
independently of IL-1. In addition, we showed that IL-1 generation, due
to IL-18 exposure, was essential for marked cartilage degradation both
in vitro and in vivo. These findings imply that IL-18 contributes, through
separate pathways, to joint inflammation and cartilage destruction.
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TNF polymorphisms are associated with the
development of joint erosions in psoriatic arthritis
D Kane1, J Balding2, W Livingstone2, L Mynett-Johnson2,
B Bresnihan1, O Smith2, O Fitzgerald1
1Department of Rheumatology, St Vincent’s University Hospital, Dublin,
Irish Republic
2Department of Genetics, Trinity College, Dublin, Irish Republic
Arthritis Res Ther 2003, 5 (suppl 1):44
Objective:  To determine whether functional cytokine gene polymor-
phisms influence disease susceptibility and phenotype in patients with
psoriatic arthritis (PsA).
Methods: DNA was obtained from 147 PsA patients (mean age of
arthritis onset=35.2±13.4 years; oligoarticular=43 [29%], polyarticu-
lar=104 [71%]) and 389 healthy Irish blood donors. Seven functional
proinflammatory (IL-1β +3953, IL-6 -174, TNF-α -308, TNF-β +252)
and anti-inflammatory (IL-10 -1082, IL-10 -592, IL-1Ra [intron 2, 86bp
VNTR]) gene polymorphisms were detected by PCR and RFLP assays.
Results:  No significant difference in genotype frequencies was
observed between the control population and the PsA population, and
no association with ACR functional class, disease classification (pol-
yarticular or oligoarticular), the presence of spinal involvement, or age
of PsA onset was observed. Age of onset of psoriasis was significantly
associated with the TNF-β (P=0.0011) and TNF-α (P=0.01) polymor-
phisms. The TNF-β B2/B2 and TNF-α -308 AA genotypes were associ-
ated with the earliest mean age of psoriasis onset. Plain radiographs of
the hands and feet were obtained in 114 patients (64 with joint ero-
sions, 48 with periostitis). The presence of joint erosions was signifi-
cantly associated with the TNF-α -308 A (P<0.0001) and TNFB1
(P=0.0009) alleles. Sequential radiographs were obtained in 52/61
patients who presented with early PsA (<2 years’ duration) with 19/52
(37%) increasing the number of joint erosions (progressors) over a
median interval of 24 months. The TNF-α -308 A allele and the
TNFB B1 allele were significantly increased in the progressor group
(P=0.014 and P=0.048 respectively).
Conclusion:  The TNF-α -308 and TNFB polymorphisms are signifi-
cantly associated with the presence of joint erosions in PsA and with
the progression of joint erosions in early PsA.
Available online http://arthritis-research.com/supplements/5/S1S14
45
Defect of Th1 immune response of whole blood cells
from active patients with rheumatoid arthritis (RA)
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Background:  Cases of severe tuberculosis have been reported in
patients with RA during anti-TNF-alpha (TNF-α) treatment. In addition
to TNF-α, IFN gamma (IFN-γ) and the cellular immunity are known to be
important to prevent the development of tuberculosis infection.
Objective and methods: We examined mRNA expression of IFN-γ,
IL-4, T-bet, GATA-3, and TNF-α by peripheral whole blood from RA
patients (n=28) and healthy controls (n=16), using real-time RT-PCR.
Results: IFN-γ, IL-4, and TNF-α expression was significantly higher in
RA than in healthy blood (P=0.0023, 0.003, and 0.0004, respec-
tively). In RA samples, T-bet expression correlated with that of IFN-γ
(r=0.738,  P<0.0001) and negatively correlated with serum CRP
levels (r=–0.516, P=0.004). No correlation between T-bet and IFN-γ
expression was observed in healthy blood. Next, we separated RA
patients into two groups according to their serum CRP levels. In com-
parison with healthy or mild RA (CRP <40mg/l, n=19), active RA
blood (CRP >40mg/l, n=9) showed significantly lower ratio of
T-bet/β-actin (P=0.014,  P=0.0009) or T-bet/GATA-3 (P=0.0035,
P=0.0085, respectively). Active RA blood expressed significantly
lower IFN-γ mRNA in comparison with that of mild RA (P=0.014).
There was no difference of IFN-γ expression between active RA and
healthy blood, but active RA showed higher expression of IL-4 than that
of healthy samples (P=0.025). TNF-α expression by active RA blood
was lower than that of mild RA (P=0.013) and healthy blood, though
not significantly so.
Conclusion: These findings demonstrate that IFN-γ, T-bet, or TNF-α
expression by whole blood cells may be influenced by disease activity
of RA, and the combination of the defect of TNF-α and Th1 immune
response indicated by low IFN-γ and T-bet with high IL-4 expression in
the active RA blood, with the additional effect of blockade of TNF acti-
vation on T cells, may represent critical conditions for the development
of tuberculosis.
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TNF-α α dependency of IL-17-induced joint pathology
differs under naive and arthritis conditions in vivo
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Background: T-cell IL-17 is a proinflammatory cytokine present in the
synovium of RA patients. IL-17 is an inducer of other cytokines, such as
IL-1 and TNF. It can have both additive and synergistic effects on
cytokine induction and tissue destruction with these cytokines, but may
have direct pathological effects as well.
Objective and methods: In the present study, we examined the
dependency of TNF-α in the IL-17-induced joint inflammation and carti-
lage damage under naive and arthritis conditions using an adenoviral
vector expressing mIL-17 (AdIL-17).
Results: IL-17 overexpression in the knee joint of naive mice resulted in
joint inflammation and cartilage proteoglycan depletion, which gradually
increased with time. No effects were noted with the same dose of the
control vector. IL-17 induced elevated expression of IL-1 mRNA levels
in the synovium in comparison with the control group. However, no dif-
ference in IL-17-induced joint pathology was noted in IL-1α/β-deficient
mice. Of high interest, using TNF-α deficient mice, the IL-17-induced
joint inflammation and cartilage damage were almost completely
absent. This strongly indicates that under naive conditions in vivo the
IL-17-induced joint inflammation and cartilage destruction are mediated
by TNF and not necessarily by IL-1.
Since it is known that in streptococcal-cell-wall (SCW) arthritis, TNF
and IL-1 induction can be uncoupled, we did similar experiments in this
acute SCW arthritis model. Overexpression of T-cell IL-17 in this
macrophage-mediated model results in an elevation of joint inflammation
and cartilage proteoglycan depletion in comparison with the control
vector group. Furthermore, this T-cell cytokine turns this acute model
into a more chronic one. Although knocking out TNF-α did have some
effect on inflammation and cartilage damage, the dependency of TNF in
IL-17 induced pathology was not as strong as under naive conditions.
Conclusion:  These data show a direct relation of IL-17 and TNF-α
induction under naive conditions in vivo. However, the presence of IL-1
during arthritis conditions and the collaboration of IL-17 with IL-1 mod-
ulates the TNF-α dependency during arthritis.
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Background: T cells are considered to be pivotal cells in the pathogen-
esis of rheumatoid arthritis (RA) and therefore represent a potential
target for treatment. The novel disease-modifying antirheumatic drug
(DMARD) leflunomide inhibits pyrimidine biosynthesis. T cells are espe-
cially susceptible to inhibition of this enzyme due to increased demand
for pyrimidines after activation, together with the absence of a salvage
pathway.
Objective: We investigated the effects of leflunomide on cytokine pro-
files in vivo and in vitro to provide more insight into the mechanism of
action of leflunomide in RA.
Methods: Serum samples from 100 RA patients, treated with either
leflunomide (n=50) or methotrexate (n=50), were collected at base-
line, after 12 weeks and after 1 year of treatment. In these samples,
serum levels of interleukin-6 (IL-6) and interferon gamma (IFN-γ) were
determined by ELISA. The effects of the active metabolite of lefluno-
mide (A77-1726; 0–200µM) on IL-6 and IFN-γ production by periph-
eral blood mononuclear cells (PBMCs) from healthy volunteers (n=6)
and RA patients (n=3) were studied by ELISA after activation (with
phytohemagglutinin, lipopolysaccharide, and αCD3/αCD28) by ELISA.
In addition, monocytes and lymphocytes were isolated from two healthy
volunteers by density-gradient centrifugation methods, and effects of
A77-1726 on IL-6 production after activation (with phytohemagglutinin
or lipopolysaccharide) were measured by ELISA and PCR. Effects on
cell proliferation (3H-thymidine incorporation), were measured as well.
Results: Serum levels of IFN-γ were significantly reduced after lefluno-
mide treatment (baseline 43pg/ml±10 [mean±SEM]; 1 year 29±7
[P=0.015]), whereas we did not observe a change in IL-6 concentra-
tions in serum (baseline 158±41, 4 months 151±48). In contrast, both
IFN-γ and IL-6 serum levels were significantly reduced after methotrex-
ate treatment. Consistent with these data, in vitro experiments revealed
a dose-dependent inhibition of IFN-γ production by activated PBMCs in
both healthy volunteers and RA patients in the presence of A77-1726,
without a clear-cut effect on IL-6 production. IL-6 production by mono-
cytes was not inhibited (measured by ELISA and PCR). Production of
IFN-γ by lymphocytes was inhibited by A77-1726.
Conclusion: The results presented here show inhibition of IFN-γ pro-
duction by leflunomide without a clear-cut effect on IL-6 production.
This differential effect supports the hypothesis that leflunomide prefer-
entially affects activated T cells. The effects on T cells could be
explained by both DHODH inhibition and effects on signal transduction
pathways.
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Alveolar macrophages in scleroderma lung disease
are activated by TGF-β β and IL-4 but not TNF-α α
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Background: We reported previously that alveolar macrophages from
scleroderma patients with lung inflammation are characterized by an
activated gene expression profile.
Objective: The purpose of this study was to identify the molecular
mediators that have activated alveolar macrophages in scleroderma
lung disease, through an analysis of transcription factor activation.
Methods: Freshly isolated alveolar macrophages were negatively
selected by depleting CD3+ cells from BAL cells of six patients with
lung inflammation. Nuclear translocation of 55 transcription factors was
evaluated using a protein/DNA array system (Panomics). Data were
analyzed using hierarchical clustering.
Results and conclusion: Three distinct clusters of translocated tran-
scription factors were notable. One cluster included Smad3/4 as well
as other factors involved in or activated by TGF-β signaling, including
CREB/p300, Fast-1, the glucocorticoid receptor element, and
GAS/ISRE. A second cluster included Stat5/6 and other factors acti-
vated by IL-4 signaling, including GATA, Sp1, and early-response
element. The third cluster included factors that were translocated to
the nucleus in low levels in only a few samples. This cluster included
NF-κB, which is critical in signaling by TNF-α and IL-1, and several
other transcription factors activated by TNF-α signaling. In animal
models, macrophages that are activated by TGF-β or IL-4 have been
associated with the subsequent development of fibrosis. Thus, we
directly demonstrate cellular activation by the profibrotic factors TGF-β
and IL-4 in involved tissues from scleroderma patients.
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Background: Infliximab is an anti-tumor-necrosis-factor (anti-TNF) anti-
body used for the treatment of rheumatoid arthritis.
Objective: To clarify heterogeneity in patient response, a bioassay was
established to measure functional circulating tumor necrosis factor (TNF).
Results: Culture of TNF activated synoviocytes with plasma samples
before and after infliximab treatment showed an increased production
of IL-6 that was strongly reduced by treatment. This pattern was asso-
ciated with a good clinical response, and bioactive TNF levels detected
with this bioassay were correlated with TNF levels measured by ELISA.
This was not observed in patients with a poor response. The functional
circulating bioactive TNF was significantly (P<0.001) more elevated in
subset with a good biological response than bad responders. No cor-
relation was observed with levels of soluble receptors.
Conclusion: This result suggests the importance of systemic bioactive
TNF in such response.
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Background: Modalities of infliximab treatment for active rheumatoid
arthritis (RA) have been established following randomised clinical trials.
Objective: In a postmarketing study, we compared the clinical presen-
tation of RA patients from the same geographic area treated by inflix-
imab or not. We checked for markers linked with selection for infliximab
treatment focusing on the shared epitope (SE).
Methods: RA patients (897 ) from the Rhone-Alpes area, France, were
enrolled. Clinical indices of disease activity and joint destruction,
including age, sex, disease duration, Ritchie articular index, and right
Larsen wrist index, were collected. Biological data included erythrocyte
sedimentation rate, rheumatoid factor (RF), and SE status. SE determi-
nation was performed by enzyme-linked oligosorbent assay.
Results and conclusion: All patients had the typical clinical and biologi-
cal features of RA. The patients were predominantly white women and
64.6% were RF-positive. The distribution of the SE was 44.74% for 0
copy, 43.33% for 1 copy, and 11.93% for 2 copies. The risk of develop-
ing joint destruction was associated with the presence of the SE, with a
dose effect. SE heterozygote patients were almost twice as likely to
develop erosions as SE-negative patients (OR=2.18; 95% CI
1.48–3.22, P<0.001). Patients with two copies of the SE were more
likely to develop erosions (OR=4.73, CI 2.67–8.36, P<0.001). When
patients treated with infliximab were isolated, RA severity parameters,
such as the Ritchie and Larsen indices, RF, and the presence of the SE,
were associated with infliximab treatment. The frequency of the SE in RA
patients treated with infliximab was approximately twice as high for SE
heterozygote carriers (OR=2.18; 95% CI 1.43–3.31, P<0.001), and 4
times as high for SE homozygotes (OR=3.88; 95% CI 2.25–6.68,
P<0.001). Thus RA patients with the SE were more often selected for
infliximab treatment extending the link between SE and severity.
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with other inflammatory arthritides
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Background: We have earlier shown that polyethylene glycol (PEG)
precipitates from sera of active SLE patients can induce monokine pro-
duction, possibly through immune complexes.
Objective: We have now investigated monokine production induced by
PEG precipitates from arthritis patients.
Methods: Paired synovial fluid (SF) and serum samples from 26 RA
patients and 20 patients with other inflammatory arthritides were sub-
jected to combined PEG precipitation and purification. The IgG
content was determined by ELISA. Precipitates were added to periph-
eral blood mononuclear cell (PBMC) cultures, and supernatant levels of
TNF-α and IL-10 determined by ELISA after 20 hours.
Results: In both the investigated PBMC donors, the highest median
values of TNF-α were found in SF-PEG cultures. In one of the PBMC
donors, this difference was significant in paired analysis for all patients
and for the RA group only, but not for non-RA patients only. The corre-
lation between the TNF-α and IL-10 production was higher for RA than
for non-RA patients, and higher for SF than for serum precipitates. No
correlation was noted between the IgG content of the precipitates and
cytokine levels.
Conclusion: In this preliminary study, PEG precipitates from RA SF
induced higher production of TNF-α than did corresponding serum pre-
cipitates, possibly through stimulation by immune complexes in SF. Since
no correlation was observed between the IgG content and cytokine
induction, it is likely that immune-complex composition rather than the
IgG content of the precipitates determines the cytokine response.
Available online http://arthritis-research.com/supplements/5/S1S16
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Background: Discovering safe, novel immunomodulators that are
effective in RA is currently a major therapeutic objective. Long-term
immune system deviation is most striking in the host–parasite relation-
ship, in which microbes may coexist with a human host.
Objective: We have investigated our previously discovered filarial
derived ES-62 for therapeutic potential in RA.
Methods: ES-62 was administered during collagen-induced arthritis
(CIA) either at immunization (prophylactic) or 24 hours after the onset of
clinically evident disease (therapeutic). Cytokine and antibody responses
were measured in ex vivo cultures. RA synovial cultures were also made.
Results: ES-62 exhibited powerful immunomodulation of CIA, preventing
initiation of inflammatory arthritis. Crucially, ES-62 suppressed even estab-
lished disease. These effects were due to inhibition of cytokine release,
specifically TNF-α, and reversal of collagen specific Th1 responses associ-
ated with reduced expression of IFN-γ. The physiologic relevance of these
observations was confirmed, as ES-62 down-regulated the release of
proinflammatory cytokines (TNF-α and IL-6) from patient-derived samples.
Conclusion: The host–parasite relationship has long promised thera-
peutic potential. Our data clearly show that ES-62, a filarial-derived
moiety, can profoundly alter cytokine expression in vitro and in vivo in
inflammatory arthritis. This in turn suggests an intriguing role for ES-62
in treating chronic inflammatory diseases. Finally, our data have implica-
tions for the mechanisms that might underpin previously reported epi-
demiologic interactions between chronic infection and autoimmunity.
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Objective: Our objective was to characterize the molecules responsi-
ble for crosstalk between synovial fibroblasts (SFibs) and T lympho-
cytes (TLs) in RA and test the effect of methotrexate (MTX).
Methods: SFibs were obtained from RA patients. TLs were isolated
from peripheral blood of healthy controls and RA patients, and from RA
synovial fluid by Ficoll–Hypaque gradient and magnetic depletion of
non-T cells; purity was 99%. Cocultures were established in six-well
plates; adhesion molecules and surface and intracellular cytokines
were determined by flow cytometry.
Results: Synovial fluid TLs (SFTLs) from RA patients (n=10) and periph-
eral blood TLs (PBTLs) from untreated recent-onset RA (n=10) induced
an up-regulation of intercellular adhesion molecule (ICAM)-1, intracellular
IL-8, IL-15 and surface IL-15 in SFibs. SFTLs and PBTLs showed an up-
regulation of IFN-γ, IL-17, CD25 and CD69 when cocultured with SFibs.
Freshly isolated PBTLs from healthy controls (n=10) did not induce SFib
cytokine production. Pretreatment of SFs with MTX (0.1–1µM) pre-
vented the TL-stimulated increase of IL-8 and IL-15. Pretreatment of TLs
with MTX (0.1–1µM) prevented the SFib-induced up-regulation of IFN-γ,
IL-17, CD25 and CD69. Blocking MoAbs to IL-15, but not an isotype-
control antibody, prevented the increased TL secretion of IFN-γ and IL-17
induced by SFibs. Blocking MoAbs to IL-17 significantly decreased the
TL-induced up-regulation of IL-8 and IL-15 in SFibs. Cocultures of TLs
and SFibs using 0.4µM plate inserts did not induce a significant up-regu-
lation of adhesion molecules or cytokines. Paraformaldehide-fixed TLs did
up-regulate IL-8 and IL-15 in SFibs. This suggests that direct cell contact
is an important contributor to the observed effects.
Conclusion: SFib production of IL-8 and IL-15 may contribute to the
influx and proliferation of TL in the RA joint. In turn, TL cytokines IFN-γ
and IL-17 stimulate the production of IL-8 and IL-15 by Sfibs, thereby
creating a feedback loop that leads to persistent synovial inflammation.
MTX seems to disrupt this loop, acting at both the SFib and TL level.
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Background and objective: Activated T helper CD4+ T cells, by their
production and secretion of cytokines, seem to have functional similari-
ties with plasmocytes secreting immunoglobulins. The morphotype and
phenotype of IL-17- and IFN-γ-producing cells in both in vitro and
in vivo situations remain to be clarified. Oligoclonal activation of normal
peripheral blood mononuclear cells with the superantigen SEB and
polyclonal activation with PMA/PHA for 4, 24, and 48 hours were used
as in vitro models. This study was extended to various in vivo situations
such as RA, dermatomyositis (DM), and normal activated lymph nodes.
Methods: We looked at the phenotype of IL-17 and IFN-γ-producing cells
by immunohistochemistry, using the CD3 and CD4 T-cell markers, the
CD20 B-cell marker, the CD38, and the kappa and lambda light-chain
immunoglobulins plasmocytes markers. We also focused on the expression
of two chemokine receptors, CCR6 and CCR7, involved with their associ-
ated ligands CCL20 and CC19/CCL21 in the migration of T lymphocytes.
Results and conclusions: IL-17 and IFN-γ-producing cells acquire a
plasma-cell-like morphotype associated with the reduced expression of
CD3 and the persistence of CD4 after both polyclonal and oligoclonal
activation. In RA, DM, and activated lymph nodes, IL-17- and IFN-γ-pro-
ducing cells presented the same morphotype. In RA synovium, these
plasmacytoid-like Th1-producing cells still express the CD4 marker but
not the CD3 and are CD20–, CD38–, kappa– and lambda–. In both
in vitro and in vivo conditions, some of the Th1-producing cells can
produce the CCR6 and CCR7 chemokine receptors, a finding which
supports the argument that CCL20/CCR6 and CCL19,21/CCR7 play
a role in the homing of T cells.
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antagonist (IL-1Ra) synthesis in chondrocytes and
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Objectives: We analyzed the effects of the active metabolite of lefluno-
mide, A77-1726, on IL-1Ra production by chondrocytes and synovial
fibroblasts, with regards to the relevance of its use in RA and other car-
tilage damaging diseases.
Methods and results: Cartilage was obtained from joints replaced for
osteoarthritis or broken femoral neck. Synovial membranes were
obtained from joints replaced for osteoarthritis. Cells were isolated by
collagenase digestion; chondrocytes were used either directly (primary
cells) or between passages 1 and 5 (dedifferentiated cells). IL-1Ra con-
centrations in cell conditioned media (CM) or cell lysates were assessed
using a sandwich ELISA. In chondrocytes and synoviocytes, A77-1726
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dose-dependently enhanced the stimulatory effects of IL-1β or TNF on IL-
1Ra production (average 2 fold increase in primary chondrocytes, 10 fold
increase in synoviocytes). A maximal response was observed at 100 µM.
In synoviocytes, A77-1726 increased the production of soluble (s; as
measured in CM) and intracellular (ic; as measured in cell lysates) IL-
1Ra; in contrast, no significant amounts of icIL-1Ra were recovered from
primary chondrocytes. We next investigated putative pathways involved,
first focusing on known effects of A77-1726 on uridine and
prostaglandin E2 (PGE2) synthesis. The addition of exogenous uridine did
not modify the effects of A77-1726. The addition of PGE2 partially
reversed the effects of A77-1726 in chondrocytes and synoviocytes.
Indomethacin also increased IL-1Ra production, although less potently
than A77-1726, and its effects were completely annulled by low doses of
PGE2. A77-1726 at 100 µM inhibited by 95-98% the production of
PGE2 induced by IL-1β and TNF-α; this was not significantly different
from the inhibition achieved by optimal doses of indomethacin.
Conclusion: A77-1726 may thus possess chondroprotective effects
by increasing IL-1Ra release by chondrocytes and synoviocytes. The
effects of A77-1726 seem to arise partially through inhibition of PGE2
synthesis, but other mechanisms likely concur to its stimulatory effect
on IL-1Ra production.
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accumulation in fibroblast-like synoviocytes
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Background: IL-10 has been shown to be beneficial in a series of ail-
ments, inflammatory arthritis among them.
Objective: In an attempt to study possible mechanisms we investi-
gated the effect of IL-10 on mRNA accumulation of genes encoding
hyaluronan. Hyaluronan and/or its degradation products have been
implicated in the many detrimental effects associated with disease pro-
gression. Here we report that IL-10 suppresses noninduced as well as
induced mRNA accumulation of certain genes encoding hyaluronan.
Methods: Human fibroblast-like synovial cells (FS) were studied for
their potential to synthesize hyaluronan synthase (HAS) mRNA. Expres-
sion levels of mRNA for HAS1, HAS2 and HAS3 were monitored by
RT-PCR. IL-10 was added to FS cultures for 6 hours.
HAS3 is constitutively expressed in FS. We found that treating FS with
IL-10 inhibited HAS3 mRNA accumulation in a dose-dependent manner.
Similar to HAS3, HAS2 mRNA was readily detectable in unstimulated FS.
Our experiments show that in contrast to HAS3, IL-10 has no significant
effect on HAS2 mRNA. Furthermore, in contrast to HAS3 and HAS2
mRNA levels in untreated FS, HAS1 mRNA is below or close to the detec-
tion limit in unstimulated FS but can be readily induced by stimulating these
cells with TGF-β (1ng/ml for 6 hours). We tested the potential of IL-10 to
inhibit TGF-β-induced HAS1 mRNA synthase and found that IL-10 also
inhibited TGF-β induced HAS1 mRNA, albeit to a lesser degree.
Conclusion: IL-10 can be a potent inhibitor of induced as well as non-
induced HAS activation. While 10ng/ml of IL-10 can reduce HAS3
levels in FS by more than 90%, the effect of IL-10 on TGF-β induced
HAS1 levels is less pronounced. Taken together, it is tempting to spec-
ulate that the observed beneficial effects of IL-10 in rheumatoid arthritis
are at least in part due to its inhibitory effect on HAS mRNA activation.
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long-term follow-up in patients with rheumatoid arthritis
P Sidiropoulos1, G Kakavouli1, DT Boumpas2, K Voudouris1
1First General Hospital of Thessaloniki, Thessaloniki, Greece
2University of Crete, Heraklion, Greece
Arthritis Res Ther 2003, 5 (suppl 1):57
Background and objectives: Although treatment with anti-TNF
therapy is effective in controlling disease activity in patients with refrac-
tory rheumatoid arthritis (RA), approximately 30% of patients do not
respond. Moreover, in certain patients, adjustments in therapy are
needed after an initial response. We sought to better delineate this in a
cohort of RA patients receiving anti-TNF therapy.
Patients and methods: Sixty-four patients (50 females and 14 males,
mean age 52.6 years and mean disease duration 10.3 years), with
active rheumatoid arthritis despite treatment with disease-modifying
antirheumatic drugs (DMARDs) received infliximab. In these patients,
treatment with a mean of 2.9 DMARDs had previously failed. Treatment
with methotrexate was continued in 48 patients (mean dose
10.1mg/wk) and with various DMARDs in 6. Concomitant pred-
nisolone (mean dose 8.5mg/d) was used in 43 (67.2%). The DAS
index (44 joints) was applied to assess clinical efficacy. The dose of
infliximab was 3mg/kg per infusion administered every 8 weeks after
the third dose on week 6.
Results: In this cohort, 19 (29.7%) patients discontinued therapy
(42% for lack of insurance coverage, 26% because of inefficacy, 21%
because of infections and 11% because of allergic reactions). No
patient discontinued therapy for any reason after the 30th week. All
clinical parameters were significantly improved (P<0.01) after the
fourth infusion. Forty-five patients completed 6 infliximab infusions
(mean 30 weeks) and 29 of them 12 infusions (mean 75 weeks of
treatment). In the last group, clinical response was sustained through-
out the 75 weeks of treatment and the dose of prednisolone was signif-
icantly decreased (P<0.0001) while 24% (6 of 25) of patients
discontinued steroids. To achieve clinical response, the frequency of
infliximab infusions was increased to every 6 weeks in 31% of patients,
while methotrexate was significantly increased in 38% of patients
(21 patients, mean dose from 10.1 to 12.3mg/wk, P<0.04).
Conclusion: The clinical response of RA patients treated with inflix-
imab is sustained during 75 weeks of treatment. However, in approxi-
mately one-third of patients, the frequency of infliximab infusions has to
increase after initial response in order to sustain it.
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Infliximab treatment reduces synovial cellularity as
early as 48 hours after initiation of treatment, but not
by induction of apoptosis
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Background: The mechanism of action of TNF-α-targeted therapies,
which may have a beneficial effect soon after initiation of treatment in
rheumatoid arthritis (RA) patients, is as yet not completely understood.
Previous work has shown that TNF-α blockade results in decreased
cellularity in the synovium, which can be explained in part by reduced
cell migration. In the present study we investigated whether treatment
with the chimeric anti-TNF-α antibody infliximab could also reduce cel-
lularity by induction of apoptosis in the RA synovium.
Methods: Twenty-four RA patients with active disease (DAS 4.8 or
higher), who had failed at least 2 DMARDs, were randomized to
receive either infliximab (3mg/kg) (n=12) or placebo (n=12) intra-
venously. All 24 patients were subjected to an arthroscopic synovial
biopsy directly before initiation of treatment. In all 24 patients, a second
arthroscopic synovial biopsy of the same index joint was performed
48 hours after the first procedure. After the second arthroscopy, the
patients who had initially received placebo were also treated with inflix-
imab (3mg/kg) in an extension study. A third arthroscopy was per-
formed in all 24 patients on day 28. Immunohistologic analysis was
performed using monoclonal antibodies (mAbs) against CD3 (T cells),
CD22 (B cells), CD38 (plasma cells), CD68 (macrophages), CD55
(fibroblast-like synoviocytes [FLS]), and granzyme B. In situ detection
of apoptosis was performed by TUNEL (transferase-mediated UTP end
labeling) assay. Sections were analysed by computer-assisted image
analysis. For statistical analysis, the Wilcoxon signed-rank test and the
Mann–Whitney U test were used.
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Results: As early as 48 hours after initiation of infliximab treatment,
there was a significant reduction in the number of intimal macrophages
(–49 cells/mm2±67 [median±SEM]; P=0.009), which was not
observed in the placebo group (+10±54). The number of T cells
tended to be decreased in patients treated with infliximab (–52±32)
but not in the placebo group (+10±25); this difference did not reach
statistical significance. The numbers of B cells, plasma cells, and
granzyme B+ cells were unchanged 48 hours after treatment with either
infliximab or placebo.
Of interest, the TUNEL assay did not reveal any increase in the number
of apoptotic cells after infliximab treatment (–0.7±13.6 in the infliximab
group; +6.9±10.8 in the placebo group; both not significant). Simi-
larly, the extension study in 24 patients revealed that there was no
increase in apoptosis in the synovium on day 28.
Conclusion: Infliximab therapy may reduce the number of inflammatory
cells in rheumatoid synovial tissue as early as 48 hours after initiation of
treatment, but apparently not by induction of apoptosis. Presumably,
decreased cell infiltration primarily results from early inhibition of cell
migration.
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Background: A large body of evidence implicates interleukin (IL)-1, a
proinflammatory cytokine, in the pathogenesis of a variety of human
inflammatory disorders such as rheumatoid arthritis (RA). RA patients
experience a markedly increased frequency of cardiovascular disease.
IL-1 is expressed within the endothelium of atherosclerotic plaques and
may participate in inflammatory mechanisms of atherogenesis. IL-1
receptor antagonist (IL-1Ra) is a natural IL-1 inhibitor. The term ‘IL-1Ra’
refers to four different isoforms, one of which is secreted (sIL-1Ra) and
the other three of which are intracellular (icIL-1Ra1, 2, 3). sIL-1Ra com-
petitively inhibits receptor binding of IL-1. In patients with RA, the
administration of recombinant human sIL-1Ra ameliorates the clinical
parameters of disease activity and decreases the progression of joint
damage.
Objective: The purpose of this study was to determine whether
sIL-1Ra influences the formation of atherosclerotic plaques in vivo.
Methods: Transgenic mice expressing high amounts of human sIL-1Ra
were crossed with apolipoprotein-E-deficient mice (ApoE–/–), which
develop atherosclerotic lesions when fed a high-cholesterol diet, in
order to obtain ApoE–/– IL-1Ra-wild-type and ApoE–/– IL-1Ra-trans-
genic mice of identical genetic background. Twelve-week-old males of
both groups (n=6 per group) were fed a cholesterol-rich diet (1.25%)
for 10 weeks. Increase in serum lipid profiles (total cholesterol, triglyc-
erides) did not differ between both groups. Development of atheroscle-
rotic lesions was measured as the extent of sudanophilic lesions, by
computer image analysis.
Results: The average lesion area within aortic roots was significantly
decreased (47%, P<0.001) in transgenic mice (0.49±0.06mm2) as
compared with controls (0.93±0.05mm2). The extent of sudanophilic
lesions was also reduced within the thoracoabdominal aorta in trans-
genic mice (–36%). Preliminary analysis of the cellular composition of
atherosclerotic plaques showed a decrease in the percentage of
macrophage-positive areas (–49%) in IL-1Ra transgenic mice as com-
pared with control mice.
Conclusion: Our results show that sIL-1Ra exerts a protective effect
on the progression of atherosclerosis in mice. These findings suggest
that the administration of IL-1Ra may also exert beneficial effects on
cardiovascular complications in patients with RA.
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production in human Th1 T-cell clones but not IL-4
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Background: Anti-CD4 antibodies have been described for treatment
of certain autoimmune diseases. In vitro experiments have shown that
anti-CD4 antibodies are able to inhibit immune responses mediated by
T helper cells.
Objective: However, it became unclear whether or not these experi-
ments performed in bulk cultures represent merely regulatory effects or
cell biological differences between functionally different populations of
T helper cells.
Methods: Therefore, we established human Th1 T-cell and Th2 T-cell
clones, which were treated with anti-human CD4 antibodies. The T-cell
clones were stimulated via the T-cell receptor and the CD28 molecule,
and cytokine production was determined for TNF-α, IFN-γ and IL-4.
Results: TNF-α and Interferon-γ are produced exclusively by Th1-T cells
and inhibition of cytokine production by anti-CD4 was nearly total for
TNF-α production but much less pronounced for IFN-γ. No effect of anti-
CD4 on IL-4 production in human Th2 T-cell clones was observed.
Conclusion: Our data may help us to understand the mechanisms of
anti-CD4-mediated modulation of immune responses.
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memory expression of  interleukin-4 in Th lymphocytes
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T lymphocytes can become imprinted for the expression of particular
cytokines. This functional memory may be an essential and basic com-
ponent in the control of rheumatic inflammation. We have shown before
that epigenetic modification of cytokine genes is involved in the estab-
lishment of a cytokine memory for IL-4.
Here we report identification of a region of the first intron of the inter-
leukin-4 (IL-4) gene that is methylated in naive Th cells and in Th1 cells,
but demethylated in IL-4 expressing Th2 cells. This intron sequence
(CIS) is conserved in the IL-4 genes of all species analysed so far. The
CIS contains two GATA-binding sites. Both binding sites, their orienta-
tion and distance are required for specific binding of GATA-3 from Th2
cells. Th cells in which part of the IL-4 gene, including the CIS, is
replaced by a gfp-gene, are impaired in their memory for IL-4.
The CIS thus provides a GATA-3 specific nucleus of epigenetic modifi-
cation of the IL-4 gene, imprinting it for memory expression upon res-
timulation of the T cell by antigen alone.
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A polymorphism in the IL-10 promoter affects
autoantibody production and subsequent joint
destruction in rheumatoid arthritis
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Background: Rheumatoid arthritis (RA) is a multifactorial, polygenic
disease, in which the relevant pathways involved in its various stages
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are poorly understood. Interleukin-10 (IL-10) is known for its wide
range of both anti-inflammatory and inflammatory effects on various cell
types involved in RA.
Objective: To gain a better understanding of the role of IL-10 in RA, we
analyzed in a prospective cohort of RA patients (n=283) the –2849
A/G IL-10 promoter polymorphism, as this polymorphism is highly asso-
ciated with high (AG/GG variants) or low (AA variant) IL-10 production.
Results: In our cohort, the IL-10 genotype was, in comparison with
controls, not a risk factor for RA. But,RA patients with the –2849 geno-
types associated with high IL-10 production, had, at baseline, signifi-
cantly higher titers of IgG autoantibody (anti-CCP and IgG rheumatoid
factor), but not of IgM autoantibody (IgM rheumatoid factor). Moreover,
a higher rate of joint destruction was observed in RA with genotypes
associated with high IL-10 production. However, invasiveness of
fibroblast-like synoviocytes, which are thought to be important effectors
of joint destruction, was not correlated with IL-10 genotypes.
Conclusion: The –2849 IL-10 promoter polymorphims associated with
high IL-10 production were found in RA patients with high IgG autoanti-
body titers and an increased rate of joint destruction. As IL-10 is crucially
involved in class-switching and function of B-cells, we propose that genet-
ically determined differences in IL-10 production mediate their effect on
joint destruction via increased autoantibody production by B cells.
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Objective: We tested the association of certain cytokine gene poly-
morphisms with juvenile idiopathic arthritis (JIA) in Czech Caucasians.
Methods: In a case–control study, genotypes of 130 patients with JIA
(63 males, 67 females; age at onset 7.6±4.4 years; 43 oligoarticular,
72 polyarticular, 15 systemic form) were compared with those of 102
healthy unrelated blood donors. Using polymerase chain reaction with
sequence-specific primers designed by J Mytilineos, 24 single-
nucleotide polymorphisms were tested within 13 different genes for
cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-α, TGF-1β,
INF-γ) and related molecules (IL-1R, IL-1RA, IL-4Rα). Risk was
expressed using OR calculated from allelic, genotypic, and phenotypic
frequencies, and the P values were corrected for 13 tested molecules.
Results: Two polymorphisms were significantly associated with JIA.
The IL4 -1098 G phenotype was present in 10% of cases and 25% of
controls (OR=0.32, CI 95% 0.16–0.67, P corrected=0.039). The
IL-1β +3962 C phenotype was present in 96% of cases and 84% of
controls (OR=4.65, CI 95% 1.64–13.2, Pcorrected=0.05). There
was also a tendency towards a lower prevalence of the TNF-α -238
A phenotype in cases (5%) than in controls (16%), but it became
insignificant after correction for the number of tested molecules.
Conclusions: Our associations with IL-1β or with IL-4 have not been
yet reported from other populations.
Acknowledgement: Supported by grant MSMT CR 111 300 003 and
MZ CR 0000 6042.
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Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has
been closely associated with regulation of the immune response and
pathogenesis of autoimmune diseases. The expression of TRAIL was
found in CD8 T cells that had undergone oligoclonal expansion in the
lungs of patients with systemic sclerosis and were able to stimulate col-
lagen production in lung fibroblasts. Soluble, multimerized TRAIL and
normal human lung fibroblasts were used as a model of selective TRAIL
influence on fibroblasts. TRAIL was found to increase both α2(I) colla-
gen mRNA expression and total soluble collagen secretion, with peak
response at 1ng/ml TRAIL. DNA microarray analysis suggested that
fibroblast response to TRAIL might be mediated by c-Jun N-terminal
kinase (JNK). The increase in JNK1 expression and phosphorylation as
well as phosphorylation of its specific substrate were confirmed by
Western blotting. The treatment of fibroblasts with TRAIL also enhanced
the expression of a number of genes involved in tissue remodeling,
including those related to the transforming growth factor (TGF) beta
pathway. The increase in TGF-β1 mRNA level was confirmed by North-
ern blotting and by measurements of active TGF-β1 in culture super-
natants. In addition, antibody-mediated blocking of TGF-β was shown to
abrogate TRAIL-induced collagen synthesis. These data suggest that
TRAIL can enhance extracellular matrix production in fibroblasts by trig-
gering expression of TGF-β, which acts in an autocrine manner. If this
process continues uncontrolled, it may contribute to the development of
fibrosis, particularly in the lungs of patients with systemic sclerosis.
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To investigate the efficacy of isolated and combined blockade of TNF-,
IL-1- and RANKL-pathways on synovial inflammation, bone erosion and
cartilage destruction in a TNF-driven arthritis model, human TNF trans-
genic (hTNFtg) mice were treated with anti-TNF (infliximab), IL-1 recep-
tor antagonist (IL-1Ra) or osteoprotegerin (OPG). In addition, each of
three possible double combination therapies and a triple combination
therapy was applied. Therapy was followed by histological assessment
of synovial inflammation, bone erosion and cartilage damage.
Synovial inflammation was inhibited by anti-TNF (–51%), but not IL-1Ra
or OPG monotherapy. Combinations of anti-TNF with IL-1Ra (–91%)
or OPG (–81%) were additive and almost completely blocked inflam-
mation. Bone erosion was effectively blocked by anti-TNF (–79%) and
also by OPG (–60%), but not by IL-1Ra monotherapy. Combination of
anti-TNF and IL-1Ra, however, completely blocked bone erosion
(–98%). The effects on inhibition of bone erosion were accompanied
by reduction of osteoclast numbers within synovial tissue. Cartilage
destruction was inhibited by anti-TNF (–43%), weakly, but not signifi-
cantly by IL-1Ra, and not at all by OPG monotherapy. Combination of
anti-TNF with IL-1Ra was the most effective double combination
therapy in preventing cartilage destruction (–80%). In all analyses, a
triple combination of anti-TNF, IL-1Ra and OPG was not superior to
double combination therapy with anti-TNF and IL-1Ra. Articular
changes caused by chronic TNF overexpression are not completely
blockable by monotherapies, which target TNF, IL-1 or RANKL.
However, combined approaches that reduce TNF load and block IL-1
or RANKL as downstream mediators of TNF can lead to a complete
remission. Differences in their efficacy to block synovial inflammation,
bone erosion and cartilage destruction further strengthen the rationale
for combined blockade of more than one proinflammatory pathway.
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MHC and autoimmune disease
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Background: The QKRAA amino acid motif of HLA-DRB1*0401 helps
the development of rheumatoid arthritis by an unknown mechanism. In
human B cells, we have observed that the QKRAA motif carries original
properties. The constitutive 70-kDa heat-shock protein hsp73 binds
HLA-DRB1*0401 and targets it directly from endoplasmic reticulum to
lysosomes, bypassing the normal route through golgi and endosomes.
Objective: To evaluate how well different HLA-DRB1 alleles bound
hsp73, we developed quantitative assays.
Results: By precipitation assay using total and lysosomal protein
extracts, we found that alleles associated with rheumatoid arthritis
bound hsp73 better than alleles not associated with rheumatoid arthri-
tis. HLA-DRB1*0401 is the best hsp73 binder. By a direct binding
assay with purified protein, we confirmed that HLA-DRB1*0401 that
carries the QKRAA motif is the best hsp73 binder.
Conclusion: These properties may help particular antigen processing and
presentation by HLA-DRB1*0401, potentially leading to autoimmunity.
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Objective:  Peptide 263–275 is the immunodominant epitope of
HC gp-39, a candidate autoantigen in rheumatoid arthritis (RA). The
present aim is to analyse HLA-DR SE/HC gp-39263–275 complexes in
synovium of RA patients versus inflammatory controls.
Methods: Synovial biopies were obtained from swollen knee joints in
65 RA patients and 67 controls (30 with spondylarthropathy, 16 with
psoriatic arthritis, 10 with crystal-induced arthritis, 7 with osteoarthritis,
and 4 with PMR), and from knee joints without synovitis in 9 RA
patients. Synovial sections were stained with mAb 12A, which recog-
nizes specifically HLA-DR SE/HC gp-39263–275 complexes.
Results:  mAb 12A revealed mononuclear cells located near lympoid
aggregates and positive for CD1a, a marker of dendritic cells. Positive cells
were found in 40 of 65 (61.5%) inflamed RA synovia but only in 2 of 30
with spondylarthropathy and 0 of 37 other controls (3.0%) (P<0.001). In
RA, there were no differences between the 12A+ and 12A– patients for
disease duration, rheumatoid factor, SE, C-reactive protein, erythrocyte
sedimentation rate, nonsteroidal anti-inflammatory drugs, disease-modifying
antirheumatic drugs, and corticosteroid. Histological analysis of 12A+
versus 12A– RA synovia indicated a higher score for global inflammation
(P=0.025), CD3 (P=0.013), CD1a (P=0.032) and a trend for CD20
(P=0.066). Accordingly, no 12A+ cells were detected in the nine RA knee
joints without effusion (6 were SE+). HC gp-39 expression was higher in
12A+ versus 12A– samples (P=0.001). Finally, intracellular citrullinated
peptides, which are another specific histological marker for RA synovium,
were found in only half of the 12A+ samples but also in some 12A–
samples, indicating that the two markers are independent.
Conclusion:  HLA-DR SE/HC gp-39263–275 complexes are frequently
detected in inflamed RA synovia but not in inflamed control samples
and in noninflamed RA samples. This suggests that dendritic cells
actively present the immunodominant epitope of HC gp-39 at the
primary site of inflammation in RA. Moreover, the specificity of the stain-
ing offers a new and independent tool for the histopathological diagno-
sis of rheumatoid arthritis.
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Objective: Recently HC gp-39 was identified as a candidate autoanti-
gen in RA. The aim of this study is to generate and validate monoclonal
antibodies (mAbs) to HLA DRαβ1*0401/HC gp-39263–275 complexes
to further investigate the relevance of this antigen in RA.
Methods:  Spleen cells from mice immunised with HLA
DRαβ1*0401/HC gp-39263–275 complexes were selected and submit-
ted to a B-cell culture and minielectrofusion procedures. The resulting
set of mAbs were characterised for their specificity by ELISA and
FACS. Functionally, they were tested for inhibition of HC gp-39263–275-
specific DRαβ1*0401-restricted T-cell hybridomas. Finally, one of the
mAbs was used for staining of specific complexes in RA synovium.
Results: We have generated a set of five mAbs to a combination epitope
of the specific MHC/peptide complexes. FACS studies revealed that
these mAbs recognize specific complexes on homozygous DRαβ1*0401-
positive BLCL pulsed with HC gp-39263–275. The best mAb, 12A, was
further characterized using a set of irrelevant DRαβ1*0401-binding pep-
tides, and truncated/elongated versions of HC gp-39263–275 itself. The
minimal epitope recognized in combination with DRαβ1*0401 was
HC gp-39263–273. Peptides not encompassing HC gp-39263–273 were not
recognized. Three out of five mAbs were able to inhibit (up to 90%) the
response of HC gp-39263–275-specific DRαβ1*0401-restricted T-cell
hybridomas to peptide-pulsed antigen-presenting cells or purified com-
plexes. Moreover, mAb 12A localised and identified dendritic cells that
present DRαβ1*0401/HC gp-39263–275 complexes in synovial tissue of
DRαβ1*0401-positive RA patients.
Conclusions: These data indicate local presentation of the
HC gp-39263–275 epitope in the inflamed target tissue by professional
antigen-presenting cells and support a role of HC gp-39 in the local
autoimmune response that leads to chronic inflammation and joint
destruction.
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HLA-B27/hb2-microglobulin transgenic rats spontaneously develop a
multisystem inflammatory disease resembling the human spondy-
loarthropathies. This disease in rats is dependent on the presence of a
bacterial flora and mediated by T cells, but antigen-presenting cells
(APCs) may also play a critical role. Splenic dendritic cells (DCs) have
been reported to be defective in allogeneic mlR in this model.
Here, we investigated the functional defect of APCs. We observed a
defective stimulation of allogeneic and syngeneic CD4+, and CD8+ LN
T lymphocytes, by DC and B cells, from disease-prone 33-3 HLA-B27
transgenic, but not from healthy homozygous 120-4 HLA-B7 trans-
genic rats, even if stimulation was driven in the presence of Con A or
anti-TCR mAbs. Pretreatment of HLA-B27 DCs with lipopolysaccha-
ride or IFN-γ did not enhance their stimulatory capacity. In competitive
culture, and transwell assay, we found no evidence for an inhibitory
factor or a lack of diffusible factor produced by HLA-B27 DCs. When
comparing class II MHC, CD2, B7, ICAM1, and LFA-1 molecules at the
surface of DC from 33-3, 120-4, and nontransgenic rats, we found no
difference. However, the proportion of conjugates formed between
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33-3 DC and allogeneic or syngeneic T cells was decreased, which
could account for a defective stimulation of those T cells. We have
confirmed a defective stimulation of T cells by APCs in disease-prone
33-3 rats, the mechanism of which appears to implicate APC/T-cell
contact, independently of TCR engagement. It must involve accessory
cell function, and could explain a loss of tolerance towards microbial
flora in this model of spondyloarthropathy.
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Background: Macrophagic myofasciitis (MMF) is characterised by
specific myopathological alterations with inflammatory infiltrates of the
monocyte/macrophage lineage containing aluminic inclusions.
Objective: The aim of this study was to analyse the HLA-DRB1 poly-
morphism in determining genetic susceptibility to MMF.
Methods: HLA-DRB1 alleles were defined by polymerase chain reac-
tion SSOP/SSP genotyping in 10 European Mediterranean MMF
patients and 230 unrelated healthy controls.
Results: An increased frequency of HLA-DRB1*01 was observed in
MMF patients (66%) in comparison with controls (17%) (OR 9.8, CI
2.0–62.2) (P<0.002, Pc<0.03). There was no significant difference in
the distribution of the remaining HLA-DRB1 alleles frequencies
between MMF and controls.
Conclusion: In Southern France, HLA-DRB1*01 is significantly associ-
ated with MMF.
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Background: HLA-DRB1 alleles coding for the shared epitope (SE),
an amino acid motif in the third hypervariable region of the beta 1 chain
of HLA-DR, are associated with RA. The underlying biological mecha-
nism is unknown. A model was recently proposed (Reviron et al. Arthri-
tis Rheum 2001; 44:535–540), based on the electric charge (EC) of
the fourth antigenic peptide-binding pocket (P4) of the HLA-DR mole-
cule. SE alleles carrying a strong positive EC at P4, the model postu-
lates that the negative EC of the P4 has a protective effect for RA that
modulates the effect of the SE.
Objective: To test that model, taking advantage of familial-based asso-
ciation analysis.
Methods: The DNA of 100 Caucasian French families with one RA
patient and both parents were genotyped for HLA-DRB1. Genotypes
were stratified in susceptible (S), neutral (N) and protective (P) groups:
S for the genotype SE/SE and the genotype SE/EC+ (non SE allele
with a positive EC); N for the genotype SE/EC– (non SE allele with a
negative EC) and the genotype EC+/EC+; P for the genotype EC–/ EC–
and the genotype EC–/EC+.
The analysis was performed with a genotype relative-risk method com-
paring the RA patient genotypes with the virtual control genotypes
reconstructed from parental untransmitted alleles. The expectations
from the model were: S genotype more frequent in RA, N genotype
with similar frequency in RA and controls and P genotype more fre-
quent in controls.
Results: The S genotype was more frequent in RA (55% versus 29%,
P=1.9×10–4), the N genotype had similar frequencies (33% in RA
versus 29% in controls, not significant) and the P genotype was more
frequent in controls (42% versus 12%, P=1.8×10–6).
Conclusion: Our results are in keeping with a protective effect of the
negative EC of the P4 HLA-DR pocket modulating the SE effect on RA
susceptibility.
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Background: In mice, CD25+ CD4+ T regulatory cells have been impli-
cated in the control of immune responses and may have the potential to
be used in therapies for autoimmune diseases, such as rheumatoid
arthritis.
Objective: In order to evaluate their involvement in chronic arthritis, we
depleted CD25+ cells in DBA/1 mice, which are susceptible to colla-
gen-induced arthritis (CIA).
Results: Significant increases in severity and collagen-specific anti-
bodies were seen in mice that were depleted before immunization with
collagen.  In vitro tests with splenocytes from depleted mice also
showed increased proliferation of collagen-specific T cells, indicating
that CD25+ regulatory cells are involved in CIA. In humans, the
HLA-DQ8 molecule is strongly associated with rheumatoid arthritis.
Since CD25+ CD4+ T regulatory cells are probably selected in the
thymus, specific MHC class II molecules could hinder their develop-
ment, which could explain the association between HLA and disease
susceptibility. In order to explore this possibility, we performed similar
experiments in HLA-DQ8 transgenic mice. We found that depletion of
CD25+ cells had the same effect on CIA as seen in the DBA/1 mice.
Furthermore, DQ8-restricted CD25+ CD4+ T cells were found to be as
capable of suppressing the proliferation of PHA stimulated splenocytes
as CD25+ CD4+ T regulatory cells isolated from DBA/1 mice.
Conclusion: These findings indicate that CD25+ regulatory cells can
modulate arthritis and that HLA-DQ8 does not interfere in the genera-
tion of functional CD25+ CD4+ T regulatory cells.
Gene and cell therapy
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Effect of synovial fluid on adeno-associated virus
mediated gene transfer to chondrocytes
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Background: Direct intra-articular gene tranfer with adeno-associated
virus (AAV) vectors is a promising strategy to allow efficient therapeutic
transgene expression within the joint. However, over 90% of humans
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demonstrate antibodies against AAV which could alter AAV transduc-
tion efficiency in vivo.
Objective: Our objective was to determine the influence of synovial
fluid (SF) and serum from arthritic patients on AAV-mediated gene
transfer to chondrocytes in vitro.
Methods: SF and sera derived from 21 patients suffering from various
(inflammatory or mechanical) origins were collected. Neutralizing activ-
ity against AAV/IL-4 was determined by assessing the ability of SF or
serum to inhibit transduction of AAV/IL-4 into the C20A4 human chon-
drocyte cell line. Total IgGs were purified from SF by salt-dependent
chromatography.
Results: In SF and sera, inhibition of AAV-mediated gene transfer to
chondrocytes was observed in all arthritic patients. Purified IgG from
SF exhibited inhibition patterns similar to those seen with unfraction-
ated SF. A correlation was observed between levels of inhibition by the
SF and the serum (P<0.0001, r=0.813). Lastly, we have shown that
the inhibition of AAV/IL-4 infection on C20A4 cells by SF and sera
could be reversed by increasing the number of AAV/IL-4 particles, with
a dose-dependent effect.
Conclusion: SF and sera from all patients show a neutralizing activity
against AAV infection on chondrocytes. Neutralizing factors were IgG
antibodies present in the SF. This inhibition can be reversed by increas-
ing AAV doses. In the future, these data might be useful to adapt intra-
articular AAV gene therapy to each individual patient.
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Background: The Dox-inducible reverse tetracycline transactivator
(rtTA) is often used to control gene activity in cells and transgenic
animals. However, the Tet-on system is limited by the high levels of
transgene expression in the absence of doxycycline administration.
Objective and methods: To overcome this unregulated expression, we
used the tetracycline-dependent transcriptional silencer (tTS) that
binds the tetO inducible promoter in the absence of Dox. Controlled
gene expression was analyzed in vivo by delivering combinations of the
Dox-regulated luciferase reporter construct, the rtTA and the tTS
expression plasmids into the tibialis anterior muscles of adult mice,
using electrotransfer.
Results: Elevated luciferase expression levels were observed in the
absence of doxycycline, and a 10-fold induction was obtained after
drug administration. In contrast, when tTS was added, background
expression was dramatically lowered, by three to four orders of magni-
tude, and induction was maintained. The tTS system was then used to
control expression of a therapeutic gene in experimental arthritis. The
tibialis anterior muscle of DBA1 mice was coinjected with plasmids
encoding the anti-inflammatory cytokine viral interleukin-10 (vIL-10)
under the control of the tetO promoter, the rtTA and tTS. Electropora-
tion of injected muscles resulted in a dose-dependent increase in
vIL-10 expression, maintained over a 3-month period. The Dox-regu-
lated vIL-10 secretion showed significant inhibitory effects on collagen-
induced arthritis, as paw swelling was reduced and the onset of
disease was delayed in the Dox-treated group in comparison with the
control group without Dox.
Conclusion: The use of tTS significantly improves the utility of the rtTA
system for somatic gene transfer by reducing background activity.
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Background: Dendritic cells (DCa) play an important role for initiation
and regulation of immune response in arthritis. Immature DCs with a
low expression of MHC class II and of coactivation molecules CD86
have a tolerigenic potential in vivo. Previous studies have shown that
genetically modified DCs and TNF-α-matured DCs may prevent
autoimmune diseases or allograft rejection.
Objective: Therefore, we explored the immunological effects of differ-
entially matured DCs on the development of collagen-induced arthritis
in mice.
Methods: Murine bone-marrow-derived DCs where cultured in the
presence of granulocyte/macrophage-colony-stimulating factor and
IL-4 and incubated with collagen type II (CII). Maturation of the DCs
was blocked with IL-10, or induced with TNF-α or lipopolysaccharide
(LPS). The DC differentiation and maturation steps were controlled by
CD11c and CD86 expression, which was assessed by flow cytometry.
Seven days before immunisation with bovine CII, mice were injected
intraperitoneally with 500,000 DCs obtained at different stages of mat-
uration. Mice were boosted on day 21 after arthritis induction and the
disease course was monitored until day 43. DC function was assessed
through mlR assays.
Results: While injection with IL-10-blocked or LPS-matured DCs had
no significant influence on the onset and development of arthritis,
administration of TNF-matured DCs resulted in a reduction of arthritis
severity in comparison with the control group. In contrast, mice treated
with immature DCs showed a delayed arthritis onset and a decrease in
the arthritis clinical score.
Conclusions: Collagen-induced arthritis may be prevented by pretreat-
ment with antigen-specific immature DCs or TNF-matured DCs. Fur-
thermore, the principle of DC-mediated tolerance may have promising
immunotherapeutic potential in arthritis.
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Background and objective: Synovial membrane fibroblasts in rheuma-
toid arthritis induce the destruction of cartilage and bone. We have iso-
lated a fibroblast cell line which induces a rapid destruction of articular
cartilage following intraarticular instillation in SCID mice and in vitro.
Both approaches can be modulated by gene transfer.
Methods: As a cytokine with functions directed to inflammatory and
immune cells as well as fibroblasts, interleukin-11 was selected to
modulate invasive behaviour of fibroblasts. For transduction, a retroviral
vector system, particle-mediated transfer (gene gun), and a lentiviral
vector based on simian immunodeficiency virus were investigated.
Cells (500,000) were injected directly into the knee joinst of mice with
severe combined immunodeficiency (SCID). Mice were monitored for
joint swelling, serological parameters and by radiological methods.
In vitro, cells were coincubated with cartilage for 1 week. Finally, the
histology of cartilage destruction and signs of apoptosis were studied.
Results: The efficacy of gene transfer was <10% for retroviral transfer
or gene gun but >85% for lentiviral transfer. Therefore, animal testing
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and in vitro assays were performed with lentiviral-transfected cells in
comparison with nontransfected invasive fibroblasts and control cells.
Cartilage destruction within 10 days was induced by instillation of non-
transfected cells. Morphology revealed invasion of fibroblast-like cells
into the articular cartilage. Transfection with interleukin-11 did not act
on swelling but slightly reduced cartilage invasion. In vitro, this effect
was caused by reduction of apoptosis in chondrocytes.
Conclusion: Induction of cartilage destruction by intraarticular applica-
tion of fibroblast like cells into SCID mice can be modulated by gene
transfer. Lentiviral vectors systems offer a novel approach for highly effi-
cient transduction of these cells. This model provides the opportunity
to check novel therapeutic strategies for reduction of cartilage erosion.
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Background: Interleukin-4 (IL-4) has anti-inflammatory effects in colla-
gen-induced arthritis (CIA). Osteoprotegerin (OPG) inhibits bone
resorption by binding the receptor activator of nuclear factor κB ligand
(RANKL) and thereby inhibits binding of RANKL to RANK (receptor
activator of nuclear factor κB) receptors of osteoclast precursors.
Objectives: To evaluate the action of OPG and IL-4 on the inflamma-
tory process and the bone resorption associated with the inflammation.
Methods:  CIA was induced in DBA/1 mice by immunization with
bovine type II collagen (CII). Mice were treated by subcutaneous injec-
tions of OPG-Fc or with IL-4 DBA/1-transfected fibroblasts or both
OPG-Fc+IL-4. Control groups received DBA/Tst or I1gG or saline. In
one group CIA was not induced. Urinary deoxypyridinolin levels and
total-body bone mineral density (BMD, Piximus Lunar) were measured
at baseline and at sacrifice, allowing the measure of bone gain (BMD).
Spleen cells were cultured after stimulation with CII, and cytokines
were measured in the supernatants using ELISA techniques.
Results: CIA significantly improved in the IL-4 groups. OPG had no
effect on arthritis clinical scores but histologic scores were reduced in
OPG, IL-4 and OPG+IL-4 groups versus nontreated CIA mice. Treat-
ment with OPG significantly increased BMD in the total body. More-
over, the combination of IL-4 and OPG exerted an additive effect of
BMD. D-pyridinolin levels decreased by 45% in OPG-treated mice and
by 68% when mice were treated with both OPG and IL-4. INF-γ pro-
duction was inhibited in IL-4 treated mice in comparison with controls.
Interestingly, OPG also had a moderate effect on IFN-γ but potentiated
the inhibitory effect observed in IL-4-treated mice.
Conclusion: OPG and IL-4 prevent bone loss in CIA in the mouse
model and could have additive effects.
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Background and objective: Most antirheumatic therapies are given
systemically, which may result in complications because of the high
dosage needed to achieve therapeutic levels in the joints. Gene therapy
might provide a more efficient system to deliver therapeutic compounds
at the site of inflammation. The artificial chromosome expression system
(ACes) is a unique, nonintegrating, nonviral gene-expression system,
which functions like a natural chromosome. This technology offers
advantages over current expression systems because it allows stable
expression of genes producing single or multiple proteins over long
periods. We are developing ex vivo gene therapy using artificial chromo-
somes containing reporter genes (LacZ or RFP) for local delivery of
genes in rats with adjuvant arthritis. The aim of this study was to evalu-
ate the transfection efficiency in cell lines or primary cells, including rat
skin fibroblasts (RSFs) and fibroblast-like synoviocytes (FLSs). Further-
more, we investigated the feasibility of local delivery of a marker gene to
the joints of rats with adjuvant arthritis (AA) by ex vivo gene therapy.
Methods: Transfer efficiency and optimal dose of transfection agent
were determined using iododeoxyuridine (IdUrd)-incorporated ACes
complexed to Superfect (Qiagen) (Cytometry Vol 44:100-105, 2001).
Following transfection, ACes were antibody-labeled and cells were ana-
lyzed by flow cytometry and fluorescent photomicroscopy. Using opti-
mized transfection conditions and after growing the cells under
selection, we expanded the colonies and determined reporter gene
expression. Cell lines or primary cells transfected with Aces containing
the LacZ gene or control cells were injected into the right ankle joints of
rats with adjuvant arthritis on day 12 after adjuvant immunization. Joints
were harvested 2 and 7 days later and assayed for beta-gal activity.
Results: The delivery of intact artificial chromosomes was detected
within 24h post transfection. Maximum delivery rates of 27% were
observed. Flow cytometry data correlated well with microscopic analy-
sis. After growing cell lines and primary cells under selection, clones
expressing LacZ and RFP were identified. Ex vivo transfer of the LacZ
gene to the ankle joints of rats with AA resulted in expression of the
marker gene in the synovium. In the other organs, LacZ expression was
not detected two days after injection of the cells.
Conclusion: The results demonstrate that IdUrd-labelled ACes can be
detected 24h after transfection. Both cell lines and primary cells can
be efficiently transfected with ACes and express the transgene. In
addition, we show successful local ex vivo gene transfer in a rat AA
model using ACes containing a marker gene. This work demonstrates
the potential feasibility of treating arthritis and other connective tissue
diseases utilizing ACes as nonviral vectors for gene therapy.
Genetics
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Background: Paget’s disease of bone (PDB) is a chronic disease of the
skeleton that affects 3% of the Caucasian population aged over
40 years. PDB often segregates as an autosomal dominant trait.
Genetic heterogeneity has been demonstrated, with at least 2 PDB loci,
on chromosomes 18 (18q23) and 5 (5q35-qter). At the chromosome 5
locus, (Laurin et al. Am J Hum Genet 2002; 70:1582–1588) identified
in the sequestosome 1 (SQSTM1) gene, involved in the RANK (recep-
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tor activator of NF-κB) pathway, a recurrent mutation (P392L) present in
16% of the sporadic PDB patients in the French Canadian population.
Genetic testing is clinically relevant, as it could lead, in families carrying
the mutation, to early diagnosis at the clinically asymptomatic stage,
when early treatment could be attempted to prevent complications.
However, it is not known whether this mutation is specific to the Cana-
dian population or is frequent in other Caucasian populations.
Objective: To evaluate the frequency of the SQSTM1 P392L mutation
in the French Caucasian population.
Methods:  Nineteen French Caucasian patients with sporadic PDB
underwent genetic testing. The search for the mutation relied on a
PCR-RFLP assay.
Results: The P392L mutation of SQSTM1 was detected in 2 patients
out of 19 (11%).
Conclusion: The P392L mutation of the SQSTM1 gene in PDB is fre-
quent in the French Caucasian population. Investigation of other Euro-
pean populations would be of interest. Genetic testing of PDB patients
in France is indicated, aiming at early diagnosis in relatives of patients
carrying the mutation.
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Objective: Juvenile idiopathic arthritis (JIA), a chronic inflammatory joint
disease, is associated with particular alleles at three different HLA loci:
HLA-A, DR-DQ, and DP. We have recently found that a gene in the vicin-
ity of microsatellite (MS) marker D6S265 in the HLA class I region may
contribute to a predisposition to JIA. To further evaluate the implicated
region containing marker D6S265, we analyzed a denser set of polymor-
phic markers covering ~1.8Mb of the HLA region around D6S265.
Methods: We investigated 102 patients with JIA classified according
to the ACR criteria. As controls we selected 207 healthy, unrelated
individuals. Only patients and controls carrying the DR8-DQ4 haplo-
type were included in this study. We used 13MS markers covering a
region ~1Mb and ~0.8Mb centromeric and telomeric, respectively, to
D6S265. An EM- algorithm was used to estimate haplotypes, and the
distribution of MS alleles on the DR8-DQ4 haplotype was compared
between patients and controls, in order to exclude associations sec-
ondary to linkage disequilibrium (LD) with this high-risk haplotype.
Results: The strongest association with JIA was observed for allele 5
at D6S265 (OR=3.1; Pc<10 –4) (~100kb centromeric to HLA-A). LD
and haplotype analyses showed that the D6S265*5 association was
not secondary to an association to HLA-A*0201, previously reported to
be associated with JIA. Positive associations with JIA showed also:
allele 7 at D6S2704 (Pc<0.05) (~160kb centromeric to D6S265) and
allele 11 at D6S2707 (Pc<0.005) (~300kb telomeric to D6S265).
This strongly suggests that our initially observed association to
D6S265*5 is not a false positive result, but reflects the presence of a
true disease-susceptibility gene in this region. Furthermore, the analysis
of three-marker rolling haplotypes demonstrated a peak of association
close to D6S265.
Conclusion: This hitherto unidentified gene in the HLA class I region,
marked by D6S265*5 and distinct from HLA-A2, influences the risk for
JIA conferred by the DR8-DQ4 haplotype. The gene in question
remains to be identified.
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Objective: To identify rheumatoid arthritis- (RA)-specific profiles of dif-
ferentially expressed genes.
Methods: Synovial tissues from RA and osteoarthritis (OA) patients and
from normal joints were selected according to their disease-characteris-
tic histology. Gene expression was analyzed using DNA microarrays
(GeneChip; Unigene-array) and representational difference analysis
(RDA). Data were validated on larger cohorts of patients by RT-PCR.
Results: Nine hundred and eighty genes were significantly regulated in
RA synovial tissue as compared with non-RA. Specialized cluster analy-
sis identified a set of 312 genes as sufficient of unequivocally discrimi-
nating RA from non-RA patterns (class discovery). Genes of highest
regulation were associated with leukocyte activation (chemokines,
chemokine receptors, B- and T-cell genes), endothelial and angiogenic
activation, tissue destruction and remodelling [MMP-3, BMP-4, TIMPs].
Interestingly, a large set of genes was down-regulated in RA (TGF-β
superfamily, apoptosis-related genes, transcription factors). Osteopon-
tin-like genes (n=46) — up-regulated in RA — and glutathione peroxi-
dase-3-like genes (n=85) — down-regulated in RA — yielded the
highest correlation coefficients (>0.94). Megakaryocyte stimulating
factor (MSF), down-regulated in a subset of RA, may hold the key to
subclassification: a loss-of-function mutation in the MSF-encoding
gene leads to synovial hyperplasia in camptodactyly–arthropathy–coxa
vara–pericarditis syndrome, and, as in RA, also to pericardial involve-
ment. A further candidate, vitamin-D3-up-regulated protein-1 (VDUP-1),
is regulated like MSF and predisposes to premature coronary artery
disease when mutated, again a feature of a subset of RA.
Conclusion: RA specific gene profiles were identified and are useful to
improve diagnostics of the disease. Novel gene candidates not yet in
the focus of RA pathogenesis have been identified that are likely to
further the understanding of RA.
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Objective: We investigated whether there is a link between two
markers for Crohn’s disease (CD): the CD susceptibility mutations in
the CARD15 gene and the serologic anti-Saccharomyces cerevisiae
(ASCA) antibodies. Both markers may, in some way, also be associ-
ated with spondyloarthropathy (SpA), which is known to be related to
inflammatory bowel disease.
Methods: Serum samples of 109 CD patients were analysed for IgA
and IgG ASCA with a commercial ELISA kit. A RFLP-PCR technique
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was used to genotype all patients for three single-nucleotide polymor-
phisms (SNPs) in the CARD15 gene: R702W, G908R and 1007fs.
Every SNP was verified by direct sequencing.
Results: The overall carrier frequency of a CARD15 mutation in CD
was 50.5%. ASCA-positivity for IgA, IgG and IgG or IgA was found in
respectively 31.2%, 31.2% and 43.1% .
Chi-square testing showed a positive association between CARD15
mutation and ASCA IgA (P=0.001, OR=4.167, CI 1.709–10.157),
IgG (P=0.005, OR=3.406, CI 1.428–8.124) and IgA or IgG
(P=0.005, OR=3.068, CI 1.391–6.764).
Conclusion: CARD15 mutations and ASCA are not independent risk
factors for CD. Instead, they are significantly associated with each
other in a population of CD patients (both for ASCA IgA and IgG
isotype). This could be interpreted in a double way. CARD15 mutations
and ASCA may be both associated with a particular, as-yet-undefined,
phenotypic subset of CD. Or CARD15, as an immune-response gene,
may in some way modulate humoral immunity, predisposing to the gen-
erating of ASCA.
Infection
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Objective: For 20 years the Epstein–Barr virus (EBV) has been sus-
pected to contribute to the pathogenesis of rheumatoid arthritis (RA).
RA is strongly associated with shared epitope positive HLA-DR alleles.
EBV load has been extensively studied in RA patients, using semiquan-
titative PCR. Inconsistent results reflect the lack of sensitivity and accu-
racy of this technique. We quantified EBV in peripheral blood
mononuclear cells by real time PCR, to determine whether EBV load is
higher in RA patients than in controls and to test whether HLA-DR
alleles or treatment influences EBV load.
Methods: Eighty-four patients fulfilling the 1987 ACR criteria for RA
and 22 patients with rheumatic conditions other than RA were studied.
Sixty-nine healthy controls were chosen from bone marrow donors at
the Marseille blood transfusion center. HLA-DR genotyping of patients
and controls was performed by PCR-SSP. Real-time PCR was per-
formed using a Roche LightCycler. A 214-bp fragment from the highly
conserved long internal repeat IR1 was amplified. Two specific
hybridization probes were used to recognize adjacent internal
sequences within the target. EBV-positive Burkitt’s lymphoma cell line
was used as an external standard.
Results and conclusion: EBV load is expressed in EBV genome copy
number per 500ng of human genomic DNA (1.5×105 cells). We
found that patients with RA have a higher EBV load (median 8.84) than
non-RA patients (median 1.56) and healthy controls (median 0.6). EBV
load is not obviously influenced by disease-modifying antirheumatic
drugs nor by HLA-DR and is stable over time.
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Background: Bacterial infections are common and are known to be
involved in many diseases including arthritis. While some methods for
detecting bacteria are time-consuming, others are faster but lack speci-
ficity and/or sensitivity.
Methods and results: We employed a new method for DNA isolation
and compared the results with those of an established method. We
show that an equivalent of fewer than 10 bacteria of Staphylococcus
aureus (SA), methicillin-resistant Staphylococcus aureus, Staphylococ-
cus epidermitis (SE) or bacteria in general can be detected in less than
2 hours.
We found that lyses in a SDS/β-mercaptoethanol buffer and exposure
to microwaves is as well suited for detecting fewer than 10 microor-
ganisms per sample as a longer, more elaborate and more expensive
method using specific enzymes. We further confirmed the sensitivity of
our multiplex PCR method by recovery experiments using known
amounts of bacteria. Such experiments showed that bacteria present in
single-digit quantities can be detected even in viscous solutions such
as synovial fluid. We further showed that the chosen primer pairs are
suited for multiplex PCR, the simultaneous testing of samples for the
presence of SA, SE, and/or bacteria in general. We also showed that
the assay conditions are suitable for detecting the presence of methi-
cillin-resistant forms of SA. The specificity of the PCR was confirmed
by comparison of the actual size with the calculated length of the frag-
ment, and by sequencing of the PCR product.
Conclusion: Taken together, our method of rapid DNA isolation and
the optimized PCR program make it possible to confirm the presence
or absence of minute amounts of bacteria. Employing real-time PCR
would shorten this procedure even further. This method might therefore
contribute to more timely and specific interventions.
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Background: The shared epitope (SE) helps the development of
rheumatoid arthritis (RA) by an unknown mechanism. The Epstein–Barr
virus (EBV) glycoprotein gp110, a major target in the immune control of
EBV replication, contains a copy of the SE. We previously showed that
frequencies of T-cell precursors specific to EBV gp110 are influenced
by HLA-DR polymorphism and that RA patients have low frequencies
of T cells specific for EBV gp110.
Objective: To determine the frequency of T cells (limiting dilution analysis)
specific for EBV gp110 and a control antigen (Escherichia coli protein
extract) in the synovial fluid of patients with RA or various forms of arthritis.
Methods: Nine RA patients (ACR 1987 criteria; mean age
61.1±7.3 years) and 10 controls with inflammatory rheumatic diseases
(mean age 42.5±17.4 years) were studied. For RA patients, the fre-
quency of both peripheral blood and synovial T cells specific for EBV
gp110 was evaluated.
Results: In the synovial fluid, the frequency of T cells specific for EBV
gp110 was significantly higher in RA than in non-RA patients
(mean±SD 2.5±1.6×10–6 vs 0.7±0.9×10 –6;  P=0.02) (no differ-
ence for the control antigen: 1.9±3.3×10–6 vs 2.1±2.0×10 –6;
P=0.3). In RA patients, the frequency of T cells proliferating to gp110
was higher in the synovial fluid than in peripheral blood, but without
achieving statistical significance (2.5±1.6×10–6 vs 2.0±1.8×10 –6;
P=0.7) (no difference for the control antigen).
Conclusion: A high frequency of T cells specific for EBV gp110 can
be detected in the synovial fluid of RA patients, providing further
support for the argument that EBV is involved in RA pathogenesis.
Available online http://arthritis-research.com/supplements/5/S1S26
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Background: Polymyositis (PM) and dermatomyositis (DM) are charac-
terised by symmetrical muscle weakness, inflammatory infiltrates in
skeletal muscle tissue and skin rash (DM).
Objective: Our aim was to investigate the effects of high-dose intra-
venous immunoglobulin (IVIg) treatment of PM/DM patients on expres-
sion of various immunological markers in skeletal muscle tissue, e.g.
major histocompatibility complex (MHC) class I and macrophages; on
clinical signs; and on muscle status.
Methods: Six PM and four DM patients were treated intravenously with
high-dose IVIg. Skeletal muscle biopsies were collected from these
patients on three occasions: before treatment, and 24–48 hours and
3 months after treatment. Consecutive sections immunohistochemically
stained for HLA-ABC and CD163 were analysed both manually by con-
ventional microscope and by computerized image analysis. The per-
centage of positively stained areas and the number of cells per mm2
were assessed.
Results:  The skeletal muscle tissue of IVIg-treated PM/DM patients
revealed a heterogeneous change and covariation in expression of
MHC class I and macrophages. Correlations with clinical parameters
and muscle function will be determined.
Conclusions: IVIg treatment affects the expression of MHC class I and
CD163 positive macrophages in skeletal muscle tissue of PM/DM
patients in a heterogenous and covarying fashion.
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Background: Polymyositis (PM) and dermatomyositis (DM) are chronic
inflammatory muscle disorders of unknown origin. The ubiquitously
expressed nuclear protein high mobility group box chromosomal
protein 1 (H MGB1) will, when released extracellularly, act as a potent
proinflammatory molecule.
Objective: To investigate H MGB1 expression in muscle tissue from
PM and DM patients with and without inflammatory infiltrates present in
their muscle biopsy.
Methods: Muscle biopsy specimens from 10 patients (6PM, 4DM)
with and 14 patients (8PM, 6DM) without inflammatory cell infiltrates
and 8 healthy controls were investigated. HMGB1 expression was
studied by immunohistochemical staining.
Results: Patients with inflammatory cell infiltrates show HMGB1 stain-
ing mainly with a cytoplasmic localization in vascular endothelial cells,
infiltrating rounded mononuclear cells of macrophage-like morphology
for all patients and in muscle fibres in 6 of 10 patients. In patients
without inflammatory infiltrates, HMGB1 was detected in 3 of 14
patients, all with DM, in endothelial cells with a cytoplasmic manner,
there was no HMGB1 expression in the muscle fibres. No cytoplasmic
or nuclear HMGB1 expression was found in the muscle tissue speci-
mens from healthy controls.
Conclusion: HMGB1 was detected in muscle biopsies from PM and
DM patients with inflammatory cell infiltrates. HMGB1 could play a role
in maintaining the chronic inflammation. The major cell source of
HMGB1 production in myositis seems to be the mononuclear inflam-
matory cells. HMGB1 could be a molecule of potential interest for new
targeted therapy in myositis.
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Background: Antilipemic agents such as statins are extensively used
for the acute and long-term treatment of cardiovasular disease.
Adverse muscle effects commonly include myalgias and elevated
serum creatine kinase whereas a few fatal cases associated with myo-
globinuria and renal failure have been described recently.
Objective: The purpose of the present study was to investigate muscle
contraction using in vitro contracture tests (IVCT) in patients with
adverse effects from anticholesterolemic treatment.
Methods: Two patients with statin-therapy-induced mylagias and rhab-
domyolysis were included in the study. They were investigated
6 months after discontinuation of statin treatment, when signs of rhab-
domyolysis had disappeared. In vitro contracture tests in the presence
of halothane or caffeine were performed in accordance with the guide-
lines to the European Malignant Hyperpyrexia Group.
Results: Histological and immunohistochemical analyses showed
signs of rhabdomyolysis. Abnormal muscle contracture was measured
with both halothane and caffeine in the first patient. For the second
patient, muscle samples developed abnormal contracture with
halothane only. Both patients were diagnosed as having malignant
hyperthermia syndrome.
Conclusion: Our results further confirm the myotoxic effects of treat-
ment with statins. We report for the first time these effects in patients
with malignant hyperthermia syndrome for whom calcium homeostasis
is impaired in skeletal muscle. This impairment is commonly attributed
to a genetic defect affecting the ryanodine receptor, one of the calcium
channels in the sarcoplasmic reticulum membrane. Our result suggest
that toxic rhabdomyolysis could be a sign of susceptibility to malignant
hyperthermia and that muscle contraction should be investigated, using
IVCT, in subjects who develop myalgia with rhabdomyolysis during
treatment with statins.
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The diagnostic value of synovial histopathology in
undifferentiated inflammatory arthritis: a prospective
study in 154 consecutive patients
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Objective: To explore prospectively the diagnostic value of synovial
histopathology in undifferentiated inflammatory arthritis by analysing the
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positive predictive value (PPV) of single histological markers and the
additive value of multiparameter models.
Methods: Synovial biopsies were obtained in 154 consecutive patients
presenting for diagnostic work-out: 67 were clinically classified as
rheumatoid arthritis (RA), spondyloarthropathy (SpA), or other disease
at time of arthroscopy (cohort 1). Patients with undifferentiated arthritis
(n=87) were re-evaluated after 6 months, yielding a diagnosis in
53 (cohort 2). Macroscopic, histological, and immunohistochemical
synovial parameters with diagnostic value were identified in cohort 1.
Subsequently, the PPV of single parameters and multiparameter
models was tested in cohort 2.
Results: Four single parameters yielded PPVs of more than 95% in
cohort 1: anticitrulline staining, mAb 12A staining (recognising a spe-
cific MHC/peptide complex), and lining layer hyperplasia of more than
five cell layers for RA and crystal depositions for other diseases. In
undifferentiated arthritis, only anticitrulline staining, mAb 12A staining,
and crystal depositions had a PPV of more than 90%. Using these
parameters, 39.6% of the undifferentiated patients were classified, with
a PPV of 90.5%.
Using cohort 1 as a learning file, two decision trees were developed
which made a prediction in 74.6% and 67.2% of the patients, with
PPVs of 88.0% and 86.7%, respectively. When this was applied to
cohort 2, a diagnostic prediction was made in 79.2% and 71.7% of the
patients, with a PPV of 81.0% and 86.8%, respectively.
Conclusion: This study supports the idea that synovial histopathology
can be used for the early diagnosis of undifferentiated arthritis and that
multiparameter models have an additive value compared with single
parameters.
Acknowledgments:  The authors thank Annemieke Boots and Peter
Steenbakkers, Organon NV, for providing mAb 12A.
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Objective: We recently described an increase of macrophages
expressing the scavenger receptor CD163 in synovium and gut of SpA
patients. CD163 is a receptor for haemoglobin–haptoglobin (Hp) com-
plexes with highest affinity for the multimeric 2-2Hp phenotype.
CD163 can be shed from the macrophage membrane as a soluble
protein (sCD163), which has been shown to inhibit lymphocyte prolif-
eration in vitro. The present aim is to find out if the increased presence
of CD163+ macrophages in SpA is associated with Hp polymorphism
and/or local production of sCD163 in the joint.
Methods: CD163+ macrophages in synovium and sCD163 in synovial
fluid (SF) (normalized for albumin levels) were assessed by immunohis-
tochemistry and ELISA, respectively, in 26 SpA and 23 RA patients.
Serum sCD163 was analysed in 100 SpA patients, 23 RA patients,
and 20 healthy controls (HCs). Serum sCD163 was reassessed after
12 weeks of treatment with infliximab in 20 SpA patients. Finally, Hp
polymorphisms were determined in 130 SpA and 23 RA patients.
Results: The number of CD163+ macrophages was increased in both
synovial lining (P<0.001) and sublining (P<0.001) in SpA patients
versus RA patients. Within the SpA group, HLA-B27+ patients had
higher scores than HLA-B27– (P=0.022 and P=0.016 for lining and
sublining, respectively). SF median sCD163 levels were high in both
SpA (8.04mg/l) and RA (8.79mg/l), and approximately three times
higher than the corresponding serum levels. Interestingly, in SpA,
sCD163 in SF correlated with that in the synovial lining (r=0.43,
P=0.034) and in serum (r=0.33,  P=0.002). Serum sCD163 was
increased in SpA (2.2mg/l) (P=0.008) and RA (3.0mg/l) (P<0.001)
versus HCs. In SpA, serum sCD163 correlated weakly with CRP and
ESR, but was unaffected by infliximab treatment. Finally, Hp polymor-
phisms in SpA were characterised by a slight underrepresentation of
the 1-1 and overrepresentation of the 2-1 phenotype. Hp polymor-
phisms were not associated with serum or SF sCD163 levels.
Conclusion: These data confirm an increased presence of CD163+
macrophages in the SpA joint and indicate local production of
sCD163. The increased levels of sCD163 may contribute to local
impairment of T-cell proliferation and activation in SpA.
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Objective: We indicated recently that synovial histopathology can be
used for early diagnosis of undifferentiated arthritis (UA), with multipara-
meter models such as decision trees being superior to single parame-
ters. The present aim is to build a prediction method based on a neural
network approach and to compare this to the decision tree algorithm.
Methods: Synovial histopathology (including14 parameters) was per-
formed on 120 synovia of patients with knee synovitis presenting for
diagnostic workout. In 67 patients, a definite diagnosis was made at
the time of arthroscopy (32 RA, 22 SpA, 13 other diseases); this
cohort was used as learning file for the algorithms. The remaining
53 patients had real undifferentiated arthritis (UA) at presentation and a
definite diagnosis was obtained by clinical follow-up (19 RA, 21 SpA,
13 other diseases) 6 months later; this cohort was used as test file to
validate the models. A self-organizing neural network was developed
using modified Kohonen mapping in combination with a case-based
learning evaluation criterion.
Results: Classifying all 53 UA, the global positive predictive value
(PPV) of the neural network was 64.2%, including a PPV of 78.9% for
RA, 57.9% for SpA, and 63.2% for other diseases. Using the decision
tree model on the same cohort, the global PPV was 69.8%, with a PPV
of 66.7% for RA, 70.0 % for SpA, and 77.8% for other diseases. Since
it is clinically more important to classify a subset of UA with a high PPV
(>80%) than to classify all patients (resulting in a lower overall PPV), a
distance criterion was placed on top of the case-based learning evalua-
tion algorithm, resulting in the classification of 50.9% of the samples
with a PPV of 81.5%. Using the same PPV requirement for the decision
tree, 79.2% of the samples were classified with a PPV of 81.0%.
Conclusion: Although the global performance of the neural network
was slightly inferior to the decision tree model, the neural network was
superior for the classification of RA. These results warrant further
research in the neural network approach, especially for classification
systems using a high number of parameters.
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Objective: The aim of this study was to characterise the organisation of
neolymphoid structures in glands of patients with Sjögren’s syndrome
and to correlate their maturation with CXCL13 and CCL21 expression.
Methods: Salivary-gland biopsies from 28 patients with SS and 12 with
sialoadenitis were examined using immunohistochemistry (IHC). Infil-
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trates were characterised according to the score (grade 1, <50 periduc-
tal lymphocytes; grade 2, >50 lymphocytes; grade 3= grade 1 or 2 plus
GC). Follicular maturation was assessed with respect to T/B-cell segre-
gation, CD45RO and CD45RA, CD21+ FDCs, GC and MECA79+
HEVs. CXCL13 and CCL21 expression was also assessed.
Results: Grade 1 showed predominance of CD3+/CD45RO+ infiltrat-
ing lymphocytes. Grade 2 showed increased number of CD20+/
CD45RA+ and a variable degree of organization (54.55% not segre-
gated, 21.21% atypically segregated, 24.24% segregated). Grade 3
showed CD20+/CD45RA+ predominance with typical segregation.
Within grades 2 and 3, we detected CD21+ FDC clusters. MECA79+
vessels were detected on the edge of the aggregates. CXCL13
expression was detected in 4.07% of grade 1, 46.16% of grade 2 and
100% of grade 3 aggregate and in some infiltrated ducts. CCL21
expression was detected in 2.5% of grade 1, 17.85% of grade 2 and
47.62% of grade 3 aggregates.
Conclusions: The presence of fully formed lymphoid follicles charac-
terized by GC, B/T segregation, HEVs and FDCs within the target
organs for SS, and the association of these structures with chemokines
acting as regulator of lymphoneogenesis, suggest a key role of these
molecules in the pathogenesis and evolution of the disease process.
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Background: Proinflammatory or anti-inflammatory roles have been
ascribed to leptin, depending on the experimental model investigated.
We recently observed decreased severity of antigen-induced arthritis
(AIA) in leptin-deficient ob/ob mice. However, joint inflammation in AIA
depends on the immune response to an exogenous antigen, which is
impaired in ob/ob mice.
Objective: The aim of the present study was to investigate potential
effects of leptin in zymosan-induced arthritis (ZIA), a model of acute
inflammatory arthritis, which is not dependent on the adaptive immune
response.
Methods and results: Arthritis was induced in ob/ob and control +/?
C57BL/6 mice by injection of zymosan A (Zy) into the knee joint cavity.
Increased blood flow, reflecting the severity of joint inflammation, was
quantified by uptake of technetium 99m. It was similar 6 and 24 hours
after Zy injection in ob/ob and control mice. However, it persisted on
day 3 in ob/ob animals, while subsiding in controls. Histology repeat-
edly showed similar severity of arthritis in ob/ob mice and controls on
day 3, but arthritis always tended to be more severe in ob/ob than in
+/? mice at later time points (days 14 and 21). Similar observations
were made using leptin-receptor-deficient db/db mice, suggesting that
the effects of leptin are mediated via the Ob-Rb receptor. The acute-
phase response was examined in ob/ob and control mice after injection
of Zy by measuring circulating levels of interleukin (IL)-6 and serum
amyloid A (SAA). Serum IL-6 increased in all animals during the first
24 hours after Zy injection, but IL-6 levels were significantly higher in
ob/ob mice than in controls. SAA increased in all animals during the
first 3 days after Zy injection, but SAA levels were significantly higher
on days 1 and 3 in ob/ob animals than in controls. The acute-phase
response thus appeared to be more pronounced in ob/ob mice,
although corticosterone levels were significantly elevated in these
animals at baseline and throughout the experiment
Conclusion: These data suggest that the resolution of acute inflamma-
tion during ZIA is delayed in leptin-deficient animals. In this model,
leptin thus appears to display anti-inflammatory properties, limiting the
acute phase response and the chronicity of arthritis.
94
Chondrocyte number and proteoglycan synthesis in
the ageing and osteoarthritic human articular cartilage
K Bobacz, A Soleiman, L Erlacher, J Smolen, WB Graninger
Department of Rheumatology, Internal Medicine III, University of
Vienna, Vienna, Austria
Arthritis Res Ther 2003, 5 (suppl 1):94
Objective: To correlate the number of chondrocytes in healthy and
osteoarthritic human articular cartilage with age and to evaluate the
influence of senescence on total proteoglycan synthesis.
Methods: Chondrocytes were isolated from human articular cartilage
derived from hip joints with and without osteoarthritic lesions. Cell
number was assessed by light microscopy and normalized to cartilage
sample wet weight. Chondrocytes were grown as monolayer cultures
for 7 days in a chemically defined serum-free basal medium. Total pro-
teoglycan synthesis was measured by [35S]sulfate incorporation into
newly synthesized macromolecules.
Results: Chondrocyte numbers in healthy cartilage decreased signifi-
cantly with advancing age (r=–0.69,  P<0.0001). In contrast to
healthy specimens, chondrocyte numbers were decreased in OA carti-
lage irrespective of and unrelated to age and differed markedly, by an
average of 38%, from the cell numbers found in healthy cartilaginous
tissue (P<0.0001). Regarding proteoglycan synthesis, no depen-
dence on patient’s age, either in healthy or in OA specimens, were
observed in our culture settings.
Conclusions: Chondrocytes from healthy and OA joints synthesized com-
parable amounts of PG, independent of age or underlying OA disease. As
the cell count in our monolayer cultures was constant, we conclude that
the decreased chondrocyte number found in the ageing and OA joints
could be a crucial factor in limiting tissue replenishment in vivo.
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Background and objective: Pathogenic accumulation of extracellular
matrix (ECM) is a common feature of progressive renal diseases.
Cytokines such as TGF-β as well as aberrant communication of renal
cells with ECM via specific cell-surface receptors are thought to play a
pivotal role in this process. Recently, a novel receptor tyrosine kinase
subfamily has been identified and designated as discoidin domain
receptor tyrosine kinase type 1 (DDR1) and type 2 (DDR2). These are
functional collagen receptors, whose tyrosine kinase is activated upon
binding to collagen. We sought to explore the expression and regula-
tion of DDR1 in the human kidney in both normal and diseased states.
Methods: We used cultured human mesangial and tubular cells and
renal biopsies from patients with lupus nephritis or normal kidneys
obtained from nephrectomies. DDR1 expression was studied by
immunohistochemistry and Northern and Western blot analyses. Tyro-
sine phosphorylation was detected by immunoblotting using antiphos-
photyrosine blots.
Results: High levels of DDR1 expression were detected by immunohis-
tochemistry in glomerular epithelial and mesangial cells (MCs) of
normal human kidney specimens. DDR1 was also expressed in renal
tubular epithelial cells, albeit at lower levels. As compared with normal
controls, DDR1 expression was significantly decreased in mesangial
areas obtained from patients with proliferative lupus nephritis (n=7),
while it was up-regulated in tubular epithelial cells surrounded by signif-
icant interstitial fibrosis. Cultured human MCs expressed DDR1 in vitro,
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a finding verified by Western and Northern blot analysis. Stimulation of
MCs with collagen induced tyrosine phosphorylation of DDR1, indicat-
ing that mesangial DDR1 is a functional collagen receptor. Interest-
ingly, platelet-derived growth factor and basic fibroblast growth factor,
both of which are potent mitogens for MCs, significantly decreased the
expression of DDR1 both in mRNA and protein levels. TGF-β did not
exert such an effect.
Conclusion: DDR1 participates in the interaction of MCs with mesan-
gial ECM. Decreased expression of DDR1 in MCs may represent an
important process for mesangial proliferation.
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Background and objective: Depletion of platelets reduces influx of
hemopoietic cells into the glomeruli, decreases resident cell prolifera-
tion and improves renal function in animal models of glomerulonephri-
tis. However, the precise mechanisms by which platelets promote
glomerular injury are poorly understood. We explored whether platelets
induce production of monocyte chemoattractant protein-1 (MCP-1) by
cultured human mesangial cells (MCs) and the mechanisms involved.
Methods: Platelets were isolated from normal human donors and
cocultured with MCs at various ratios. The contribution of cell-to-cell
contact was examined by a double-chamber culture system. MCP-1
synthesis in cocultures was determined by semiquantitative reverse
transcription/real-time PCR and ELISA. Signal transduction was
studied by mobility gel-shift assays and phosphotyrosine immunoblots.
Results: Platelets, at 1:100 ratio (MC:platelets), induced a more than
10-fold increase in mesangial MCP-1 production, both in mRNA and
protein levels. Using a double-chamber culture system, we demon-
strated that the direct cell-to-cell contact between platelets and MC is
indispensable for MCP-1 production. Importantly, blockade of the
CD40–CD40 ligand (CD40L) pathway with neutralizing antibodies
decreased MCP-1 production by approximately 60%. Immunostaining
confirmed the expression of CD40 by cultured MCs. When added into
MC cultures, recombinant CD40L in combination with recombinant
IFN-γ, enhanced MCP-1 production twofold (relative to the basal levels
in response to recombinant IFN-γ alone), confirming that CD40 was
functionally expressed on MCs. Using gel-shift assay and a specific
inhibitors, we showed that the contact of MCs with platelets induced
NF-κB activation, which was essential for MCP-1 synthesis. In addi-
tional experiments, we found that activation of p38 mitogen-activated
protein kinase (MAPK) and protein tyrosine kinases (PTKs) are involved
in platelet-mediated MCP-1 induction by MCs.
Conclusion: Platelet/MC contact stimulates the production of MCP-1
and may contribute to glomerular inflammatory responses by recruiting
leukocytes from the peripheral blood.
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Background: Polymorphonuclear neutrophils (PMNs) are attracted
early at sites of inflammation, where they are in close proximity with
other types of immune cells. Cellular contact with stimulated T cells are
known to prime PMNs for respiratory burst, and direct cell–cell contact
between T cells and monocytes is a major mechanism that triggers the
production of inflammatory cytokines.
Methods: We analysed the direct induction of the respiratory burst in
human PMNs upon contact with stimulated T cells. The production of
reactive oxygen species (ROS) by PMNs was monitored in vitro by the
luminol-enhanced chemiluminescence assay.
Results: Membrane from PHA/PMA-stimulated human T lymphocytes
and from T-cell line HUT-78 induced a dose-dependent ROS production
by PMNs, demonstrating that stimulated T-cells are able to stimulate
PMN respiratory burst by direct cell–cell contact. Neither TNF soluble
receptors nor IL-1 receptor antagonist interfered with ROS production
induced by T-cell membranes. Monoclonal antibodies directed toward
CD-18 inhibited 60% of PMN respiratory burst induced by stimulated
T-cell membrane, while antibodies to CD11a,b,c and CD69 had no
effect. These results suggest a partial role for β-2-integrin CD18 in PMN
activation. Furthermore, HDL inhibited stimulated T-cell induced PMN
respiratory burst in a dose-dependent manner, allowing a complete inhi-
bition for 200µg/ml. Similar inhibitory effects of HDL have previously
been described in activation of monocytes by direct cell–contact.
Conclusion: These results emphasize the importance of direct cell–cell
contact in inflammatory processes and strongly suggest that at the
surface of T cells, similar molecules, although affected by different
coactivators, are involved in the activation of both monocytes–
macrophages and PMNs.
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Background: Chronic exposure of CD4+ T cells to picomolar concen-
trations of tumour necrosis factor alpha (TNF) induces a hyporespon-
sive phenotype, as measured by T-cell-receptor-(TCR)-stimulated
proliferation and cytokine production, which is similar to that of T cells
recovered from inflamed rheumatoid synovial joints. We have reported
previously that chronic exposure to TNF impairs assembly of the
TCR/CD3 complex at the cell surface by down-regulating expression of
the signal amplification module TCR zeta (TCR-ζ). TCR-induced tyro-
sine phosphorylation of ZAP-70, LAT and PLC-γ1 are attenuated in
TNF-treated cells as a consequence.
Objective and results: Here we report studies of the effects of TNF on
downstream signalling pathways using a murine T-cell hybridoma. We
show that signalling from the TCR via the extracellular signal-regulated
kinase (ERK) pathway is similar in control and TNF-treated cells, as
determined by induction of GTP-bound Ras, by phosphorylation on
ERK1/2 and the ERK substrate Elk-1, and by ERK-dependent expres-
sion of c-fos and CD69. By contrast, TCR-induced calcium flux is
greatly attenuated in TNF-treated cells. Despite preservation of ERK
signalling, induction of cytokine mRNA transcripts, whose expression
depends upon calcium signals and the generation of NFAT (functional
nuclear factor of activated T cells) or NFAT/AP-1 complexes, is
markedly suppressed in TNF-treated T cells. Further experiments reveal
that TNF alters signalling through the calcium/NFAT pathway indepen-
dently of its effects on receptor-proximal events. For example, we find
that whereas calcium responses induced by ionomycin or thapsigargin
are similar in control and TNF-treated cells, IL-2 production is greatly
reduced in TNF-treated cells as compared with controls after stimula-
tion with phorbol ester and ionomycin. As is the case for stimulation via
TCR, activation of the Ras/ERK pathway by phorbol ester is preserved
in TNF-treated T cells.
Conclusion: These data are consistent with a model in which TNF
alters NFAT function through effects on nuclear translocation, DNA
binding or transcriptional activation. The model also predicts that TNF
Available online http://arthritis-research.com/supplements/5/S1S30
may promote T-cell effector responses indirectly by suppressing NFAT-
dependent genes whose expression is required for immunoregulation
and peripheral tolerance.
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Background: Myeloid-related protein (MRP) 8 (S100A8) and MRP 14
(S100A9) are calcium-binding proteins belonging to the S100 family.
Their expression in leukocytes is restricted to neutrophils and early dif-
ferentiation stages of monocytes. In several inflammatory diseases,
serum concentrations and expression of MRP 8 and MRP 14 by infil-
trating myelomonocytic cells correlate with disease activity, indicating
that both proteins are released during inflammatory processes.
Objective: To analyze MRP 8/14 concentrations in serum and synovial
fluid (SF), and expression of MRP 8 and MRP 14 in synovial tissue in
RA and SpA.
Methods: Paired serum, SF and synovial tissue samples of 20 RA and
20 SpA patients and sera of 20 healthy controls (HCs) were analyzed.
Concentrations of MRP 8/14 in serum and SF were determined by
ELISA. The expression of MRP 8 and MRP 14 in synovium was investi-
gated using immunohistochemistry on frozen sections. Sections were
scored on a semiquantitative 4-point scale. For statistical analysis, the
Mann–Whitney test and Spearman’s Rho correlations were performed.
P values  ≤0.05 were considered significant. Bonferroni corrections
were applied when necessary.
Results: Serum concentrations of MRP 8/14 were significantly higher
in RA (medians 1285ng/ml [210–11390]) and SpA (medians
570ng/ml [230–2730]) than in HCs (medians 280ng/ml [130–680])
(RA versus HCs: P<0.001; SpA versus HCs: P=0.002). Moreover,
MRP 8/14 serum concentrations in RA were increased, in comparison
with SpA (P=0.036). Also for SF concentrations, MRP 8/14 levels
were significantly higher in RA than in SpA (medians 11,720ng/ml
[0–95,000] versus 2445ng/ml [0–33,250], P=0.049). MRP 8 stain-
ing in the lining layer was more prominent in RA than in SpA
(medians 2 [0–3] versus 1 [0–3], P=0.019), and MRP 14 staining in
the sublining layer was more abundant in RA than in SpA (medians 2
[0–3] versus 1 [0–2], P=0.026). In RA, MRP 8/14 concentrations in
serum correlated well with SF concentrations (r=0.650, P=0.002).
Conclusion: We found significantly higher MRP 8 and 14 serum con-
centrations, MRP 8 and 14 SF concentrations, and MRP 8 and 14
expression in synovial tissue in RA than in SpA. In both diseases,
MRP 8 and 14 serum levels were higher than in HCs.
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Joint destruction is a key point in many inflammatory and degenerative
diseases. This is mainly mediated by inflammation cells and resident
cells such as chondrocytes. Matrix metalloproteinases and reactive
oxygen species are widely involved.
This work shows that three different human immortalized chondrocyte
(HIC) cell lines (a gift from M Goldring) and native chondrocytes can
generate superoxide anions (O2–) constitutively and after activation
with PMA or ionomycin. The O2– produced by chondrocyte NADPH
oxidase is about 0.1% of the respiratory burst measured in phagocytic
cells such as neutrophils. All the components of NADPH oxidase were
detected by Western blot analysis: the cytosolic factors p47phox,
p67phox and p40phox and the two subunits of the cytochrome b558,
gp91phox (Nox2) and p22phox. The presence of cytochrome b558 was
also demonstrated by reduced minus oxidized differential spectra in
1% Triton X-100-soluble extract from the three HIC cell lines. The
cytochrome b558 content in chondrocytes was about 10pmol/mg of
proteins: this amount is lower than in neutrophils (200pmol/mg of pro-
teins). The presence of Nox4 and Nox2 mRNA in the three HIC cell
lines was demonstrated by RT-PCR and Northern blot analysis.
The three HIC cell lines and native chondrocytes contain phagocyte
NADPH oxidase components, and Nox2 (gp91phox) analogs as Nox4
and Nox5. The low level of superoxide anions O2– produced by chon-
drocytes in comparison with neutrophils may be involved in signal
transduction and may be implicated in the structural and functional
alterations of cartilage matrix observed in arthritis and osteoarthritis.
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Objective: To determine immunohistological markers in synovial tissue
of early rheumatoid arthritis (RA) patients, which could be used as pre-
dictors for disease outcome.
Methods: Synovial tissue was obtained from 36 RA patients within
1 year after the initial symptoms and before the initiation of treatment
with any disease-modifying antirheumatic drug. Clinical, laboratory, and
radiological assessment (Larsen score) was performed at the time of
the biopsy and at the end of follow-up (mean 58 months, range
38–72 months). Immunohistological analysis was performed to detect
T cells, B cells, plasma cells, fibroblast-like synoviocytes (FLS),
macrophages, and granzyme B+ cytotoxic cells. The sections were
evaluated by digital image analysis.
Results: Patients were divided into two groups based upon the radio-
logical progression per year of follow-up: group I with moderate pro-
gression (n=20) (by <2 points/year, Larsen score) and group II with
pronounced progression (n=16) (by ≥2 points/year, Larsen score).
Regression analysis with a univariate model revealed that female
gender (RR=10.7, P=0.015) and numbers of granzyme B+ cytotoxic
cells (RR=12, P=0.003), T cells (RR=10.1, P=0.013), and FLS
(RR=10, P=0.020) discriminated between groups I and II. A multivari-
ate model demonstrated that female gender (RR=78.42, P=0.017)
and numbers of T cells (RR=1.2, P=0.015) and FLS (RR=1.4,
P=0.013) were independent discriminators between groups I and II.
Conclusion: The numbers of granzyme B+ cytotoxic cells, T cells, and
FLS in synovial tissue of RA patients are related to the severity of joint
damage and therefore may be useful prognostic markers of disease
outcome in patients with recent-onset RA. In addition, the observations
suggest a pathogenic role of these cells in the process of joint damage.
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Background: Osteoprotegerin (OPG) and receptor activator of
nuclear factor κB ligand (RANKL) are the key regulators of osteoclasto-
genesis in inflammatory diseases, such as RA. OPG binds to RANKL,
prevents its ligation to receptor activator of nuclear factor κB (RANK)
and inhibits differentiation and activation of osteoclasts. The imbalance
of this system results in the predominance of osteoresorption and bone
erosions.
Objective: The aim of study was to compare the levels of OPG and
soluble RANKL (sRANKL) in serum (S) and synovial fluid (SF) in
rheumatoid arthritis (RA), osteoarthritis (OA) and spondylartropathies
(SpA) and to correlate these levels with inflammatory parameters. We
hypothesized that there is a higher local synthesis of both factors and
positive correlation of sRANKL in synovial fluid with the disease activity
in RA.
Methods: The paired S and knee SF samples were collected from 105
patients with RA (n=45), OA (n=46) and SpA (n=14). The OPG and
sRANKL levels were measured by sandwich ELISA (Biomedica).
Results: Concentrations of OPG and sRANKL were significantly
higher in SF than in S in all groups (Table 1). RA and SpA groups had
S-OPG and SF-OPG lower than OA. RA and OA groups differed sig-
nificantly. S-sRANKL was negative in most cases in all groups. The sig-
nificant negative correlation with serum CRP and SF leukocyte count
was found in S-OPG, SF-OPG and SF-sRANKL.
Table 1
The mean OPG and sRANKL levels in patient cohorts
RA OA SpA
S-OPG (pmol/l) 1.9 (1.6; 2.3) 2.4 (2.2; 2.7) 1.8 (0.9; 2.7)
SF-OPG (pmol/l) 3.8 (3.1; 4.4) 8.4 (7.5; 9.3) 3.5 (2.1; 4.8)
SF-sRANKL (pmol/l) 3.36 (2.5; 4.2) 3.41 (2.9; 3.8) 1.9 (1.5; 2.5)
Values are means (95% confidence interval).
Conclusion: The increased local production of OPG and sRANKL in
active joints reflects the production by inflammatory cells. Lower local
and systemic concentrations of OPG in RA and SpA, but not in OA,
are in agreement with the theory that OPG is insufficiently protective in
inflammatory arthritis. The finding that there is no difference in SF
sRANKL in RA and OA suggests that the local osteoresorption results
from cell-bound RANKL rather than from the activity of the soluble form.
Acknowledgement: Supported by grant NK/7293-3 MH CR.
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Background: The microvascular endothelium (MVE) plays a major role
in the pathogenesis of rheumatoid arthritis (RA). There is evidence to
suggest that tissue-specific MVE determinants are involved in selective
recruitment of pathogenic immune cells to sites of inflammation.
Objective: The aim of this work was to target the synovial MVE in
tissue grafts transplanted into mice with SCID (severe combined
immunodeficiency), using phage display.
Methods:  Human synovium and skin were transplanted into SCID
mice. A disulfide-constrained seven-amino-acid peptide phage library
was injected intravenously into the animals and synovial homing phage
was recovered from grafts. DNA sequencing of homing phage clones
allowed the identification of specific peptides.
Results: Synovial homing phages that distinctively bind to synovial but
not skin or mouse MVE were isolated. They retained their tissue
homing specificity in vivo independently from the phage component,
the original pathology of the transplanted tissue and the degree of
human/murine graft vascularisation. One such peptide (CKSTHDRLC)
maintained synovial homing specificity both when presented by the
phage or as a free synthetic peptide. The synthetic peptide also com-
peted and inhibited in vivo the binding of the parent phage to the
cognate synovial MVE ligand.
Conclusions: We report the isolation of peptides with homing proper-
ties specific for human synovial MVE. The identification of such pep-
tides opens the possibility of using these sequences to construct
joint-specific drug delivery systems that may have a considerable
impact in the treatment of arthritic conditions.
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Background and objective: Alterations in periarticular tendons have
been described in osteoarthritis (OA), but the specific properties of OA
tenocytes and particularly the regulation of apoptosis in these cells
remain poorly understood. Therefore, we analyzed the expression of
Fas and sentrin-1/SUMO-1, a small ubiquitin-like modulator of Fas sig-
naling, in tenocytes of patients with knee OA and studied the suscepti-
bility of these cells to FasL-induced apoptosis.
Methods: Tenocyte cultures were established from tendon specimens
of the quadriceps femoris muscle of OA patients and characterized by
FACS analysis with antibodies against fibroblast markers (AS02, 5B5)
and monocyte markers (CD45, CD68). Expression levels of Fas and
sentrin-1/SUMO-1 were determined by quantitative real-time PCR
(TaqMan, Applied Biosystems). Levels of soluble Fas (sFas), and
soluble TNF receptor I (sTNFRI) were measured by ELISA. To induce
apoptosis, tenocytes were stimulated with 100ng/ml rhFasL for
16 hours. Apoptosis was determined through the detection of cytoplas-
matic mononucleosomes and oligonucleosomes (Cell Death ELISA,
Roche). The effects of TNF-α were studied by stimulation with 1, 10 or
100ng/ml TNF-α alone or 24 hours prior to the induction of apoptosis.
Tenocytes from non-OA patients were used as controls.
Results: FACS analysis confirmed the fibroblast-like nature of teno-
cytes and excluded the presence of monocyte-derived cells in the cul-
tures. Quantitative PCR showed significantly higher levels of Fas
mRNA in OA tenocytes in comparison with healthy controls. As demon-
strated by ELISA, tenocytes from OA patients produced lower levels of
apoptosis-inhibiting sFas. No differences were seen in the expression
of sentrin-1/SUMO-1 and sTNFRI. After stimulation with rhFasL, teno-
cytes from OA patients exhibited higher rates of apoptosis than control
cells. TNF-α prevented FasL-induced apoptosis in OA tenocytes but
had no effects in normal tenocytes.
Available online http://arthritis-research.com/supplements/5/S1S32
Conclusion: The data suggest an association between knee OA and
higher susceptibility of periarticular tenocytes to FasL-induced apoptosis.
Increased expression of Fas receptor and lower levels of sFas may
provide the basis for these alterations that in turn may promote the rupture
of tendons. The antiapoptotic effects of TNF-α in OA tenocytes but not in
normal cells most likely reflect regenerative attempts. They should be con-
sidered when anti-TNF-α strategies are discussed for the treatment of OA.
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Objective: To relate the production of BCA-1 and SLC to lymphoid
neogenesis in the rheumatoid arthritis (RA) synovium, in order to
analyse their expression in relationship to the development of lymphoid
features (T/B cell segregation, follicular dendritic cells [FDC] and
expression of peripheral node addressin [PNAd]).
Methods: Fifty synovial-membrane samples from 20 RA patients were
studied using immunohystochemistry and in situ hybridization. Samples
were stained for T, B and FDC, PNAd, BCA-1 and SLC. In situ hybridi-
sation was performed for BCA-1 and SLC. Grading analysis was
assessed according to the radial cell count from the central blood
vessel to the point of widest infiltration: grade 1 (2–5 cells), grade 2
(6–10) and grade 3 (>10). The percentage of aggregates positive for
each factor within each grading group was calculated.
Results: Samples from 17 patients showed the presence of grade 2
and/or 3 aggregates; in three cases only perivascular cuffing was
demonstrated. Fully formed follicular-like structures, with centrally
located CD21+ FDC and T/B segregation, were seen in 7 of the
20 patients (35%). BCA-1 and SLC were expressed within lympho-
cytic clusters in 18 of 20 and 15 of 20 patients, respectively. BCA-1
and SLC expression was associated with mature follicular organisa-
tions. However they were detected also in the absence of fully formed
lymphoid-like structures. Production of BCA-1 and SLC was estab-
lished by in situ hybridisation to localize within lymphocytic clusters but
even in the absence of mature follicles.
Conclusions: This study confirms that the expression of BCA-1 and
SLC is associated with the ectopic lymphoid organisation seen in RA.
Furthermore, it demonstrates by in situ hybridisation the precise site of
production of these chemokines. Finally, grading analysis indicates a
relationship between their expression and the progressive enlargement
and organisation of infiltrating cell.
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In a recent report, we implicated a PI3-kinase and nuclear-factor-κB-
(NF-κB)-dependent pathway in IL-18-induced expression of vascular cell
adhesion molecule-1 (VCAM-1) expression in RA synovial fibroblasts. We
showed that IL-18 activates PI3 kinase/Akt, NF-κB, c-Src and Erk1/2.
Here, we tested various oligonucleotides (ODNs) targeting signalling
molecules induced by IL-18 signalling pathways. We also tested these
antisense ODNs on IL-18-induced VCAM-1 expression. We evaluated
IL-18-activated signalling molecules by Western blot and VCAM-1
expression by flow cytometry. Treatment with antisense c-Src ODN
reduced IL-18-induced Erk1/2 expression by 32% in comparison with
control treatment, suggesting the upstream role of src in Erk1/2 activa-
tion. In addition, antisense c-Src ODN treatment also inhibited Akt
expression by 74% in comparison with that in controls. Blocking PI3-
kinase through treatment with antisense PI3-kinase ODN almost com-
pletely inhibited its known effector Akt expression. In an alternative
pathway, inhibition of IRAK with antisense ODN to IRAK reduced IL-18-
induced expression of the transcription factor NF-κB, which was not
affected by inhibition of c-Src by antisense ODN. Finally, the IL-18-
induced expression of VCAM-1 was inhibited by treatment with anti-
sense ODN to c-Src, NF-κB, PI3-kinase and Erk1/2 to 43%, 57%, 59%
and 68% versus control treatment with the respective sense ODNs.
Conclusion: These data support the role of IL-18 in the activation of
two novel pathways during RA synovial fibroblast stimulation, in addi-
tion to signalling through NF-κB. They suggest that these two novel
pathways are controlled by Src kinase. The potential benefit of anti-
sense ODN as selective inhibitors in down-regulating signalling events
is also supported by the real decrease in IL-18-induced VCAM-1
expression seen after treatment of the RA synovial fibroblasts with anti-
sense ODNs. Antisense ODNs constitute an interesting approach to
block intracellular signalling pathways.
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Background: Matrix metalloproteinases (MMPs) play a pivotal role in
many diseases. Inhibition of these enzymes is therefore also an impor-
tant therapeutic target in rheumatoid arthritis and osteoarthritis, in
which elevated levels of MMPs contribute to joint destruction. We
reported earlier that mepacrine may effect MMPs by interfering with the
activation of the transcription factor AP-1. Here we demonstrate that
mepacrine may exert certain beneficial effects by suppressing MMP
up-regulation in mononuclear cells.
Objective and methods: THP-1 and blood cells freshly isolated by
density-gradient centrifugation were used. This cell population was pre-
treated with mepacrine and was subsequently stimulated with PMA for
4 hours to induce MMPs. RT-PCR was used to monitor the effect of
mepacrine on cytokine- and PMA-induced MMP1, MMP2, MMP3 and
MMP8 up-regulation.
Mepacrine has been used successfully to tether certain forms of
rheumatic diseases. In order to account for these findings, we investi-
gated possible effects of mepacrine on TNF as well as PMA-induced
MMP up-regulation.
Results: Mepacrine dose-dependently inhibited the PMA-induced up-
regulation of MMP1, MMP2 and MMP8. The observed effects are spe-
cific, since mepacrine did not interfere with MMP3 activation. Western
blot and RT-PCR experiments showed that treatment of mononuclear
cells (MNCs) with mepacrine blocked the MMP up-regulation at the
transcriptional level. Furthermore, electrophoretic mobility shift assays,
using the AP-1 consensus element and MNC nuclear extract, demon-
strated that, similar to human synovial fibroblast-like cells, mepacrine
blocked AP-1-DNA interactions.
Conclusion: These effects of mepacrine on MMP up-regulation in
MNCs may contribute to the beneficial effects of this drug seen in the
past. To what degree events upstream of AP-1 are affected by
mepacrine is currently under investigation.
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favors autoimmunity by preventing the membrane
expression of CD5
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Background and objective: The B-cell population comprises B1 and
B2; the B1 population is subdivided into B1a, which express CD5, and
B1b, which do not. B1 cells contribute to autoimmune disease, and a
negative regulation has been ascribed to CD5. We recently described
an alternative exon1 (referred as exon1B) and pursued the issue of the
interplay of two exons 1 in the pathogenesis of lupus.
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Methods: B cells, including the B1a, B1b and B2 subpopulations, and
T cells, were sorted from periperal blood (PB), tonsils, cord blood (CB)
and CLL samples. Jurkat and Daudi cells were used as positive and
negative controls, respectively. Conventional, nested and real-time
PCR, in situ hybridization and EBV transformation were used, and CD5
molecules were counted.
Results: Exon 1B was shown to encode an additional mRNA in B cells
and to be functional. It was never found in T cells, including those acti-
vated by anti-CD3 plus IL-2 or PMA. There was a gradient expression of
exon 1A: PB T cells >B CLL>tonsil B (B1a>B1b>B2), >PB B>CB
B cells. This correlated with the CD5 molecule at the membrane. In situ
hybridization of cytospan cells and germinal center sections confirmed
this statement. Exon 1A substituted to exon 1B in activated (anti-µ plus
IL-2), but not in further advanced (anti-µ plus IL-4) B cells. The leader
peptide of exon-1B-induced protein was hydrophilic (not expressed)
while that of exon-1A-induced protein was hydrophobic (expressed).
Conclusion: An aberrant exon 1B usage prevents transportation of
CD5 to the membrane. Given the negative control exerted by CD5 in
the vicinity of the BCR, B-cell-mediated autoimmune disease might
thus occur as a failure to express CD5.
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Objective: The aim of the present study was to analyze the relationship
between systemic levels of proMMP3, MMP8, and MMP9 and MMP
activity in α2M/MMP complexes and the progression of joint destruc-
tion in patients with early rheumatoid arthritis (RA).
Methods: One hundred and nine patients diagnosed with probable or
definite RA of recent onset were entered in this study. The patients
were followed up for 2 years; clinical data, blood samples and radi-
ographs were obtained at baseline, at 1 year and at 2 years. MMP
levels were quantified using ELISA and MMP activity assays.
Results:  During the 2-year study, joint damage progressed from
0 to 10 (median Sharp score, P<0.001) and the Disease Activity
Score (DAS) decreased from 3.4 to 2.5 (P<0.001). Stable levels of
proMMP3 and α2M/MMP and a significant decrease in proMMP8 and
proMMP9 levels was observed throughout the 2 years. Regression
analysis showed that serum proMMP3 levels at the disease onset were
independently associated with the progression of joint damage
(B: 0.37, 95% CI 0.13–0.61, P=0.003).
On the basis of the rate of joint destruction, the patients were divided
into two subgroups: according to whether the progression of joint
damage was mild or severe. The proMMP3 levels were significantly
higher in the severe vs mild group at all time points. Mild progressors
showed a decrease in the levels of proMMP8, proMMP9 and
α2M/MMP complexes (P=0.01 and P<0.001,  P=0.009, respec-
tively), whereas no changes in proMMP8, proMMP9 and α2M/MMP
levels were found in the severe group.
Conclusion: ProMMP3 levels at the onset of disease are predictive of
joint damage progression.
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Background: In rheumatoid arthritis (RA), fibroblast-like synoviocytes
(FLSs) have an aberrant behaviour. We have shown that FLSs from
patients with RA display a different expression profile of matrix metallo-
proteinases, a different rate of proliferation and a different behaviour in
an in vitro invasion model as compared with FLS from patients with
osteoarthritis (OA) or fractures. Others have shown that FLSs in
patients with RA show characteristics of transformation, such as an
increased rate of proliferation, anchorage-independent growth and
invasiveness in a SCID mouse invasion model. Interestingly, microdis-
section studies recently showed that RA synovial tissue sections from
different regions of the synovium were characterised by different p53
transition mutations, suggesting that oxidative stress leads to different
mutations and can lead to different behaviour of FLSs. This observation
suggests that even within a joint, the inflammatory stress can lead to
differences in FLS behaviour.
Objective: We therefore wished to evaluate the differences between
FLS populations obtained from different joints of the same patient, to
gain a better understanding of the potential differences in invasive
behaviour of FLSs within one patient. To do this, we analysed the inva-
siveness of FLSs obtained from different joints from one patient in an
in vitro model.
Methods: Synovium was obtained from 11 patients (8 with RA and
3 with OA) at joint replacement surgery and FLSs were isolated from
the tissue using enzymatic digestion. When the cells had grown to con-
fluence, invasion was tested in transwells coated with Matrigel.
Results: The results show that the variation within one patient is smaller
than the variation between patients (Fig.1). These data suggest that the
inflammatory process that drives the transition of synoviocytes to inva-
sive FLSs is similar in different joints taken from the same patient.
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Background: In the cartilage of the joint, the matrix proteins are very
pronounced in relation to the scattered chondrocytes in the tissue. In
recent years, many different small molecules have been described with
close relation to the collagen fibers and with activities that could be
important in protecting the collagen fiber structure. One of these pro-
teins is cartilage oligometric protein (COMP).
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Figure 1
Invasiveness of FLSs (in Matrigel) of two different joints from one
patient.
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Objective: The aim of our study was to investigate the serum level of
COMP in psoriatic arthritis, to determine whether cartilage destruction
is taking place.
Methods: Thirty-six psoriatic arthritis patients (22 women, 14 men), with
an avarage disease duration of 7 years, were examined. For every patient,
the disease activity on a visual analogue scale, the number of painful and
swollen joints and the Ritchie index were recorded, as well as the sedi-
menation rate and CRP. The level of COMP was measured. Correlations
between the activity parameters and the level of COMP were evaluated.
Results: A good correlation was found between the Ritchie index and
the serum level of COMP (r=0.4) . Low correlation was seen between
the level of COMP and the number of painful joints (r=0.1). No correla-
tion was found between COMP and any of CRP, sedimentation rate or
number of swollen joints.
Conclusion: The serum level of COMP can be used as one of the activity
indicators of arthritis activity, though the correlation with other activity
parameters in PsA is not so strong as in rheumatoid arthritis. The reasons
for this difference may lie in the additional activity of the skin disease.
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Background: In earlier studies, we found that using FcγRII–/– mice, the
inhibiting FcγRII is an important regulator of joint inflammation and carti-
lage destruction during immune-complex arthritis (ICA) and that this
receptor probably acts by down-regulating activatory FcγR functions.
Objective: In the present study, we investigated the in vivo role of
FcγRII during ICA in the absence of activatory FcγR, using FcγRI/III–/–
and FcγRI/II/III–/– mice.
Results: At day 3 after ICA induction, a strongly elevated inflammation
(exudate and infiltrate respectively 2200% and 270%) was found in
knee joints of FcγRI/II/III–/– as determined by histology whereas inflam-
mation was almost absent in knee joints of FcγRI/III–/–. Eight hours after
injection of heat-aggregated IgG, significantly more IgG was detected
in knee joints of FcγRI/II/III–/– in comparison with wild-type controls
which was mainly associated with the lining layer. Although inflamma-
tion was much higher in knee joints of FcγRI/II/III–/– and the inflamma-
tory cells still expressed an inflammatory phenotype, severe cartilage
destruction (matrix-metalloproteinase-mediated neoepitopes in the
matrix and chondrocyte death) was completely prevented, in contrast
to the marked destruction observed in the wild type.
Conclusion: Our study indicates that FcγRII reduces joint inflammation in
the absence of activating FcγR by promoting clearance of immune com-
plexes from the joint. Infiltrating cells that fail to express FcγR, although they
still become activated, are no longer able to induce cartilage destruction.
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Objective: To evaluate the effects of BiP, which has recently been
shown to prevent collagen-induced arthritis, on the differentiation of
monocytes into immature dendritic cells (IDCs).
Methods: Monocytes from healthy blood donors were cultured for
3 days with GM-CSF and IL-4 to generate IDCs, either alone or in the
presence of BiP (20µg/ml) or β-galactosidase (20µg/ml) as a control.
TNF-α and IL-10 levels were measured by ELISA from the culture
supernatants collected at 24 and 72 hours. Neutralisation experiments
with IL-10 blockers were performed. Immunoflurescent staining and
FACS analysis were carried out on cells harvested at day 3. Mixed
leukocyte reactions were performed by coculturing the different mono-
cyte populations with purified allogenic T cells (ratio 1:10) for 5 days.
Results: Addition of BiP to monocytes cultured with GM-CSF and IL-4
i) significantly inhibited down-regulation of CD14 and up-regulation of
HLA-DR, CD80, CD86 and CD1a, the pattern of surface markers
usually consistent with IDC differentition, ii) induced a significantly
higher production of IL-10 within the supernatants and iii) strongly
inhibited the proliferation of allogeneic T cells. Many of the effects
mediated by BiP can be reversed by the addition of anti-IL10 antibody.
Conclusion: These findings support the concept that BiP may have
immunomodulatory properties that could have therapeutic benefit in
rheumatoid arthritis.
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Background: The T-cell receptor zeta (TCR-ζ) chain plays an impor-
tant role not only in the assembly of the TCR/CD3 complex but also in
coupling cell surface receptors to downstream intracellular signalling
pathways. We have recently identified a subset of T cells in the periph-
eral blood that expresses low levels of TCR zeta (TCR-ζ-dim). Since
several groups have documented reduced expression of TCR-ζ chain
in synovial-joint T cells from patients with rheumatoid arthritis, we set
out to test the hypothesis that peripheral blood TCR-ζ-dim T cells rep-
resent a subset of circulating memory effector T cells.
Objective: To characterise the cell surface markers and cytokine-pro-
ducing capacity of the TCR-ζ-dim T cells.
Methods: Three-colour staining and flow cytometry (FACS) were per-
formed on fixed and permeabilised cells to study cell-surface markers
and the expression of intracellular TCR-ζ. Intracellular TNF-α and IFN-γ
expression were also detected by FACS after stimulation with phorbol
ester and ionomycin in the presence of monensin, and the expression
in TCR-ζ-bright and TCR-ζ-dim populations was compared.
Results: Engagement of TCR on peripheral blood T cells in vitro led to
down-regulation of TCR-ζ. Furthermore, levels of TCR-ζ from inflamed
joints were also dramatically reduced in comparison with that from the
peripheral blood. As expected, synovial-fluid and membrane T cells
expressed more CD45RO, CD45RB-dull and CD62L-neg than periph-
eral blood T cells. In comparison with the CD3+ TCR-ζ-bright popula-
tion, peripheral blood TCR-ζ-dim T cells were also enriched for
CD45RO expression, and expressed the CD45RB-dull and CD62L-
neg markers of memory T cells. A significant proportion of TCR-ζ-dim
T cells were found to be CD28-negative. After stimulation in vitro,
TCR-ζ-dim cells were found to be enriched for TNF-α and IFN-γ pro-
ducers in comparison with the TCR-ζ-bright T-cell subset from the
sample individual. Preliminary data suggest that TCR-ζ-bright and
TCR-ζ-dim T-cell subsets can be distinguished on the basis of their rel-
ative expression of CD52.
Conclusion: CD3+ TCR-ζ-dim cells are characteristic of T cells acti-
vated through the TCR and are enriched for cells capable of express-
ing TNF-α and IFN-γ. We postulate that this T-cell subset may
represent circulating effector cells that may play a role in promoting the
chronic inflammatory process.
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Introduction: Downregulation of TNF-α levels in synovial fluid of
rheumatoid arthritis (RA) has been described following treatment with
methotrexate (MTX). Although the mechanism of action of MTX is
unknown, inhibition of methylenetetrahydrofolate reductase (MTHFR)
could be implicated. Polymorphisms in MHTFR have been described
(A1298T and C677T) that may condition clinical response.
Aim: To determine whether MHTFR genotype is related to the ‘in vitro’
cytokine inhibition and ‘in vivo’ clinical response to MTX.
Materials and methods: Twenty-three patients with early RA were
studies along with 23 healthy donors. Blood (1/10 diluted in LPS-free
Iscove’s) was cultured in the presence of 1 µg/ml anti-CD3 and
1 µg/ml anti-CD28, with or without MTX (0.152 to 625 ng/ml; 
L. Aarden, personal communication). The effect of MTX was reverted
with folinic acid (3 µg/ml). TNF-α, IFN-γ and IL-6 concentrations were
measured by ELISA in sera and culture supernatants after 72 hours.
MTHFR polymorphisms were determined by PCR-RFLP. DAS was
used to evaluate the clinical effect of MTX at 6 months.
Results: 1) Basal and stimulated cytokine production was similar in
controls and patients. 2) 40 ng/ml of MTX significantly inhibited IFN-γ,
TNF-α and IL-6 production of T cells stimulated by anti-CD3+anti-
CD28 (P < 0.001). 3) A statistically significant correlation (P < 0.05)
was found between ID-50 for TNF-α and clinical improvement as
assessed by DAS (% decrease of DAS score). ID-50 for TNF-α was
not related to MHTFR polymorphisms (P = 0.076). Median ID-50 was
27.13 for TNF-α (25th percentile = 18.5; 75th percentile = 34.16) and
19.74 for IFN-γ (25th percentile = 13.08; 75th percentile = 24.00). 
4) ID-50 for IFN-γ was lower in homozygous individuals A1298A
(P < 05), but was not associated with clinical outcome. No statistical
differences were associated to the C677T mutation.
Conclusions: MTX inhibits stimulated T cell cytokine production. Indi-
vidual susceptibility for MTX inhibition of cytokine production could
help predict clinical response to the drug. Mutations in the MHTFR
gene were associated with a lower response to MTX ‘in vitro’.
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Objective: Gene therapy has been developed as a promising tool for
the treatment of autoimmune diseases such as rheumatoid arthritis
(RA). In order to achieve the goal of establishing a targeted delivery of
potentially immune-modulating gene products to inflamed joints in RA,
the concept of adoptive cellular gene therapy was developed in an
animal model of RA, collagen-induced arthritis (CIA). Adoptive cellular
gene therapy utilizes immune cells with specific homing capacity as
“vehicle cells” to deliver therapeutic gene products locally after ex vivo
retroviral transduction. For the evaluation of adoptive cellular gene
therapy two goals have to be achieved. One is the monitoring of cellu-
lar trafficking and homing to areas of inflammation. The other is the
analysis of molecular effects in the synovium of inflamed target joints. In
order to approach these goals, we have tested two analysis powerful
techniques on animal and human specimens. For in vivo, real-time visu-
alization of cellular trafficking, bioluminescence imaging has been
developed in animal models. For the analysis of compartment-specific
analysis of gene expression in human RA synovium, we established the
combination of laser-mediated microdissection and differential display
to analyze distinct gene expression profiles of histologically defined
areas in RA synovium.
Methods: In the CIA model, antigen-specific T-cell hybridomas and
dendritic cells (DC) were adoptively transferred into recipient animals
after  ex-vivo retroviral transduction to express luciferase. Repeated
injection with the substrate luciferin and bioluminescence imaging on
consecutive days allowed in vivo tracking of the adoptively transferred
cells. For development of compartment-specific molecular analysis,
cryosections derived from RA synovial tissues were used to obtain
cells samples from synovial lining and sublining using a microbeam
laser microscope. RNA was isolated and analyzed using nested RAP-
PCR for differential display fingerprinting. Differentially expressed
bands were cut out, PCR products were eluted, cloned and
sequenced. Differential expression of identified sequences was con-
firmed by in situ hybridization and immunohistochemistry.
Results: It could be demonstrated that adoptively transferred T-cell
hybridomas and DC homed to and accumulated in inflamed joints of
CIA mice. In addition, microdissected RA synovial tissue sections con-
taining about 600 cells were shown to yield sufficient RNA for a stable,
reproducible RNA fingerprint. This method allowed us to identify
several known and unknown genes as being expressed differentially
between the synovial lining and sublining layers, including throm-
bospondin in the linig, Ciz/cip-1 in the sublining and fibronectin in both
layers of RA synovium. All three molecules could be confirmed on the
mRNA and protein level.
Conclusion: We tested two novel analysis techniques on animal and
human specimens. Bioluminescence imaging allowed in vivo monitor-
ing of the migration pattern of therapeutic “vehicle cells” in adoptive
cellular gene therapy of CIA, an animal model of RA. Laser microdis-
section and subsequent RAP-PCR reliably enabled us to obtain novel
insights into the area-dependent differential regulation of gene expres-
sion in human RA synovium and distinction between different cell
types. In combination, these methods present a powerful tool for the
evaluation of cellular gene therapy of RA.
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